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A major focus of the Leighton group is on the development of chemistry to aid in the 
efficient and scalable synthesis of polyketides. Over the past several years, our group has been 
interested in utilizing strained silanes to rapidly access the structural motifs commonly found in 
polyketides. Notably, our EZ-CrotylMix methodology allows for the crotylation of deactivated 
and sterically hindered aldehydes that popular methods, such as the Brown crotylation, fail to 
achieve. In order to improve the practicality of our crotylation methodology, we have developed 
a new, more powerfully activating diamine ligand scaffold that provides access to highly active 
allyl- and crotyl-silanes. These silanes can be generated in situ, precluding the need for a 
laborious isolation of the moisture sensitive crotylsilane reagents that is necessary for our 
previously reported methodology. The group’s crotylation methodology has proved useful in our 
current efforts toward the total synthesis of spongistatin 1 and its analogs. Work on the synthesis 
of an analog of spongistatin 1, specifically on the completion of the northern ABCD hemisphere, 
will also be discussed. 
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 1 
Chapter 1: Introduction 
 
Non-aromatic polyketide natural products represent an exceptional class of compounds 
with great structural diversity and immense pharmaceutical importance, which can be attributed 
to their often high biological activity, including many with anticancer properties. Despite posses-
sing some of the most potent activity against cancer ever recorded, the progress of non-aromatic 
polyketides into and through clinical trials is often hindered by their limited availability from 
natural sources. While synthetic chemistry can address this obstacle, the development of new 
methodologies for more efficient access to complex polyketides remains a worthy challenge. 
 
Figure 1.1. Anticancer polyketides of interest to the Leighton Group 
 In efforts to aid the advancement of polyketides into the clinic, the Leighton group has 
focused on developing scalable, efficient, and practical synthetic methodology to quickly build 
the structural complexity typical of polyketide natural products.1-5 These methodologies have 
been utilized in various syntheses reported by our group, such as epothilone B and dictyostatin 
(Figure 1.1), wherein the desired products were prepared in only a fraction of the steps that were 
previously required for their synthesis.6-7 Although our group’s methodological advances have 
had a powerful impact in the synthesis of these compounds, the unique challenges of another 



















































on the development of an asymmetric crotylation reaction and its application toward the scalable 
synthesis of spongistatin 1, and analogs thereof. 
 
1.1. Spongistatin 1 background 
1.1.1. Isolation and bioactivity spongistatin 1 
 
Figure 1.2. Initially reported structures of spongistatin, altohyrtin and cinachyrolide 
A unique series of macrolide natural products, referred to as spongistatins 1 and 2, 
cinachyrolide A, and altohyrtins A, B, and C (Figure 1.2), was independently isolated in 1993 
from various marine sponges by the Pettit,8-11 Fusetani,12 and Kitagawa groups,13-14 respectively. 
The isolation of the same polyketide natural products from different marine sponge species 




























R = Cl: spongistatin 1




























R = Cl: altohyrtin A
R = Br: altohyrtin B






























isolated macrolactones were very similar in terms of bond connectivity, but had discrepancies 
largely in the relative configuration of the E-ring and the AB and CD spiroketals. Although 
isolated in exceedingly limited quantities (e.g. 7.6 mg isolated from 112 kg of wet sponge), the 
Kitagawa group was able to use extensive circular dichroism and NMR studies to establish the 
relative and absolute stereochemistry of altohyrtin.15-16 Their structural assignment was later 
verified by the first synthesis of altohyrtin C by Evans and coworkers, who also concluded that 
spongistatin 2 and altohyrtin C are the same compound.17-20 
Table 1.1. Inhibition of L1210 murine leukemia cell growth and average GI50 values for spongistatin 1-921 
 
 
Of the 9 naturally occurring spongistatins (Table 1.1), spongistatin 1 (1.1) was among the 
most potent, with an average GI50 value of 0.15 nM against the National Cancer Institute of 60 
human carcinoma cell lines.9 Even more impressively, spongistatin 1 exhibited picomolar poten-
cy (typical GI50 = 0.025-0.035 nM) against a subset of highly chemoresistant tumor types.8 Smith 
and coworkers also demonstrated that spongistatin 1 is highly selective for inhibiting cancer cell 
























































1 (1.1): R = Cl, R1 = R2 = Ac
2 (1.2): R = H, R1 = R2 = Ac
3 (1.3): R = Cl, R1 = H, R2 = Ac
4 (1.4): R = Cl, R1 = Ac, R2 = H
6 (1.6): R = R2 = H, R1 = Ac
5 (1.5): R = Cl, R1 H
7 (1.7): R = R1 = H
8 (1.8): R = H, R1 = Ac




























than fully-quiescent IMR-90 cells.22 Preliminary in vivo melanoma and ovarian xenografts 
studies showed spongistatin 1 to have curative responses without toxicity at low doses.23 Initial 
investigation into spongistatin 1’s mechanism of action revealed that its cytotoxic activity results 
from inhibition of mitosis via microtubule destabilization.24 Additional competitive inhibition 
studies by Hamel and coworkers provided evidence that suggests spongistatin 1 binds near the 
vinca domain of β-tubulin, preventing the assembly of microtubules.25  
 
1.1.2. Spongistatin analogs and SAR studies 
By analyzing the structures and activities of spongistatins 1-9, several factors that impact 
bioactivity become apparent. Structural elements that are required for optimal activity include 
the C50 chloride (1.1 vs. 1.2) and the C5 acetate (1.1 vs. 1.3), whereas the C15 acetate (1.1 vs. 
1.4) and ring G (1.1 vs 1.9) are not essential for maintaining activity. The importance of the side 
chain for bioactivity was demonstrated by a report from Paterson and coworkers, where 
truncating the side chain (as in 1.10, Figure 1.3) resulted in complete loss of activity.26 The C23 
stereocenter on the CD spiroketal of spongistatin 1 is not entirely crucial for cytotoxicity, as 
observed by the Kishi group, when unintentional epimerization of C23 led to congener 1.11 (R = 
 

























































Cl, Figure 1.3), which “exhibits potent cytotoxicity”.27 Similarly, Smith and coworkers also 
observed that the C23 epimer of spongistatin 2 (1.11, R = H) was also cytotoxic, albeit slightly 
attenuated, with an average GI50 of 0.2 uM.28 This data suggests that while the side chain and the 
AB and EF fragments are necessary for tubulin binding, the CD spiroketal may not necessarily 
be important for tubulin binding. 
Owing to the size and complexity of spongistatin 1, much effort has been dedicated to 
identifying less complex analogs that retain potency and are easier to synthesize. In this regard, 
several simple analogs, which contain a fraction of the structural motifs found in spongistatin 1 
have been synthesized and tested, including 1.12-1.16 (Figure 1.4).28-32 These compounds were 
found to be only weakly cytotoxic, with the best activity in the low micromolar range (Figure 
1.4). This led to the conclusion that perhaps the overall structure of spongistatin is necessary for 
potent activity. Even though the CD spiroketal may not be crucial for binding, it may serve as a 
scaffolding element to hold the ABEF fragment into the required conformation. 
 














































































Figure 1.5. Smith diminutive analog (1.17) and its solution structure over lapped on spongistatin 121,33 
Taking lessons from previous analog work, Smith and coworkers recently disclosed the 
synthesis of analog 1.17 (Figure 1.5). The design of 1.17 was based on spongistatin’s solution 
structure, which was elucidated by extensive molecular modeling.21,33-34 The alkyl linker bet-
ween the E and B-rings was designed to constrain the ABEF portion of the molecule in a similar 
way to that which is observed in spongistatin’s solution structure. Upon biological testing, 1.17 
exhibited impressive nanomolar (80-300 nM) inhibitory activity, and evidence suggests that its 
mechanism of action is similar to that of spongistatin 1. Although this work provided an import-
ant contribution towards the identification of a simplified analog, 1.17 was still about three 
orders of magnitude less active than spongistatin 1. Nonetheless, the discovery that the CD-
spiroketal is not essential for tubulin binding is a noteworthy advance and has several 
implications for the work contained in this thesis, as will be described in Section 1.3. 
 
1.2. Previous syntheses of spongistatin 
The extraordinary activity of spongistatin 1 captured the attention of the biomedical 
community; however, its extremely limited availability precluded extensive clinical testing. In a 
larger isolation campaign lead by Pettit, only 35 mg of spongistatin 1 was isolated from 13 tons 
of wet sponge.35 Consequently, spongistatin also attracted considerable interest from the 






















Spongistatin 1 is a 42-member macrolactone, containing 24 stereocenters spanning across 
2 spiroketals and a densely functionalized tetrahydropyran subunit. Additionally, the sensitivity 
of the chlorotriene side chain and the contra-thermodynamic, singly anomeric CD spiroketal 
further complicates the strategy required to synthesize spongistatin 1. Several research groups 
have taken on this formidable synthetic challenge and, to date, 7 research groups: Evans,17-20 
Kishi,27,36 Smith,35,37-46 Paterson,47-57 Crimmins,58-62 Heathcock,63-69 and Ley70-74 groups have 
reported total syntheses of either spongistatin 1 and/or 2. In terms of scalability towards the goal 
of increasing the supply of spongistatin 1, perhaps the most notable syntheses are the Heathcock 
synthesis and Smith synthesis, which afforded 250 mg and 1.0 g of spongistatin 1, respectively.  
 
Figure 1.6. Key disconnections of spongistatin 
As established by the Evans group in the first synthesis of spongistatin 2,17 all reported 
total syntheses utilized a macrolactonization and Wittig olefination disconnection to join the 
ABCD and EF fragments and a majority of the syntheses couple the AB and CD fragments 
through an anti-aldol reaction (Figure 1.6).75-76 The work in this thesis will focus on the 
preparation of the CD fragment and its elaboration to the final ABCD fragment, and as such, the 
following brief overview of previous synthetic efforts will highlight the challenges faced and the 





































1.1: R = Cl (spongistatin 1)
1.2: R = H (spongistatin 2)
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1.2.1. Strategies toward the preparation of the CD fragment 
 
Figure 1.7. Possible spiroketal configurations 
While the AB spiroketal is doubly anomeric, the CD spiroketal is only singly anomeric in 
its naturally occurring form. It has been suggested that a hydrogen bond between the C25 hydro-
xyl and the C19 ketal oxygen, and the structural constraints of a macrocycle help to stabilize the 
CD spiroketal (Figure 1.7A).20 Despite that, these two favorable forces are not present until the 
macrocycle is formed and the C25 hydroxyl is deprotected, usually in the last few steps of the 
total synthesis. Since the doubly anomeric isomer is generally favored by about 2.4 kcal/mol 
(Figure 1.7B) for steric and stereoelectronic reasons,77 selective formation of the CD spiroketal 
and preventing its isomerization during downstream chemistry are some of the key challenges 
encountered in the synthesis of spongistatin.  
Most strategies to prepare the CD spiroketal rely on acid-mediated spiroketalization with 
subsequent reequilibration, and only a handful of reports demonstrated a selective spiroketaliza-
tion. Acid-mediated reequilibration of the doubly anomeric CD spiroketal was employed by 
several research groups, including Evans,18 Kishi,36 Paterson,57 Smith,39,44 and Ley.71 These 
studies showed that protic acid conditions can only afford the desired singly anomeric spiroketal 
as a 1:1 mixture, at best, and more frequently largely favoring the doubly anomeric spiroketal. 
Reequilibration is more efficient in the presence of Lewis acid chelators. Evans and coworkers 
were able to reequilibrate the undesired doubly anomeric CD spiroketal 1.19 in the presence of 




































Smith and coworkers also utilized a similar strategy to equilibrate a mixture of doubly anomeric 
1.22 and singly anomeric 1.23 in the presence of Ca(ClO4)2, favoring the desired spiroketal 1.25 
in a 4:1 mixture (Scheme 1.1B).39 Metal chelate type intermediates (1.21 or 1.24) were invoked 
by both the Evans and Smith groups to explain the observed selectivity. 
 
Scheme 1.1. Lewis acid-mediated equilibration of axial-axial CD spiroketal by A) Evans and B) Smith group 
Reequilibrating material can be an effective method to access the CD spiroketal, but this 
strategy poses a major synthetic bottleneck when attempting to prepare large quantities of the CD 
fragment since multiple cycles are required. Consequently, a number of research groups, such as 
Heathcock,64 Paterson,52 Crimmins,58 and Roush,78 have pursued strategies for more selective 
kinetically controlled spiroketalization. A remarkable demonstration of complete selectivity was 
achieved by the Heathcock group, who relied on a kinetically controlled spiroketalization of β-
diketone 1.28 (Scheme 1.2).64 The observed high selectivity was a direct consequence of the 
order of bond formation during the spiroketalization. Since β-diketones exist primarily in its 
enolic form, the first bond to form was between C2 hydroxyl and C6. Tautomerization of the 
resulting intermediate 1.29 to give 1.30 allows for the C10 hydroxyl to add to the oxocarbenium 
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ion through the kinetically favored axial addition via a chair transition state (1.30). This reaction 
selectively provided the desired product in a high 80% yield. 
 
Scheme 1.2. Heathcock's stereoselective spiroketalization63 
 Regardless of the efficiency or selectivity of the spiroketalization reaction, isomerization 
during downstream chemistry is still possible, especially with the use of acidic conditions, and a 
number of groups have found this limitation to be a major obstacle.18,36-37 If suitable conditions 
cannot be identified, then reequilibration is possible, albeit with a significant amount of material 
loss. In order to design a truly scalable synthesis of spongistatin 1, the sensitivity of the CD-
spiroketal must be addressed. 
 
1.2.2. Overview of AB-CD coupling strategies 
 Upon completion, the CD-fragment is coupled with the AB-fragment, usually through an 
anti-aldol reaction. Evans and coworkers pioneered the Felkin-Anh selective, anti-aldol strategy 
to forge the C15-C16 bond in their synthesis of spongistatin 2, accessing the desired product 1.34 
in 70% yield and 9:1 dr (Scheme 1.3).18 These impressive results for such a complex system 
have caused this method to become the most popular approach for coupling the AB and CD 
fragment. As previously mentioned, six of the seven research groups who have synthesized 
spongistatin employed this anti-aldol reaction, which consistently provided the product in greater 












































Scheme 1.3. Evan's anti-aldol AB-CD coupling 
Indeed, this coupling reaction is excellent for small-scale reactions; however, several 
aspects of this reaction could be liabilities on larger scales. The starting AB fragment used in this 
reaction is an α-chiral-β-γ-unsaturated aldehyde (1.32), which was noted by Evans and 
coworkers to be “too labile for chromatographic purification,” and “must be used immediately” 
in the aldol reaction.20 This type of aldehyde is prone to epimerization of the α-chiral center and 
isomerization of the double bond to give the corresponding α,β-unsaturated aldehyde. 
Furthermore, this anti-aldol reaction is preformed under cryogenic conditions and requires two 
equivalents of the CD-ethyl ketone (1.33). Although the excess CD-ethyl ketone can be 
recovered in greater than 80% yield, the use of stoichiometry closer to equimolar would be a 
more straightforward and efficient process. 
 
Scheme 1.4. Nakata's AB-CD coupling strategy 
An interesting approach that does not utilize a α-chiral-β-γ-unsaturated aldehyde was 
disclosed by the Nakata group (Scheme 1.4).79 In their report, the AB fragment 1.35, function-
alized as a crotyl stannane, was added to CD-aldehyde 1.36 in the presence of BF3•Et2O to afford 
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were required to covert C14 and C15 to the correct stereochemistry. Although far from the 
perfection observed in the popular anti-aldol coupling reaction, we were intrigued by the 
potential of the underlying coupling by crotylation strategy. 
 
1.3. Leighton group strategy to develop spongistatin 1 as an anti-cancer therapeutic 
1.3.1. Overall goals 
In the Leighton group, we are interested in devising a more scalable synthesis of 
spongistatin 1, or an analog thereof, with the ultimate goal of developing spongistatin as a useful 
anti-cancer drug. Due to the size and complexity of spongistatin 1, total synthesis alone will not 
be able to realistically produce the necessary quantities of spongistatin 1. However, if the 
quantities required for a therapeutic effect can be reduced, then a highly robust and scalable 
synthesis could certainly provide sufficient quantities of spongistatin 1. One such approach to 
accomplish this goal is through the use of targeted drug delivery, for example with antibody drug 
conjugates (ADC).  
 
Figure 1.8. ADC mechanism of action80 
ADCs are able to deliver drugs directly to tumor cells through recognition of tumor speci-
fic antigens (Figure 1.8). Once bound to a tumor cell, the ADC enters the cell through endocyto-
cysis at which time the drug is cleaved from the antibody, usually in the lysosome.80 The ability 
= Drug
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of ADCs to directly target tumor cells lessens non-specific toxicity of the drug toward normal 
cells, thus reducing side effects that are common of chemotherapies. Furthermore, the ADC-
targeted drug delivery strategy has been demonstrated to be able to bypass drug efflux that is 
mediated by the multidrug resistance-associated p-glycoprotein transmembrane pump.81 Because 
of this ability and the fact that the drug is only being delivered to tumor cells, less drug material 
is required for therapeutic effect. Due to the advantages of targeted drug delivery, ADCs have 
recently gained immense popularity, with many currently in clinical trials and two with FDA 
approvals.82-83  
We believe a robust synthesis of spongistatin coupled along with an ADC strategy will 
offer opportunities to realize spongistatin as an anti-cancer drug. In order to devise a robust 
synthesis of spongistatin 1 as a ‘warhead’ candidate, our overarching synthetic strategy must be 
amenable to functionalizing spongistatin 1 with linkers for conjugation to antibodies and must 
also address the sensitivity of the singly-anomeric CD spiroketal. In considering the location of 
the linker on spongistatin, caution should be taken to not affect the ability of spongistatin to bind 
tubulin. From previously reported analog studies, specifically that of the Smith group where 
C12-C28 was replaced with a simple alkyl strap (1.17, Figure 1.5), it seems as though there is 
flexibility in the C12-C28 region to accommodate a linker. Accordingly, we will focus on this 
region for linker derivatization. 
This analog work from the Smith group also has implications on the structure of the CD 
spiroketal. Taken together with all previous analog studies, evidence suggests that the CD 
fragment is not crucial for tubulin binding, but is structurally important for activity. The simple 
alkyl strap between the B and E-rings (Figure 1.5) may have been an over simplification, and 
perhaps a CD-analog with more structural rigidity would be more appropriate. Targeting a CD-
 14 
analog could provide opportunities to circumvent the synthetic challenges faced when working 
with a singly anomeric spiroketal, and eliminate the associated sensitivity risks, which are 
unacceptable for such precious material. 
 
1.3.2. Retrosynthetic plan 
 
Scheme 1.5. Proposed disconnections 
For our synthesis of spongistatin, we are focused on developing strategies for increased 
step-economy and scalability. It would be difficult to improve upon the previously established 
Wittig olefination and macrolactonization disconnection strategy to join the ABCD and EF (not 
shown) fragments (Scheme 1.5), which divides spongistatin 1 into two roughly similar sized 
fragments, allowing for a highly convergent synthesis. However, we felt that improving the AB-
CD coupling reaction could positively impact the scalability of the spongistatin synthesis. As 
described in section 1.2.2, several liabilities arise from using the anti-aldol AB-CD coupling 
strategy on large scales. Consequently, we decided to explore an alternative crotylation-based 













































































coupling strategy (Scheme 1.4), which used an organostannane, we opted to utilize silicon to 
affect the coupling reaction. We propose that the use of a chiral, strained silane would allow us 
to forge the C14-C15 bond while also controlling the diastereoselectivity (Scheme 1.6), which 
was not possible in Nakata’s case.  
 
Scheme 1.6. Proposed alternative AB-CD coupling strategy 
 
Scheme 1.7. Asymmetric Leighton crotylation of aldehydes 
It has been established by our group that chiral strained silanes 1.41 are able to enantio-
selectively crotylate deactivated and sterically hindered aldehydes in the presence of catalytic 
Sc(OTf)3 (Scheme 1.7),4 which was previously not possible without Sc(OTf)3,4,84 as will be dis-
cussed in Chapter 2. Since our AB-CD coupling requires an α,β-chiral aldehyde (1.40, Scheme 
1.5), which tend to be sterically hindered, we were interested in applying this methodology to the 
AB-CD coupling. Towards that goal, we have recently demonstrated that chiral silanes 1.41 with 
alkyl substitution at C2, which would be necessary for our coupling, are also able to “crotylate” 
aldehydes.3 This work culminated in the demonstrated ability to couple AB-fragment 1.44 with a 
model CD-aldehyde 1.48, via AB-diaminosilane 1.47, to afford 1.49 in 59% yield (Scheme 
1.8).85 Remarkably, this model AB-CD coupling reaction installed the C14-C15 bond and the 






































R1R21.41a: R1 = R2 = H
1.41b: R1 = Me, R2 = H






Scheme 1.8. Model AB-CD coupling 
Although this methodology represented leaps forward in terms of a more scalable AB-CD 
coupling reaction, we felt that there were still more practical improvements to be made. This 
coupling strategy suffers from a technically challenging reaction protocol that requires multiple 
solvent switches to isolate the moisture sensitive AB-diamino silane intermediate 1.47. A more 
practical procedure would preclude the isolation of 1.47 to minimize the chance for its hydro-
lysis. This limitation also plagues our asymmetric crotylation methodology,4 thereby diminishing 
its practicality. The following chapters will describe the development of an improved crotylation 
methodology, which has addressed the issue of the moisture sensitive crotylation reagent 
isolation, and the application of this methodology toward the preparation of the ABCD hemi-




















































   CH2Cl2, 0 to 23 °C
ii. concentrate, remove





















(1) Suen, L. M.; Steigerwald, M. L.; Leighton, J. L. Chem. Sci. 2013, 4, 2413. 
(2) Spletstoser, J. T.; Zacuto, M. J.; Leighton, J. L. Org. Lett. 2008, 10, 5593. 
(3) Reznik, S. K.; Marcus, B. S.; Leighton, J. L. Chem. Sci. 2012, 3, 3326. 
(4) Kim, H.; Ho, S.; Leighton, J. L. J. Am. Chem. Soc. 2011, 133, 6517. 
(5) Foley, C. N.; Leighton, J. L. Org. Lett. 2014, 16, 1180. 
(6) Ho, S.; Bucher, C.; Leighton, J. L. Angew. Chem. Int. Ed. 2013, 52, 6757. 
(7) Harrison, T. J.; Rabbat, P. M. A.; Leighton, J. L. Org. Lett. 2012, 14, 4890. 
(8) Pettit, G. R.; Chicacz, Z. A.; Gao, F.; Herald, C. L.; Boyd, M. R.; Schmidt, J. M.; 
Hooper, J. N. A. J. Org. Chem. 1993, 58, 1302. 
(9) Pettit, G. R.; Cichacz, Z. A.; Gao, F.; Herald, C. L.; Boyd, M. R. J. Chem. Soc., Chem. 
Commun. 1993, 1166. 
(10) Pettit, G. R.; Cichacz, Z. A.; Herald, C. L.; Gao, F.; Boyd, M. R.; Schmidt, J. M.; Hamel, 
E.; Bai, R. J. Chem. Soc., Chem. Commun. 1994, 1605. 
(11) Pettit, G. R.; Herald, C. L.; Cichacz, Z. A.; Gao, F.; Schmidt, J. M.; Boyd, M. R.; 
Christie, N. D.; Boettner, F. E. J. Chem. Soc., Chem. Commun. 1993, 1805. 
(12) Fusetani, N.; Shinoda, K.; Matsunaga, S. J. Am. Chem. Soc. 1993, 115, 3977. 
(13) Kobayashi, M.; Aoki, S.; Sakai, H.; Kawazoe, K.; Kihara, N.; Sasaki, T.; Kitagawa, I. 
Tetrahedron Lett. 1993, 34, 2795. 
(14) Kobayashi, M.; Aoki, S.; Sakai, H.; Kihara, N.; Sasaki, T.; Kitagawa, I. Chem. Pharm. 
Bull. 1993, 41, 989. 
 18 
(15) Kobayashi, M.; Aoki, S.; Gato, K.; Kitagawa, I. Chem. Pharm. Bull. 1996, 44, 2142. 
(16) Kobayashi, M.; Aoki, S.; Kitagawa, I. Tetrahedron Lett. 1994, 35, 1243. 
(17) Evans, D. A.; Trotter, B. W.; Côté, B.; Coleman, P. J.; Dias, L. C.; Tyler, A. N. Angew. 
Chem. Int. Ed. 1997, 36, 2744. 
(18) Evans, D. A.; Trotter, B. W.; Coleman, P. J.; Côté, B.; Dias, L. C.; Rajapakse, H. A.; 
Tyler, A. N. Tetrahedron 1999, 55, 8671. 
(19) Evans, D. A.; Trotter, B. W.; Côté, B.; Coleman, P. J. Angew. Chem. Int. Ed. 1997, 36, 
2741. 
(20) Evans, D. A.; Coleman, P. J.; Dias, L. C. Angew. Chem. Int. Ed. 1997, 36, 2738. 
(21) Smith, A. B.; Risatti, C. A.; Atasoylu, O.; Bennett, C. S.; Liu, J.; Cheng, H.; TenDyke, 
K.; Xu, Q. J. Am. Chem. Soc. 2011, 133, 14042. 
(22) Xu, Q.; Huang, K.-C.; Tendyke, K.; Marsh, J.; Liu, J.; Qiu, D.; Littlefield, B. A.; 
Nomoto, K.; Atasoylu, O.; Risatti, C. A.; Sperry, J. B.; Smith, A. B. Anticancer Res. 
2011, 31, 2773. 
(23) Pettit, R. K.; McAllister, S. C.; Pettit, G. R.; Herald, C. L.; Johnson, J. M.; Cichacz, Z. A. 
Int. J. Antimicrob. Agents 1998, 9, 147. 
(24) Bai, R.; Cichacz, Z. A.; Herald, C. L.; Pettit, G. R.; Hamel, E. Mol. Pharmacol. 1993, 44, 
757. 
(25) Bai, R.; Taylor, G. F.; Cichacz, Z. A.; Herald, C. L.; Kepler, J. A.; Pettit, G. R.; Hamel, 
E. Biochemistry 1995, 34, 9714. 
(26) Paterson, I.; Aceña, J. L.; Bach, J.; Chen, D. Y. K.; Coster, M. J. Chemical 
Communications 2003, 462. 
(27) Hayward, M. M.; Roth, R. M.; Duffy, K. J.; Dalko, P. I.; Stevens, K. L.; Guo, J.; Kishi, 
Y. Angew. Chem. Int. Ed. 1998, 37, 190. 
 19 
(28) Sfouggatakis, C. Toward the gram-scale total synthesis of (+)-spongistatin 1. Ph.D. 
Thesis, University of Pennsylvania, 2004. 
(29) Smith, A. B.; Lin, Q.; Pettit, G. R.; Chapuis, J.-C.; Schmidt, J. M. Bioorg. Med. Chem. 
Lett. 1998, 8, 567. 
(30) Smith, A. B.; Corbett, R. M.; Pettit, G. R.; Chapuis, J.-C.; Schmidt, J. M.; Hamel, E.; 
Jung, M. K. Bioorg. Med. Chem. Lett. 2002, 12, 2039. 
(31) Uckun, F. M.; Mao, C.; Vassilev, A. O.; Huang, H.; Jan, S.-T. Bioorg. Med. Chem. Lett. 
2000, 10, 541. 
(32) Wagner, C. E.; Wang, Q.; Melamed, A.; Fairchild, C. R.; Wild, R.; Heathcock, C. H. 
Tetrahedron 2008, 64, 124. 
(33) Smith, A. B.; Risatti, C. A.; Atasoylu, O.; Bennett, C. S.; TenDyke, K.; Xu, Q. Org. Lett. 
2010, 12, 1792. 
(34) Atasoylu, O.; Furst, G.; Risatti, C.; Smith, A. B. Org. Lett. 2010, 12, 1788. 
(35) Smith, A. B.; Tomioka, T.; Risatti, C. A.; Sperry, J. B.; Sfouggatakis, C. Org. Lett. 2008, 
10, 4359. 
(36) Guo, J.; Duffy, K. J.; Stevens, K. L.; Dalko, P. I.; Roth, R. M.; Hayward, M. M.; Kishi, 
Y. Angew. Chem. Int. Ed. 1998, 37, 187. 
(37) Smith, A. B.; Doughty, V. A.; Lin, Q.; Zhuang, L.; McBriar, M. D.; Boldi, A. M.; Moser, 
W. H.; Murase, N.; Nakayama, K.; Sobukawa, M. Angew. Chem. Int. Ed. 2001, 40, 191. 
(38) Smith, A. B.; Lin, Q.; Doughty, V. A.; Zhuang, L.; McBriar, M. D.; Kerns, J. K.; Brook, 
C. S.; Murase, N.; Nakayama, K. Angew. Chem. Int. Ed. 2001, 40, 196. 
(39) Smith, A. B.; Doughty, V. A.; Sfouggatakis, C.; Bennett, C. S.; Koyanagi, J.; Takeuchi, 
M. Org. Lett. 2002, 4, 783. 
(40) Smith, A. B.; Zhu, W.; Shirakami, S.; Sfouggatakis, C.; Doughty, V. A.; Bennett, C. S.; 
Sakamoto, Y. Org. Lett. 2003, 5, 761. 
 20 
(41) Smith, A. B.; Sfouggatakis, C.; Gotchev, D. B.; Shirakami, S.; Bauer, D.; Zhu, W.; 
Doughty, V. A. Org. Lett. 2004, 6, 3637. 
(42) Smith, A. B.; Lin, Q.; Doughty, V. A.; Zhuang, L.; McBriar, M. D.; Kerns, J. K.; Boldi, 
A. M.; Murase, N.; Moser, W. H.; Brook, C. S.; Bennett, C. S.; Nakayama, K.; 
Sobukawa, M.; Lee Trout, R. E. Tetrahedron 2009, 65, 6470. 
(43) Smith, A. B.; Sfouggatakis, C.; Risatti, C. A.; Sperry, J. B.; Zhu, W.; Doughty, V. A.; 
Tomioka, T.; Gotchev, D. B.; Bennett, C. S.; Sakamoto, S.; Atasoylu, O.; Shirakami, S.; 
Bauer, D.; Takeuchi, M.; Koyanagi, J.; Sakamoto, Y. Tetrahedron 2009, 65, 6489. 
(44) Smith, A. B.; Zhuang, L.; Brook, C. S.; Lin, Q.; Moser, W. H.; Lee Trout, R. E.; Boldi, 
A. M. Tetrahedron Lett. 1997, 38, 8671. 
(45) Smith, A. B.; Zhuang, L.; Brook, C. S.; Boldi, A. M.; McBriar, M. D.; Moser, W. H.; 
Murase, N.; Nakayama, K.; Verhoest, P. R.; Lin, Q. Tetrahedron Lett. 1997, 38, 8667. 
(46) Smith, A. B.; Lin, Q.; Nakayama, K.; Boldi, A. M.; Brook, C. S.; McBriar, M. D.; Moser, 
W. H.; Sobukawa, M.; Zhuang, L. Tetrahedron Lett. 1997, 38, 8675. 
(47) Paterson, I.; Chen, D. Y. K.; Coster, M. J.; Aceña, J. L.; Bach, J.; Gibson, K. R.; Keown, 
L. E.; Oballa, R. M.; Trieselmann, T.; Wallace, D. J.; Hodgson, A. P.; Norcross, R. D. 
Angew. Chem. Int. Ed. 2001, 40, 4055. 
(48) Paterson, I.; Coster, M. J.; Chen, D. Y. K.; Gibson, K. R.; Wallace, D. J. Org. Biomol. 
Chem. 2005, 3, 2410. 
(49) Paterson, I.; Coster, M. J.; Chen, D. Y. K.; Oballa, R. M.; Wallace, D. J.; Norcross, R. D. 
Org. Biomol. Chem. 2005, 3, 2399. 
(50) Paterson, I.; Coster, M. J.; Chen, D. Y. K.; Aceña, J. L.; Bach, J.; Keown, L. E.; 
Trieselmann, T. Org. Biomol. Chem. 2005, 3, 2420. 
(51) Paterson, I.; Chen, D. Y. K.; Coster, M. J.; Aceña, J. L.; Bach, J.; Wallace, D. J. Org. 
Biomol. Chem. 2005, 3, 2431. 
(52) Paterson, I.; Wallace, D. J.; Gibson, K. R. Tetrahedron Lett. 1997, 38, 8911. 
 21 
(53) Paterson, I.; Oballa, R. M. Tetrahedron Lett. 1997, 38, 8241. 
(54) Paterson, I.; Keown, L. E. Tetrahedron Lett. 1997, 38, 5727. 
(55) Paterson, I.; Wallace, D. J.; Oballa, R. M. Tetrahedron Lett. 1998, 39, 8545. 
(56) Paterson, I.; Oballa, R. M.; Norcross, R. D. Tetrahedron Lett. 1996, 37, 8581. 
(57) Paterson, I.; Coster, M. J. Tetrahedron Lett. 2002, 43, 3285. 
(58) Crimmins, M. T.; Katz, J. D. Org. Lett. 2000, 2, 957. 
(59) Crimmins, M. T.; Katz, J. D.; McAtee, L. C.; Tabet, E. A.; Kirincich, S. J. Org. Lett. 
2001, 3, 949. 
(60) Crimmins, M. T.; Katz, J. D.; Washburn, D. G.; Allwein, S. P.; McAtee, L. F. J. Am. 
Chem. Soc. 2002, 124, 5661. 
(61) Crimmins, M. T.; Smith, A. C. Org. Lett. 2006, 8, 1003. 
(62) Crimmins, M. T.; Washburn, D. G. Tetrahedron Lett. 1998, 39, 7487. 
(63) Heathcock, C. H.; McLaughlin, M.; Medina, J.; Hubbs, J. L.; Wallace, G. A.; Scott, R.; 
Claffey, M. M.; Hayes, C. J.; Ott, G. R. J. Am. Chem. Soc. 2003, 125, 12844. 
(64) Hubbs, J. L.; Heathcock, C. H. J. Am. Chem. Soc. 2003, 125, 12836. 
(65) Ott, G. R.; Heathcock, C. H. Org. Lett. 1999, 1, 1475. 
(66) Hayes, C. J.; Heathcock, C. H. The Journal of Organic Chemistry 1997, 62, 2678. 
(67) Claffey, M. M.; Heathcock, C. H. The Journal of organic chemistry 1996, 61, 7646. 
(68) Claffey, M. M.; Hayes, C. J.; Heathcock, C. H. The Journal of Organic Chemistry 1999, 
64, 8267. 
 22 
(69) Wallace, G. A.; Scott, R. W.; Heathcock, C. H. The Journal of Organic Chemistry 2000, 
65, 4145. 
(70) Ball, M.; Gaunt, M. J.; Hook, D. F.; Jessiman, A. S.; Kawahara, S.; Orsini, P.; Scolaro, 
A.; Talbot, A. C.; Tanner, H. R.; Yamanoi, S.; Ley, S. V. Angew. Chem. Int. Ed. 2005, 
44, 5433. 
(71) Gaunt, M. J.; Hook, D. F.; Tanner, H. R.; Ley, S. V. Org. Lett. 2003, 5, 4815. 
(72) Gaunt, M. J.; Jessiman, A. S.; Orsini, P.; Tanner, H. R.; Hook, D. F.; Ley, S. V. Org. 
Lett. 2003, 5, 4819. 
(73) Kawahara, S.; Gaunt, M. J.; Scolaro, A.; Yamanoi, S.; Ley, S. V. Synlett 2005, 2005, 
2031. 
(74) Kraus, H.; Français, A.; O'Brien, M.; Frost, J.; Diéguez-Vázquez, A.; Polara, A.; 
Baricordi, N.; Horan, R.; Hsu, D.-S.; Tsunoda, T.; Ley, S. V. Chemical Science 2013, 4, 
1989. 
(75) Yeung, K.-S.; Paterson, I. Chemical reviews 2005, 105, 4237. 
(76) Gerber-Lemaire, S.; Vogel, P. C. R. Chim. 2008, 11, 1382. 
(77) Deslongchamps, P.; Rowan, D. D.; Pothier, N.; Sauvé, G.; Saunders, J. K. Can. J. Chem. 
1981, 59, 1105. 
(78) Holson, E. B.; Roush, W. R. Org. Lett. 2002, 4, 3719. 
(79) Terauchi, T.; Tanaka, T.; Terauchi, T.; Morita, M.; Kimijima, K.; Sato, I.; Shoji, W.; 
Nakamura, Y.; Tsukada, T.; Tsunoda, T.; Hayashi, G.; Kanoh, N.; Nakata, M. 
Tetrahedron Lett. 2003, 44, 7747. 
(80) Schrama, D.; Reisfeld, R. A.; Becker, J. C. Nat Rev Drug Discov 2006, 5, 147. 
(81) Guillemard, V.; Uri Saragovi, H. Oncogene 2004, 23, 3613. 
 23 
(82) Sassoon, I.; Blanc, V. In Antibody-Drug Conjugates; Ducry, L., Ed.; Humana Press: 
2013; Vol. 1045, p 1. 
(83) Sliwkowski, M. X.; Mellman, I. Science 2013, 341, 1192. 
(84) Hackman, B. M.; Lombardi, P. J.; Leighton, J. L. Org. Lett. 2004, 6, 4375. 





Chapter 2: Development of a more practical and scalable 
enantioselective aldehyde crotylation methodology 
 
2.1. Introduction 
The main limitation of our key AB-CD coupling strategy (Scheme 2.1), as discussed at 
the end of Chapter 1, the need to manipulate and isolate the moisture sensitive AB diaminosilane 
intermediate 2.2, generally leads to increased possibility of its hydrolysis. Similar to Evans’ anti-
aldol AB-CD coupling approach that requires a sensitive AB fragment aldehyde, the possibility 
of decomposing 2.2 is a risk of catastrophe on large scale. To address this limitation of our AB-
CD coupling reaction, we sought to study the limitation as it applies to our crotylation method-
ology, which also requires the same laborious isolation of the crotyl silane reagents. This chapter 
will describe our approach and development of a more practical crotylation methodology. 
 
Scheme 2.1. Proposed AB-CD coupling strategy for spongistatin 1 
 
2.1.1. Overview of scalable crotylation methodology 
Asymmetric allylation and crotylation of aldehydes are among the most important and 
prevailing methods used for the construction of non-aromatic polyketides.1-7 The popularity of 
the crotylation reaction is a consequence of its highly predictable diastereoselectivity in setting 
two stereocenters while forming a C-C bond and the ability of the reaction to access diverse 
stereochemical arrays. Crotylation reactions can be classified into three types based on the 
mechanism of crotyl addition.8 Type 1 crotylations, which are the most useful, proceed through a 




















crotyl reagent (Scheme 2.2A). Type 2 crotylations proceed through an open transition state and 
the resulting product is predominantly syn, independent of the geometry of the crotyl reagent 
(Scheme 2.2B). Finally, in type 3 crotylations, the crotyl reagent isomerizes to only the trans-
crotyl reagent, which crotylates through a closed transition state, giving predominantly anti 
product (Scheme 2.2C). 
 
Scheme 2.2.Types of crotylation reactions 
Extensive efforts have been dedicated to developing a method that is characterized by (1) 
wide substrate scope and generality, (2) access to either product diastereomer with high 
selectivity, and (3) sustainable, safe, practical, and scalable reaction procedures. Despite several 
important conceptual and practical advances over the last three decades,9-17 the Brown crotyla-
tion protocol,18-19 developed in 1986, still remains the method of choice by most chemists, as it is 
the only methodology that meets most of the conditions described above. The Brown crotylation, 
which utilizes diisopinocampheylboranes, has demonstrated high levels of reagent control in 
terms of stereoselectivity, overriding the intrinsic preference of most substrates. Additionally, the 























































crotylation suffers from difficulties in product isolationa and from being quite labor intensive, 
requiring the metallation of butene under cryogenic conditions. Against this backdrop, the 
Leighton group has long been interested in developing a crotylation methodology that is more 
general, scalable, and operationally simple than the Brown method.  
 
2.1.2. Development of Leighton group asymmetric crotylation 
Table 2.1. Leighton Crotylation 
 
Among our initial contributions to the field of crotylation chemistry was the discovery of 
reagents 2.4 that are able to diastereoselectively and enantioselectively allylate and crotylate 
simple aldehydes under operationally simple conditions (Table 2.1).14,20 Inspiration for this work 
originated from a study by Utimoto and coworkers who demonstrated the allylation of aldehydes 
by allylsilacyclobutanes 2.7, while similar acyclic allylsilane 2.5 is unreactive (Scheme 2.3A).21 
In contrast to unstrained crotylsilanes, which generally require an external Lewis acid to effect 
crotyl transfer, silanes 2.7 are Lewis acidic as a result of being constrained to a 4-membered ring. 
This observed so-called ‘strain release Lewis acidity’ (a term first coined by Denmark and 
coworkers22) refers to the ability to readily accept nucleophiles to relieve angle strain by rehybri-
dizing to a new geometry. In 2.7, the bond angle at silicon is compressed to ~80° from an ideal 
angle of 109.5° for an acyclic tetrahedral geometry. Upon coordination with a nucleophile, the 
                                                
a Cleaving the borane from the product usually entails oxidative conditions that generate 2 equivalents of 









(R,R)-2.4a: R1 = R2 = H
(R,R)-2.4b: R1 = Me, R2 = H































silicon rehybridizes to a trigonalbipyramidal geometry where the compressed 80° angle is better 
accommodated by spanning an axial and an equatorial position (Scheme 2.3B).  
 
Scheme 2.3. A) Utimoto’s experiments. B) Rationale for strain release Lewis acidity22 
The Leighton group demonstrated that this concept of strain-release Lewis acidity can 
also be applied to 5-membered silacycles such as 2.4, since the long N-Si bonds and short C-N 
bonds result in a N-Si-N bond angle of ~90°.23 For both 2.4 and 2.7, upon activating aldehyde 
substrates toward nucleophilic addition, the silane rehybridizes and undergoes crotyl transfer via 
a closed transition state to provide the corresponding homoallylic alcohols. This reaction 
mechanism is supported by the observation of high diastereoselectivity, wherein the anti/syn 
product ratio reflects the E/Z ratio of the reagent. 
While the original Leighton crotylation protocol was robust and procedurally straight-
forward, the substrate scope was rather limited. As seen in Table 2.1, silanes 2.4 cannot tolerate 
deactivated and sterically hindered substrates like α-methylcinnamaldehyde.14,24 A key discovery 
that addressed this limitation came in 2011, when we observed that Brønsted and Lewis acids, 
Sc(OTf)3 in particular, are able to catalyze these crotylations reactions (Scheme 2.4A).24 This 
discovery resulted in significantly shorter reaction times and an extended substrate scope. 
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2.7a: R1 = R2 = H
2.7b: R1 = n-Pr, R2 = H











































which is a 25:1 mixture of 2.4:Sc(OTf)3 available through Sigma (737666 and 737682). A 
typical reaction entails simply adding the desired isomer of EZ-CrotylMix to a solution of the 
aldehyde at 0 °C. After complete conversion (usually 1 h), 1 M TBAF solution is added to cleave 
the silane from the product, providing the products in high yields and selectivities. Most 
impressively, in the presence of Sc(OTf)3, silane 2.4b is able to crotylate aldehydes 2.9 and 2.11 
to give homoallylic alcohols 2.10 and 2.12, respectively, which possess stereochemical arrays 
that cannot be achieved by the Brown crotylation protocol (Scheme 2.4B).25-26  
 
Scheme 2.4. A) Effects of catalytic Sc(OTf)3 on Leighton crotylation. B) Leighton crotylation of aldehydes not 
tolerated by Brown crotylation 
The remarkable increase in reactivity is believed to be due to Sc(OTf)3 activation of 
silanes 2.4 as opposed to activation of the aldehyde substrate. Sc(OTf)3 interaction with one of 
the nitrogens as depicted in 2.13 (Scheme 2.5) attenuates N to Si π-type donation. Consequently, 
the silicon becomes more Lewis acidic and more readily accepts the aldehyde substrate to 
promote crotyl transfer. Conversely, Sc(OTf)3 activation of the aldehyde would constitute a type 
2 reaction mechanism, resulting in predominantly syn-product, which is not observed.  
 









(S,S)-2.4b: R1 = Me, R2 = H
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This mechanism is further supported by previous work in our group on the allylation of 
hydrazones by silane 2.14 (Scheme 2.6A).27-28 Thorough investigation suggests the mechanism 
of this reaction as depicted in Scheme 2.6A, where the protic nucleophilic substrate 2.15 
displaces the chloride on silane 2.14, generating an equivalent of HCl that protonates the 
nitrogen and leads to a boost in reactivity. NMR analysis and x-ray crystal structure of 2.20 
(Scheme 2.6B), demonstrating the previously described key protonation event, provided 
additional evidence to support our proposed mechanism. Other groups have also shown that 
Brønsted and Lewis acids can catalyze the reaction between allylboronates and aldehydes by 
binding or protonating the boronate oxygen, as opposed to activating the aldehyde.29-35 
 
Scheme 2.6. A) Proposed mechanism for allylation of hydrazones. B) Crystal structure supporting proposed 
mechanism. 
Although the aforementioned methodology represents the most comprehensive and 
highly practical method for enantioselective aldehyde crotylation to date, it is not without its 
limitations. To start, this crotylation reaction has poor atom economy due to the bromine atoms 
required for crystallinity, which is reflected in the need for such heavy reagents (569 g mol-1) to 
transfer only four carbons. And importantly, silane 2.4 cannot be offered at a low enough price 




































































the EZ-CrotylMixes remain a highly attractive option for small-scale reactions, the important 
goal of devising an equally user-friendly and scalable yet inexpensive alternative remains unmet. 
 
2.1.3. Goals and experiment design  
In accordance with our goals for the AB-CD coupling in the synthesis of spongistatin 1, 
we were interested in developing a more practical and scalable enantioselective crotylation 
reaction by improving the reagent isolation process. Currently, preparation of the EZ-Crotyl-
Mixes involves forming the silane by the reaction of 2.21, crotyltrichlorosilane 2.22, and DBU, 
then removing CH2Cl2, triturating and filtering the DBU•HCl salts with pentane, concentrating 
the filtrate and recrystallizing 2.4, and finally admixture with Sc(OTf)3 catalyst (Scheme 2.7A). 
The additional requirement for this process to occur under strictly anhydrous conditions 
exacerbates the cost to prepare the EZ-CrotylMixes. For larger scale applications, it seems clear 
that the ideal approach would involve skipping all of these technically challenging operations 
and instead simply adding the Sc(OTf)3 catalyst and the aldehyde to the crotylsilane reagent in 
situ. Unfortunately, under these conditions no catalysis is observed (Scheme 2.7B), a failure 
which may be attributed to deactivation of the Sc(OTf)3 by the large quantities of chloride ion 
present in the mixture. 
 
Scheme 2.7. A) The procedure for preparation of the EZ-CrotylMixes. B) Attempts to form and employ the EZ-










   filter DBU•HCl salts
   with pentane
iii. concentrate, and
    recrystallize
iv. add 0.04 equiv.



















ii. add 0.04 equiv.











At the outset we were aware of two main strategies to circumvent this technically chal-
lenging isolation process: (1) develop a more moisture stable crotylation reagent, which would 
circumvent the anhydrous conditions required for reagent isolation; or (2) develop a more active 
crotylation reagent, which would eliminate the need for the Sc(OTf)3 and therefore the need for 
reagent isolation. Without any great leads on how to design a more active crotyl silane reagent, 
we targeted improving the moisture stability of the reagents. In addition to a simpler isolation 
process, the design of a new reagent may also give opportunities to reduce the molecular weight 
and increase the atom economy of the reagent. 
 
2.2. Investigation of alkoxy crotyl silanes 
Our initial approach to increasing the moisture stability of our crotyl silane reagents 
entailed studying the efficacy of their alkoxy crotyl silanes derivatives, which we hoped would 
display greater hydrolytic stability. Preparation of alkoxy silanes 2.24 - 2.25 was straightforward 
by displacement of the chloride from the corresponding chlorosilanes 2.4a and 2.23 with 
alcohols (Scheme 2.8A). After their preparation and isolation from the DBU•HCl salt 
byproducts, the alkoxy silanes 2.24 - 2.25 were evaluated in allylation reactions with trans-α-
methylcinnamaldehyde (2.26) in the presence of excess of Sc(OTf)3 (20 mol%), which was used 
to ensure reactivity, if any. As described by Scheme 2.8B, silanes 2.24a-c exhibited reactivity 
similar to the parent chlorosilane, albeit with slightly reduced enantioselectivities (entries 1-3). It 
should also be noted that in the absence of Sc(OTf)3, silanes 2.24 are unreactive towards 
aldehyde 2.26, similar to the parent chlorosilane 2.4a. Silanes 2.25a-c with methyl substitution 
on the nitrogens are also able to allylate 2.26, but provided the products with much lower yields. 
This is particularly interesting since the p-bromobenzyl substituents were originally introduced 
32 
only to induce crystallinity in the parent chlorosilanes 2.4a and it has been observed that the 
chlorosilane 2.23 with methyl substitution on the nitrogens are just as able to efficiently allylate.  
 
Scheme 2.8. A) Preparation of alkoxysilanes. B) Reactivity of alkoxysilanes. 
Hypothesizing that bulkier substituents are necessary for an efficient reaction, diisobutyl 
substituted chlorosilane 2.28 was also prepared and evaluated (Scheme 2.9). Unfortunately, both 
the yield and enantioselectivity were significantly lower than what was observed for silane 2.4a; 
consequently, the corresponding alkoxy silanes were not investigated. This data suggests that 
high enantioselectivity requires benzyl or even larger benzyl type substituents on the nitrogens, 
which were not pursued for the sake of atom economy.  
 
Scheme 2.9. Reactivity of N,N’-diisopropyldiaminoallylsilane 2.28 
In terms of moisture stability, while rigorous kinetics experiments were not performed, 
2.24 - 2.25 qualitatively did not appear to be more hydrolytically stable than 2.4a and could not 
be exposed to air for extended periods of time without decomposition. This observation suggests 

















































2.4a: R1 = p-BrC6H4CH2
2.23: R1 = Me
2.24a: R1 = p-BrC6H4CH2, R2 = Me
2.24b: R1 = p-BrC6H4CH2, R2 = Ph
2.24c: R1 = p-BrC6H4CH2, R2 = Bn
2.25a: R1 = Me, R2 = Me
2.25b: R1 = Me, R2 = Ph























that the Si-N bonds are also prone to hydrolysis. From the above data, silanes 2.24 - 2.25 seem to 
be competent allylation reagents, but require additional stabilization. 
 
2.3. Development of a more practical and scalable crotylation methodology36 
2.3.1. Discovery of a more powerfully activating diamine for allylsilylations 
In order to try to increase the moisture stability of the alkoxy silanes, we investigated 
silane 2.30, with the notion that 3 points of attachment from the tridentate ligand backbone to the 
silicon could lend itself to stabilize the resulting silane (Figure 2.1). This type of silane motif was 
previously studied in our group when silane 2.29 was developed as a Diels-Alder catalyst.20 
Using the same diaminophenol, 2.30 was formed as previously described, but unlike 2.29, 2.30 
formed as a mixture of silane products, which was unreactive towards benzaldehyde.  
 
Figure 2.1. New proposed motif for crotylsilane reagents 
Undeterred, we altered the diaminophenol to be more similar to our original crotylation 
system and arrived at silane 2.31, which formed by treatment of diaminophenol 2.32 with 
allyltrichlorosilane and DBU (Scheme 2.10). After isolation from the DBU•HCl salts, 2.31 was 
found to allylate hydrocinnamaldehyde (2.33) in the presence of 20 mol% Sc(OTf)3, and provide 
the desired product 2.34 in 52% yield and 88% ee along with recovered starting material. Despite 
significant efforts to improve the yield by varying temperature, reaction time, and concentration, 
the yield remained about the same. Ultimately, through monitoring the reaction by NMR, it was 
revealed that complete consumption of the 2.33 occurred within 2 hours, suggesting that 2.33 



















formation of a hemiacetal type intermediate 2.35; however, due to the complexity of the reaction 
NMR, it did not conclusively support acetal formation.  
 
Scheme 2.10. Initial results for allylation using silane 2.31 
Consequently, we took a more indirect approach to determine whether this side pathway 
was occurring. If 2.31 were in fact transferring its phenoxy group, then we should be able to shut 
down the process by increasing the steric bulk at the position ortho to the phenol hydroxyl. In 
this regard, silane 2.36 was evaluated (Scheme 2.11), and to our delight, methyl substitution at 
the ortho position resulted in higher yields and ee for the allylation of hydrocinnamaldehyde  
 












































(S,S)-2.36: R1 = Me
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(2.33) and similarly high yields and ee for cinnamaldehyde (2.38) and α-methylcinnamaldehyde 
(2.26). Further increasing the sterics by tert-butyl substitution on silane 2.37 led to even better 
enantioselectivities, while the yields were similar to those of silane 2.36 (Scheme 2.11).  
Silane 2.37, which gave the best results, was taken on for further optimization of the 
catalyst loading (Scheme 2.12). To determine baseline reactivity, 2.37 was reacted with 
aldehydes 2.33, 2.38, and 2.26 in the absence of Sc(OTf)3, and to our surprise, the yields and ee 
were as high as previously observed when 20 mol% Sc(OTf)3 was used (Scheme 2.11). The 
ability of 2.37 to allylate α-methylcinnamaldehyde (2.26) was especially exciting because the 
first-generation silane 2.4 is unreactive towards 2.26 in the absence of Sc(OTf)3 (Table 2.1). Our 
thoughts on the source of this extraordinary reactivity will be further discussed in Section 2.3.5. 
 
Scheme 2.12. Allylation of aldehydes in the absence of Sc(OTf)3  
 Proton NMR analysis revealed that 2.37 forms as a single major compound. Extensive 
NMR experiments to assign relevant protons enabled the observation of the key nOe interactions 
depicted in Figure 2.2, which are consistent with the assigned stereochemistry at silicon. 
 













































2.3.2. Development of a one-pot crotylation methodology 
Since our main goal was to develop a more moisture stable crotyl silane reagent, we 
qualitatively examined the moisture stability of 2.37 to exposure to air, and found that it was 
moisture-sensitive and could not be stored for extended periods of time. In hindsight, this result 
is not surprising, given the remarkably high reactivity of 2.37 toward aldehydes. Nonetheless, 
this prompted us to attempt the crotylation reaction as a one-pot procedure without the prior iso-
lation of 2.37. As previously discussed (Section 2.1.3), the isolation of the first-generation silane 
reagent 2.4 was required solely to ensure the activity of the Sc(OTf)3 catalyst, and therefore we 
were optimistic about a one-pot procedure, considering the high reactivity of 2.37 without 
Sc(OTf)3. This would be a nice solution to the main limitation of our methodology, especially 
since diaminophenol 2.40 is a bench stable crystalline solid that can be stored for extended per-
iods of time. Accordingly, 2.40 was treated with DBU and allyltrichlorosilane, forming 2.37 in 
situ (Scheme 2.13). Aldehyde 2.26 was then added directly to the reaction mixture and stirred for 
1h. Upon quenching with TBAF, the product was isolated in an impressive 94% yield and 96% 
ee. Compared to the results for the similar reaction using isolated silane 2.37 (Scheme 2.12), the 
one-pot procedure gave improved yields and similarly high levels of enantioselectivity.  
 
Scheme 2.13. Proof of concept for one-pot crotylation reaction 
Since diaminophenol 2.40 requires a few steps to prepare, as will be described in Section 
2.3.3, it is the most expensive component in this crotylation reaction. Therefore, to improve the 
practicality of this methodology, work-up conditions were devised to allow for the recovery of 
OH
1. 
    DBU, CH2Cl2,
    0 °C → 23 °C
2. cool to 0 °C,








94%, 96% ee(S,S)-2.40 2.27
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2.40. In the new work-up conditions the product is cleaved from the silane by treatment with 
TBAF, followed by an acidic aqueous workup to separate 2.40 from the product. Recrystal-
lization from a solution of hot methanol and water then provides 2.40 in greater than 90% 
recovery. However, care must be taken during the recrystallization to prevent unwanted 
decomposition of 2.40 when heated above 80 °C.  
The practicality of this methodology was further demonstrated by recycling 2.40 through 
multiple crotylation reactions of aldehyde 2.41 (Table 2.2). In these experiments, we started with 
30.0 mmol of 2.40 (8.71 g), which was able to provide 4.9 g of 2.42 (87% yield, 95% ee). 2.40 
(8.1 g, 93%) was recovered from this reaction and resubjected to a second and then a third 
crotyllation reaction. After 3 cycles, we prepared 14.1 g (68.3 mmol) of 2.42 starting from only 
30.0 mmol of 2.40, and we still had 22.2 mmol of 2.40 remaining at the end. Because of the 
experimentally straightforward procedure and efficient recovery of diaminophenol 2.40 by 
recrystallization, we believe this methodology has significant potential for commercialization. 
Table 2.2. Recycling of diaminophenol 2.40 
 
 
2.3.3. Preparation of diaminophenol 2.40 
With a robust and practical experimental procedure in place, we turned to improving the 
synthesis of diaminophenol 2.40 for experimentally straightforward production on multi-gram 
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For our initial purposes, this route reliably provided gram quantities of 2.40 in high yields,b but 
there were a number of improvements that could be made. To start, we learned, through conver-
sation with chemical companies, that 3,5-di-tert-butyl alternative to aldehyde 2.46 would be 
significantly less expensive to produce due to its wide spread use. While an additional tert-butyl 
group potentially would not affect the efficiency of the crotylation reaction, it did result in an 
oily diaminophenol, unlike 2.40, which is a crystalline solid. The crystallinity of 2.40 was desira-
ble in terms of storage, recovery from crotylation reactions, and purification by recrystallization. 
Consequently, we opted to keep 2.46, which can easily be prepared from tert-butyl phenol and 
paraformaldehyde and distilled to purity on large scales. 
 
Scheme 2.14. Preparation of diaminophenol 2.40 
The first step, entailing a mono-Boc protection of diamine 2.43, was also particularly 
troubling since it was not completely selective, relatively low yielding, and required Boc anhy-
dride, which is expensive. To solve this problem, Brian Trippe, an undergraduate in our group, 
investigated using methylchloroformate as a less expensive alternative to Boc anhydride 
(Scheme 2.15). Unfortunately, it was determined that methylchloroformate did not perform 
similarly to Boc anhydride under the same reaction conditions, giving an inseparable mixture of 
mono-protected product 2.47 and starting diamine 2.43. Upon nucleophilic addition by an amine, 
unlike Boc anhydride, methylchloroformate releases an equivalent of HCl that is able to proton-
ate another amine nitrogen and ultimately results in an incomplete reaction. 
                                                




























Scheme 2.15. Mono methyl-carbamate formation 
This result led us to test basic additives to absorb the HCl byproduct (Scheme 2.15). 
Protonated 1,2-diaminoalkanes have pKas of approximately 7 and 10 for the first and second 
proton, respectively.37-38 The difference of the pKa values is due to the electronic repulsion that 
arises from having vicinal cations. The bases we tested have pKas between 7-10 and therefore 
should not deprotonate the mono-protonated diaminocyclohexane, but are basic enough to absorb 
excess acid before the bis-protonation occurs. Of the bases screened, tetramethylpiperidine and 
NaHCO3 were effective in providing the desired product in high yields and selectivity for mono-
protection. Ultimately, NaHCO3 was chosen to be the ideal base since it is inexpensive and can 
be easily separated from the product 2.47. Furthermore, the amount of bis-protection product 
2.48 observed in Scheme 2.15 can be eliminated by slow addition of methylchloroformate at 0 
°C, providing 2.47 in 81% yield (Scheme 2.16). 
 
Scheme 2.16. Improved route toward 2.40 
The resulting synthetic sequence to prepare 2.40, as depicted in Scheme 2.16, entails a 
mono-carbamate protection of diaminocyclohexane, imine condensation, and exhaustive LiAlH4 
reduction to provide the desired product in 67% yield over 3 steps. The most attractive feature of 
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recrystallization (step 2 and 3). Furthermore 22 g of 2.40 was prepared at once without any 
noticeable impediments to larger scales. 
 
2.3.4. Substrate scope 
Table 2.3. Substrate scope for one-pot crotylation protocol36 
 
 
With a scalable and straightforward route to diaminophenol 2.40 established, we were 
able to quickly investigate the substrate scope of this methodology. We primarily focused on 
simple aldehydes that are generally used in the early stages of polyketide total synthesis, when 
large scale synthesis is most common. As seen in Table 2.3, all products were produced in high 











































































OH1. DBU, CH2Cl2,    0 °C → 23 °C, 1h
2. cool to 0 °C,










2.22a: R1 = R2 = H
2.22ba: R1 = Me, R2 = H
2.22cb: R1 = H, R2 = Me
(R,R)-2.40
All reported yields are for isolated product. TBAF/HCl work-up to also recover diamine 2.40 was employed unless otherwise noted. See experimental for 
additional information. a The geometric purity was measured to be >99:1 by 1H NMR. b The geometric purity was measured to be 95:5 by 1H NMR. 




(2.57 – 2.60) starting from the popular Roche ester derived aldehydes. The preparation of 
products 2.53 and 2.56 were particularly exciting since the alternative procedure using the first 
generation silane reagents 2.4 with Sc(OTf)3 resulted in eroded yields due to decomposition. 
This methodology has already found utility in our recently reported total synthesis of dictyosta-
tin,39-40 where the present methodology was more easily scalable compared to our first generation 
crotylsilane reagent, allowing access to product 2.62 in 79-88% yield and 15:1 dr on scales up to 
10 grams without significant deprotection of the acetal, unlike with reagent 2.4b (Scheme 2.17).  
 
Scheme 2.17. Application of one-pot crotylation to the synthesis of dictyostatin 
 
2.3.5. Explanations for observed reactivity 
The remarkable and dramatic difference in reactivity between silane 2.24b and 2.37 
(Table 2.4) is intriguing due to the similarities of their structures, and requires comment. We 
propose that the increase in reactivity in 2.37 can be attributed to stereoelectronic effects that 
render it more Lewis acidic. The 29Si NMR chemical shifts are consistent with our hypothesis; 
the silicon in 2.24b and 2.37 have chemical shifts of -25.2 ppm and -15.4 ppm, respectively 
(entry 1, Table 2.4). This data suggests 2.37 is less electron rich relative to 2.24b.  
In collaboration with Dr. Michael Steigerwald, DFT calculations of 2.24b and 2.37 were 
performed in order to gain insight into the nature of these stereoelectronic effects.36 From Table 
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2.62 79-88%, 15:1 dr
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suggestive of π-type donation from oxygen to the Si-N1 antibonding orbital, which reduces the 
Lewis acidity of the silicon. And while the differences are small, the shorter O-Si bond distance 
and larger C3-O-Si bond angle (entry 3 and 4) in 2.24b are consistent with greater O to Si π-type 
donation and therefore reduced Lewis acidity. Transition state effects are also most likely 
relevant, such that silane 2.24b is freer to rotate than is 2.37, allowing for constant O to Si 
donation along the reaction coordinate, which is not possible for 2.37. Additionally, N to Si π-
type donation is implicated by the observed planarization of N1 in the case of both 2.24b and 
2.37 (entry 5). In contrast, N2 in 2.37 is more pyramidalized than in 2.24b (entry 6), due to 
occupying a bridgehead position, which forces the N2 lone pair out of alignment for N to Si π-
type donation and raises the Lewis acidity of 2.37. From this analysis, we’ve discovered a new 
mode of silicon activation in our family of allylsilane reagents. In the case of the first-generation 
chlorosilanes 2.4, Sc(OTf)3 catalyst serves to bind to nitrogen to attenuate its π-type donation to 
the Si-Cl antibonding orbital (Scheme 2.5). Alternatively, conformational constraints can also 
counteract these deactivating interactions, as observed in 2.37.   












































2.4. Summary and outlook 
Through this work, we discovered a new mode of silicon activation, thereby broadening 
our understanding of this class of strained silane reagents. We believe the extraordinary 
reactivity of silane 2.37 is due to conformational constraints that attenuate stereoelectronic 
deactivation of silicon. This discovery in turn led to the development of a highly practical and 
scalable one-pot crotylation procedure, which was made possible by eliminating the need for the 
use of the expensive Sc(OTf)3 catalyst. The practicality of this one-pot crotylation protocol was 
illustrated by the ability to recover and recycle 30 mmol of diaminophenol 2.40 to prepare nearly 
70 mmols of a desired homoallylic alcohol with 95% ee and still have 22 mmol of 2.40 
remaining after 3 cycles, highlighting the significant potential for commercialization of this 
methodology. 
 Although we have established computational data suggesting the role of conformational 
constraints in silicon activation, we are interested in experimentally verifying this concept, which 
is current ongoing work. In the meantime, we are excited about the discovery of a one-pot 








2.5. Experimental procedures36 
General Information. All reactions were carried out under an atmosphere of nitrogen in flame-
dried glassware with magnetic stirring unless otherwise indicated. Degassed solvents were 
purified by passage through an activated alumina column. Thin-layer chromatography (TLC) 
was carried out on glass backed silica gel TLC plates (250 mm) from Silicycle; visualization by 
UV light and/or phosphomolybdic acid (PMA). HPLC analysis was carried out on an Agilent 
1200 Series using either a Chiralpak AD-H (250 x 4.5 mm ID) column or Chiralcel OD-H 
(250x4.5 mm ID) column. 1H NMR spectra were recorded on a Bruker AVIII 300 (300 MHz), 
AVIII 400 (400 MHz), AVIII 500 (500 MHz) or AVIII 500 Ascend (500 MHz) spectrometer and 
are reported in ppm, relative to residual protonated solvent peak (CDCl3, 7.26 ppm; C6D6, 7.16 
ppm). Data are reported as follows: (bs= broad singlet, s = singlet, d = doublet, t = triplet, m = 
multiplet, dd = doublet of doublets, ddd = doublet of doublet of doublets, ddt = doublet of 
doublet of triplets, td = triplet of doublets; coupling constant(s) in Hz; integration). Proton 
decoupled 13C NMR spectra were recorded on a Bruker AVIII 400 (100 MHz), AVIII 500 (126 
MHz) or AVIII 500 Ascend (126 MHz) spectrometer and are reported in ppm from CDCl3 
internal standard (77.23 ppm). 29Si NMR spectra were recorded on a Bruker AVIII 400 (79 
MHz) or AVIII 500 (100 MHz) and are reported in ppm relative to TMS (0.00 ppm) internal 
standard. 19F NMR spectra were recorded on a Bruker AVIII 400 (376 MHz) and are reported in 
ppm relative to α,α,α-trifluorotoluene (-63.72 ppm) internal standard. Infrared spectra were 
recorded on a Nicolet Avatar 370DTGS FT-IR. Optical rotations were recorded on a Jasco DIP-
1000 digital polarimeter. (APCI)-MS was conducted on a JMS-LCmate LCMS (JEOL). Melting 
points were determined using a Stanford Research Systems DigiMelt apparatus. 
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2.5.1. Preparation of diaminophenol 2.40 
 
Compound 2.44 was prepared using a modified literature procedure.41 To a cooled (0 °C) 
solution of conc. HCl (32.4 mL, 394 mmol) in MeOH (126 mL) was added (R,R)-diaminocyclo-
hexane (45.0 g, 394 mmol). The ice water bath was removed, and after 15 min, water (42.0 mL) 
was added. After 30 min, a solution of Boc2O (90.6 mL, 394 mmol) in MeOH (42 mL) was 
added slowly and the resulting mixture was stirred for 12 h. The mixture was concentrated and 
the residue was resuspended in Et2O (100 mL), and collected by filtration, rinsing with Et2O to 
remove any unprotected diaminocyclohexane. The resulting residue was treated with 3 N NaOH 
(285 mL) and extracted with CH2Cl2 (3 x 125 mL). The combined organic layers were dried over 
MgSO4, filtered and concentrated to give 2.44 as a beige solid (55.2 g, 257 mmol, 65%) that was 
used without further purification. 1H NMR (400 MHz, CDCl3) δ 4.43 (bs, 1H), 3.23 – 2.95 (m, 
1H), 2.31 (td, J = 10.4, 4.0 Hz, 1H), 2.06 – 1.88 (m, 2H), 1.78 – 1.63 (m, 2H), 1.45 (s, 9H), 1.38 
– 0.99 (m, 6H). The 1H NMR spectroscopic data is in agreement with data reported in 
literature.41-42 
  
To a cooled (0 °C) solution of conc. HCl (8.0 mL, 96.5 mmol) in MeOH (30.4 mL) was 
added (R,R)-diaminocyclohexane (11.0 g, 96.5 mmol), rinsing with MeOH (10.0 mL). The ice 
water bath was removed, and after 15 min, water (10.0 mL) was added followed by NaHCO3 
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stir, was cooled to 0 °C and a solution of methylchloroformate (7.5 mL, 96.5 mmol) in MeOH 
(10.0 mL) was added dropwise. The resulting mixture was stirred for 12 h as the ice bath thawed 
to room temperature. The mixture transferred to a separatory funnel with water (50 mL) and 
washed with Et2O (2 x 50 mL). The organic layes were discarded and the aqueous layer was 
treated with NaOH (15% aqueous solution) until the pH was greater than 10. The desired product 
was extracted with CH2Cl2 (5 x 50 mL) and the combined organic layers were dried over 
Na2SO4, filtered and concentrated to give 2.47 as a white solid (13.4 g, 77.9 mmol, 81%) that 
was used without further purification. 1H NMR (300 MHz, CDCl3) δ 4.80 (s, 1H), 3.64 (s, 3H), 
3.13 (qd, J = 9.7, 4.0 Hz, 1H), 2.33 (td, J = 10.2, 4.0 Hz, 1H), 2.03 – 1.85 (m, 2H), 1.75 – 1.60 
(m, 2H), 1.44 – 1.33 (m, 2H), 1.31 – 1.01 (m, 4H). The 1H NMR spectroscopic data is in 
agreement with data reported in literature.43 
 
Aldehyde 2.46 was prepared using a modified literature procedure.44 To a solution of 2-
tert-butyl phenol (30.6 mL, 200 mmol) in acetonitrile (400 mL) was added paraformaldehyde 
(40.4 g, 1.35 mol), MgCl2 (28.6 g, 300 mmol) and Et3N (104.4 mL, 748 mmol). The resulting 
mixture was heated to reflux and stirred for 5 h. The mixture was cooled to room temperature 
and 5% HCl (200 mL) was added. The mixture was extracted with CH2Cl2 (3 x 125 mL). The 
combined organic layers were concentrated and the residue was partitioned between Et2O (250 
mL) and H2O (250 mL). The layers were separated and the Et2O layer was washed with brine (1 
x 100 mL), dried over Na2SO4, filtered and concentrated. The resulting oil was vacuum distilled 
(bp ~73 °C @ ~5 mm Hg) to give aldehyde 2.46 as a pale yellow oil (20.7 g, 116 mmol, 58% 











7.40 (dd, J = 7.7, 1.7 Hz, 1H), 6.95 (t, J = 7.7 Hz, 1H), 1.43 (s, 9H). The 1H NMR spectroscopic 
data is in agreement with data reported in literature.44 
 
To a solution of compound 2.44 (24.9 g, 116 mmol) in EtOH (1.1 L), was added alde-
hyde 2.46 (20.7 g, 116 mmol). The mixture was heated to reflux and stirred for 3 h. The mixture 
was cooled to room temperature and concentrated. The residue was recrystallized from minimal 
boiling EtOH to give imine 2.45 as long yellow crystals (39.2 g, 105 mmol, 90% yield). m.p. 
153 – 155 °C; 1H NMR (400 MHz, CDCl3) δ 13.73 (bs, 1H), 8.35 (s, 1H), 7.32 (dd, J = 7.8, 1.7 
Hz, 1H), 7.11 (dd, J = 7.6, 1.7 Hz, 1H), 6.81 (t, J = 7.6 Hz, 1H), 4.37 (bs, 1H), 3.73 – 3.40 (m, 
1H), 3.04 (bs, 1H), 2.18 – 2.02 (m, 1H), 1.98 – 1.87 (m, 1H), 1.87 – 1.64 (m, 3H), 1.46 – 1.30 
(m, 3H) 1.45 (s, 9H), 1.31 (s, 9H); 13C NMR (101 MHz, CDCl3) δ 165.02, 160.64, 155.39, 
137.55, 129.85, 129.44, 118.87, 117.82, 79.49, 77.43, 72.87, 54.55, 35.02, 33.64, 32.00, 29.57, 
28.37, 25.06, 24.31; IR (thin film, cm-1) 3437, 3338, 2936, 2859, 2243, 1688, 1630, 1505, 1436, 






























 To a solution of compound 2.47 (17.2 g, 100 mmol) in EtOH (330 mL), was added 
aldehyde 2.46 (19.0 mL, 110 mmol). The mixture was heated to reflux and stirred for 3 h. The 
mixture was cooled to room temperature and concentrated. The residue was recrystallized from 
minimal boiling hexanes to give imine 2.49 as yellow crystals (30.2 g, 91 mmol, 91% yield). 1H 
NMR (500 MHz, CDCl3) δ 13.69 (s, 1H), 8.32 (s, 1H), 7.31 (dd, J = 7.8, 1.7 Hz, 1H), 7.09 (dd, J 
= 7.6, 1.6 Hz, 1H), 6.80 (t, J = 7.6 Hz, 1H), 4.66 (s, 1H), 3.66 (tdd, J = 13.1, 10.3, 5.7 Hz, 1H), 
3.56 (s, 3H), 3.11 (s, 1H), 2.19 – 1.98 (m, 1H), 1.92 – 1.83 (m, 1H), 1.83 – 1.73 (m, 2H), 1.73 – 
1.61 (m, 1H), 1.44 (s, 9H), 1.44 – 1.31 (m, 4H). 13C NMR (126 MHz, CDCl3) δ 165.07, 160.47, 
156.56, 137.39, 129.82, 129.42, 118.67, 117.80, 77.42, 77.36, 77.16, 76.95, 76.91, 71.61, 55.00, 
52.08, 34.91, 33.61, 31.76, 29.43, 24.77, 24.13. IR (thin film, cm-1) 3312.00, 2937.66, 2859.38, 
1699.65, 1628.09, 1539.35, 1435.57, 1359.46, 1306.81, 1261.40, 1196.75, 1145.44, 1032.34, 
850.06, 750.88. OR [α]D26 -86.1º (CHCl3, c 1.0). HRMS (ASAP+) calculated for C19H29N2O3 
[M+H]+ 333.2178; Found 333.2195. 
 
A 2-L roundbottom flask equipped with an addition funnel was charged with LiAlH4 
(13.0 g, 343 mmol) and THF (600 mL) and the resulting mixture was cooled to 0 °C. A solution 
of 2.45 (42.8 g, 114 mmol) in THF (300 mL) was added slowly via the addition funnel, with a 
THF rinse (100 mL). The mixture was warmed to room temperature and stirred for 2 h. The 
addition funnel was replaced with a reflux condenser and the mixture was heated to reflux for 12 
h. The mixture was cooled to 0 °C, and the reaction was quenched by the CAREFUL and SLOW 














organic layers were dried over MgSO4, filtered and concentrated. The resulting beige solid was 
purified by recrystallization from minimal boiling hexanes to give diaminophenol 2.40 as white 
crystals (30.2 g, 104 mmol, 91% yield). m.p. 114-116 °C; 1H NMR (400 MHz, CDCl3) δ 7.17 
(dd, J = 7.9, 1.6 Hz, 1H), 6.92 – 6.80 (m, 1H), 6.70 (t, J = 7.6 Hz, 1H), 4.01 (d, J = 13.4 Hz, 1H), 
3.83 (d, J = 13.5 Hz, 1H), 2.39 (s, 3H), 2.24-2.08 (m, 4H), 1.82 – 1.64 (m, 2H), 1.42 (s, 9H), 
1.31 – 1.11 (m, 3H), 1.03 – 0.85 (m, 1H); 13C NMR (126 MHz, CDCl3) δ 157.49, 136.88, 
126.27, 125.77, 124.47, 118.16, 62.46, 62.22, 51.02, 34.85, 33.59, 31.24, 31.16, 29.74, 25.33, 
24.83; IR (thin film, cm-1) 3299, 3217, 2927, 2854, 2797, 2641, 1590, 1430, 1352, 1240, 1084, 
747; HRMS (FAB+) calculated for C18H31ON2 [M+H]+ 291.2436, found 291.2443. 
  
A 2-L roundbottom flask equipped with an addition funnel was charged with LiAlH4 
(9.60 g g, 253 mmol) and THF (600 mL) and the resulting mixture was cooled to 0 °C. A 
solution of 2.49 (28.0 g, 84.2 mmol) in THF (200 mL) was added slowly via the addition funnel, 
with a THF rinse (40 mL). The mixture was warmed to room temperature and stirred for 1 h. The 
addition funnel was replaced with a reflux condenser and the mixture was heated to reflux for 12 
h. The product was isolated using the Fieser and Fieser workup as follows. The mixture was 
cooled to 0 °C, and the reaction was quenched by the CAREFUL and SLOW sequential addition 
of water (9.6 mL), 15% aq. NaOH (9.6 mL) and additional water (28.8 mL). The resulting 
mixture was stirred for 10 min at room temperature. The mixture was dried by stirring with 
excess MgSO4 for an additional 20 min. The fine white solids were removed filtration and the 














from minimal boiling hexanes to give diaminophenol 2.40 as white crystals (22.1 g, 76.1 mmol, 
91% yield). The 1H NMR spectroscopic data is in agreement with data reported in literature.36 1H 
NMR (500 MHz, CDCl3) δ 7.17 (dd, J = 7.9, 1.6 Hz, 1H), 6.89 – 6.79 (m, 1H), 6.70 (t, J = 7.6 
Hz, 1H), 4.01 (d, J = 13.5 Hz, 1H), 3.83 (d, J = 13.5 Hz, 1H), 2.98 (s, 1H), 2.39 (s, 3H), 2.27 – 
2.05 (m, 4H), 1.79 – 1.62 (m, 2H), 1.42 (s, 9H), 1.23 (dddd, J = 20.0, 16.6, 11.4, 8.6 Hz, 3H), 
1.05 – 0.88 (m, 1H), 0.48 (s, 1H). See above for characterization data. 
 
2.5.2. Preparation of crotyltrichlorosilanes 2.22 
 
cis-Crotyltrichlorosilane 2.22b was prepared using a modified literature procedure.45-46 
To a cooled (-78 °C) solution of Pd(PPh3)4 (0.88 g, 0.76 mmol) in THF (400 mL) was added 1,3-
butadiene (50 mL, 573 mmol, condensed into a graduated cylinder cooled to -78 °C) followed by 
trichlorosilane (38.6 mL, 382 mmol). After 15 min, the cooling bath was removed and the mix-
ture was allowed to warm to room temperature. After 17 h, an aliquot was removed and 1H NMR 
analysis showed complete consumption of the trichlorosilane. The reaction flask was fitted with 
a short-path distillation head and the THF was removed by distillation. The residue was trans-
ferred to a distillation-head equipped, 250-mL roundbottom flask with a THF rinse. The THF 
was removed by distillation and the residue was distilled under reduced pressure (bp ~60 °C @ 
~30 mm Hg) to give 2.22b as a clear and colorless liquid (56.2 g, 297 mmol, 78% yield). 1H 
NMR spectroscopic analysis revealed that the cis to trans ratio was ≥99:1. 1H NMR (300 MHz, 
CDCl3) δ 5.84 – 5.62 (m, 1H), 5.54 – 5.31 (m, 1H), 2.50 – 2.24 (m, 2H), 1.76 – 1.58 (m, 3H). 
The 1H NMR spectroscopic data is in agreement with data reported in literature.45 
HSiCl3
1 mol% Pd(PPh3)4





trans-Crotyltrichlorosilane 2.22c was prepared according to a modified literature proce-
dure.45,47 trans-Crotylalcohol was purchased from Sigma Aldrich as a 19:1 (E:Z) mixture, which 
was confirmed by 1H NMR spectroscopic analysis. To a cooled (0 °C) solution of trans-crotyl-
alcohol (121 mL, 1.41 mol) in hexachloroacetone (470 mL) was added PPh3 (386 g, 1.47 mol) 
portion-wise over 3 h. The ice/water bath was allowed to melt and warm to room temperature 
slowly, and after 12 h the reaction flask was fitted with a short-path distillation head. Distillation 
(bp ~85°C @ 760 mm Hg) gave trans-crotylchloride as a clear and colorless liquid (83.2 g, 919 
mmol, 65% yield). 1H NMR (500 MHz, CDCl3) δ 5.88 – 5.73 (m, 1H), 5.69 – 5.52 (m, 1H), 4.06 
– 3.98 (m, 2H), 1.75 – 1.68 (m, 3H). 
A 2 L round bottom flask equipped with an addition funnel was charged with Et3N (104 
mL, 1.03 mol) and Et2O (450 mL). The solution was cooled to 0 °C and copper(I)chloride (4.2 g, 
43 mmol) was added. A solution of trichlorosilane (104 mL, 1.03 mol) and trans-crotylchloride 
(77.4 g, 855 mmol) in Et2O (150 mL) was prepared and transferred to the addition funnel. This 
solution was then added very slowly (over the course of 1 h) to the reaction mixture, so as to 
maintain a reaction mixture temperature near 0 °C. After the addition was complete, the mixture 
was allowed to warm to room temperature and after 2 h, analysis of an aliquot by 1H NMR 
spectroscopy showed complete consumption of the trans-crotylchloride. The solution was trans-
ferred to a 2 L round bottom flask by cannulation through a glass microfiber filter (Grade GF/D) 
equipped teflon tube (3/16 i.d.) to filter the Et3N•HCl salts. The flask was fitted with a distilla-
tion head and the Et2O and Et3N were removed by distillation. The residue was transferred to a 
250 mL pear-shaped flask by cannula with an Et2O rinse. The flask was fitted with a short-path 
distillation head and the excess Et2O was removed by distillation and the residue was distilled 







(bp ~140-145 °C @ 760 mm Hg) to give trans-crotyltrichlorosilane 2.22c as a clear and colorless 
liquid (74.4 g, 392 mmol, 46% yield). 1H NMR spectroscopic analysis revealed that the trans to 
cis ratio was 95:5. 1H NMR (400 MHz, CDCl3) δ 5.67 – 5.53 (m, 1H), 5.48 – 5.32 (m, 1H), 2.31 
– 2.20 (m, 2H), 1.76 – 1.69 (m, 3H). The 1H NMR spectroscopic data is in agreement with data 
reported in literature.45 
 
2.5.3. Preparation and characterization of 2.24b and 2.37 
 
To a cooled (0 °C) solution of (S,S)-2.4a (1.00 g, 1.8 mmol) in CH2Cl2 (7.0 mL) was 
added DBU (270 µL, 1.8 mmol) followed by freshly distilled phenol (170 mg, 1.8 mmol). The 
ice/water bath was removed and after 1.5 h, the flask was fitted with a distillation head and the 
volatiles were removed by distillation. The residue was treated with pentane (10 mL) and the 
mixture was stirred vigorously for 10 min to ensure complete precipitation of the DBU•HCl 
salts. The mixture was then filtered through an air-free filter frit, and the filtrate was concen-
trated to give (S,S)-2.24b as a thick oil, which was analyzed without further purification. 1H 
NMR (400 MHz, CDCl3) δ 7.40 – 7.35 (m, 2H), 7.31 – 7.27 (m, 2H), 7.25 – 7.19 (m, 4H), 7.08 – 
6.97 (m, 3H), 6.90 – 6.84 (m, 2H), 5.04 – 4.84 (m, 2H), 4.09 (dd, J = 15.6, 3.6 Hz, 2H), 3.80 (dd, 
J = 18.8, 15.6 Hz, 2H), 2.87 – 2.64 (m, 2H), 1.76 – 1.48 (m, 6H), 1.22-1.03 (m, 2H), 1.02 – 0.82 
(m, 2H); 13C NMR (101 MHz, CDCl3) δ 154.62, 141.40, 141.29, 132.80, 131.27, 131.23, 129.62, 
129.35, 122.00, 120.46, 120.28, 120.15, 115.37, 66.68, 65.99, 48.12, 48.05, 31.19, 30.94, 24.91, 

















To a cooled (0 °C) solution of (S,S)-2.40 (1.00 g, 3.4 mmol) in CH2Cl2 (11 mL) was 
added DBU (1.54 mL, 10.3 mmol). Allyltrichlorosilane (0.55 mL, 3.8 mmol) was then added 
slowly. The reaction mixture was allowed to warm to room temperature and after 1 h the flask 
was fitted with a distillation head and the volatiles were removed by distillation. The residue was 
treated with Et2O (15 mL), and the resulting mixture was stirred vigorously for 10 min to ensure 
complete precipitation of the DBU•HCl salts. The mixture was then filtered through an air-free 
filter frit, and the filtrate was concentrated to give (S,S)-2.37 as a thick oil, which was analyzed 
without further purification. 1H NMR (500 MHz, CDCl3) δ 7.23-7.18 (m, 1H), 6.90 – 6.84 (m, 
1H), 6.82 (t, J = 7.5 Hz, 1H), 5.95 (ddt, J = 16.9, 10.1, 7.8 Hz, 1H), 5.16 – 5.07 (m, 1H), 5.04 – 
4.95 (m, 1H), 4.23 (d, J = 15.6 Hz, 1H), 3.69 (d, J = 15.7 Hz, 1H), 2.54 – 2.42 (m, 1H), 2.47 (s, 
3H), 2.13 (ddd, J = 10.5, 9.0, 3.3 Hz, 1H), 2.06 – 1.90 (m, 4H), 1.74 – 1.63 (m, 2H), 1.39 (s, 9H), 
1.26 – 1.15 (m, 1H), 1.14 – 1.03 (m, 2H), 0.86 – 0.73 (m, 1H); 13C NMR (126 MHz, CDCl3) δ 
152.93, 139.64, 135.86, 132.00, 130.16, 129.31, 127.17, 125.92, 121.56, 120.54, 115.69, 64.94, 
62.57, 54.65, 48.97, 47.52, 38.13, 34.85, 32.33, 30.26, 30.13, 29.98, 29.94, 29.86, 29.60, 29.31, 
24.96, 24.75, 24.29, 19.81, 18.88; 29Si NMR (99 MHz, CDCl3) δ -15.38; HRMS (FAB+) 
Calculated for C21H33ON2Si [M+H]+ 357.2362, found 357.2351.  
The stereostructure of 2.37 was proved by NMR spectroscopic analysis. COSY, HSQC, 
and HMBC experiments allowed the unambiguous assignment of all of the relevant protons in 
















consistent only with the silicon stereochemistry shown in structure (S,S)-2.37. Copies of the 




2.5.4. Establishment of substrate scope (data for Table 2.3) 
General Procedure for the one-pot allylation or crotylation of aldehydes with (R,R)-2.40: 
 
To a cooled (0 °C) solution of (R,R)-2.40 (1.45 g, 5.0 mmol, 1.1 equiv.) in CH2Cl2 (16.5 
mL) is added DBU (2.24 mL, 15.0 mmol, 3.3 equiv). The allyltrichlorosilane 2.22a or cis-crotyl-
trichlorosilane 2.22b or trans-crotyltrichlorosilane 2.22c (2.22a: 0.80 mL, 2.22b or 2.22c: 0.84 
mL, 5.5 mmol, 1.2 equiv) is then added slowly. The ice/water bath is removed and after 1 h the 
mixture is recooled to 0 °C. The aldehyde (4.5 mmol, 1.0 equiv) is added and the solution is 
maintained at 0 °C for 1 h. The progress of the reaction may be monitored by TLC, 1 h is 
generally sufficient for full conversion. 
 
(A) General procedure for the acidic workup with recovery of 2.40: The reaction mixture is 
concentrated and the residue is suspended in Et2O (27.0 mL). The mixture is stirred vigorously 


















OH1. DBU, CH2Cl2,    0 °C → 23 °C, 1h
2. cool to 0 °C,










2.22a: R1 = R2 = H
2.22b: R1 = Me, R2 = H
2.22c: R1 = H, R2 = Me
(R,R)-2.40
55 
through a frit, and the filtrate is treated with TBAF (5.0 mL, 1 M in THF, 5.0 mmol, 1.1 equiv). 
After 2 h, 1 M aqueous HCl (25.0 mL, 25.0 mmol, 5.5 equiv) is added and the mixture is 
transferred to a separatory funnel. The layers are separated and the aqueous layer is extracted 
with Et2O (3 x 50.0 mL). The combined organic layers are washed with H2O (2 x 25.0 mL) and 
saturated aqueous NaHCO3 (1 x 25.0 mL), dried over MgSO4, filtered and concentrated. The 
residue is purified by chromatography on silica gel to provide the allylation or crotylation 
product, and we have found that a simple filtration through a pad of silica is generally sufficient.  
 
Recovery of 2.40: The combined aqueous layers from above are treated with 1 M aqueous 
NaOH (50 mL, 50 mmol) and extracted with CH2Cl2 (5 x 50.0 mL). The combined organic 
layers are washed with water (2 x 25.0 mL), dried over MgSO4, filtered and concentrated. The 
residue is dissolved in minimal hot 9:1 MeOH:H2O (during the dissolution process the temp-
erature should not be allowed to exceed 80 °C, as the ligand may start to undergo decomposition 
at higher temperatures). The hot saturated solution is allowed to cool to room temperature, and 
distilled water (10.0 mL) was added to ensure complete crystallization of 2.40. The white solid is 
collected by filtration through a frit with a cold 1:1 MeOH:H2O rinse and then dried in vacuo to 
give recovered diaminophenol 2.40.  
 
(B) General procedure for the simplified workup for acid-sensitive substrates without reco-
very of 2.40: The reaction mixture is treated with TBAF (4.5 mL, 1 M in THF, 4.5 mmol, 1.0 
equiv) and the ice/water bath is removed. After 30 min the mixture is concentrated and the resi-
due is purified by chromatography on silica gel to provide the allylation or crotylation product. 
56 
Aldehydes employed in this study: 
The six aldehydes employed in Table 1 are all known compounds and were prepared according 
to literature procedures as follows: 
   
   
ref. 48 ref. 49 ref. 50 ref. 51 ref. 51 ref. 52-53 
Data for the products in Table 2.3: 
  
Workup procedure A was used. Product 2.50 was isolated as a colorless oil (83% yield, 
>99% ee). 1H NMR (400 MHz, CDCl3) δ 7.42 – 7.27 (m, 5H), 5.83 (ddt, J = 17.2, 10.2, 7.1 Hz, 
1H), 5.20 – 5.04 (m, 2H), 4.56 (s, 2H), 3.92 – 3.85 (m, J = 10.0, 6.7, 3.4 Hz, 1H), 3.52 (dd, J = 
9.5, 3.4 Hz, 1H), 3.38 (dd, J = 9.5, 7.4 Hz, 1H), 2.31 (d, J = 3.5 Hz, 1H), 2.29 – 2.25 (m, 2H). 
The 1H NMR spectroscopic data is in agreement with data reported in literature.54 The enantio-
meric excess was determined by chiral HPLC analysis: OD-H column, 98.5:1.5 hexanes:iPrOH, 
1 mL/min, 254 nm. The absolute configuration was determined by optical rotation and compar-
ison to the literature value: [α]D22 +2.3° (CHCl3, c 2.0); lit: [α]D23 +2.0° (CHCl3, c 2.3) for the (S) 
enantiomer with 94% ee.54 
  
Workup procedure B was used and product 2.51 was isolated as a colorless oil (81% 
yield, 98% ee). 1H NMR (500 MHz, CDCl3) δ 5.84 (ddt, J = 17.2, 10.2, 7.1 Hz, 1H), 5.17 – 5.03 
(m, 2H), 3.74 – 3.67 (m, 1H), 3.63 (dd, J = 9.9, 3.7 Hz, 1H), 3.46 (dd, J = 9.9, 6.9 Hz, 1H), 2.39 


























data is in agreement with data reported in literature.55 The enantiomeric excess was determined 
by 19F NMR (376 MHz, CDCl3) analysis of the Mosher ester.56-57 The absolute configuration was 
determined by optical rotation and comparison to the literature value: [α]D22 +2.4° (CHCl3, c 
2.0); lit: [α]D20 +1.7° (CHCl3, c 0.24) for the (S) enantiomer with 59% ee.55  
 
  
Workup procedure B was used to prepare product 2.42 (for convenience on small scale, 
not because it is acid sensitive), which was isolated as a colorless oil (94% yield, 96% ee, 98:2 
dr). 1H NMR (500 MHz, CDCl3) δ 7.43 – 7.27 (m, 5H), 5.74 (ddd, J = 17.2, 10.3, 7.9 Hz, 1H), 
5.14 – 4.98 (m, 2H), 4.55 (s, 2H), 3.65 – 3.62 (m, 1H), 3.56 (dd, J = 9.5, 3.1 Hz, 1H), 3.40 (dd, J 
= 9.5, 7.7 Hz, 1H), 2.40 – 2.27 (m, 2H), 1.08 (d, J = 6.8 Hz, 3H). The 1H NMR spectroscopic 
data is in agreement with data reported in literature.14 The enantiomeric excess and diastereomer 
ratio were determined by chiral HPLC analysis: OD-H column, 98:2 hexanes:iPrOH, 1 mL/min, 
254 nm. The assay was developed using a 3:1 anti:syn mixture of racemic diastereomers. The 
absolute configuration was determined by optical rotation and comparison to the literature value: 
































































Workup procedure A was used to prepare product 2.52, which was isolated as a colorless 
oil (88% yield, 97% ee, 94:6 dr).  1H NMR (400 MHz, CDCl3) δ 7.44 – 7.27 (m, 5H), 5.90 – 5.74 
(m, 1H), 5.13 – 5.03 (m, 2H), 4.59 – 4.50 (s, 2H), 3.71 – 3.63 (m, 1H), 3.55 (dd, J = 9.6, 3.2 Hz, 
1H), 3.43 (dd, J = 9.6, 7.6 Hz, 1H), 2.43 – 2.29 (m, 1H), 2.25 (d, J = 3.3 Hz, 1H), 1.04 (d, J = 6.9 
Hz, 3H). The 1H NMR spectroscopic data is in agreement with data reported in literature.58 The 
enantiomeric excess and diastereomer ratio were determined by chiral HPLC analysis: OD-H 
column, 98:2 hexanes:iPrOH, 1 mL/min, 254 nm. The assay was developed using a ~3:1 anti:syn 
mixture of racemic diastereomers. The absolute configuration was determined by optical rotation 
and comparison to the literature value: [α]D22 -7.1° (CHCl3, c 2.0); lit: [α]D20 -5.6° (CHCl3, c 1.2) 
for the (S,S) enantiomer with 99% ee.14 
  
Workup procedure A was used and product 2.53 was isolated as a pale yellow oil (92% 
yield, 93% ee, >99:1 dr). 1H NMR (500 MHz, CDCl3) δ 7.26 – 7.14 (m, 2H), 6.94 – 6.78 (m, 
2H), 5.78 (ddd, J = 17.2, 10.4, 7.6 Hz, 1H), 5.13 – 4.98 (m, 2H), 4.45 (s, 2H), 3.80 (s, 3H), 3.70 
(ddd, J = 9.2, 5.7, 4.6 Hz, 1H), 3.66 (m, 1H), 3.61 (ddd, J = 9.3, 8.2, 4.4 Hz, 1H), 2.87 (d, J = 3.0 
Hz, 1H), 2.30 – 2.21 (m, 1H), 1.81 – 1.64 (m, 2H), 1.05 (d, J = 6.8 Hz, 3H). The 1H NMR 
spectroscopic data is in agreement with data reported in literature.14 The enantiomeric excess and 
diastereomeric ratio were determined by chiral HPLC analysis of the 3,5-dinitrobenzoate ester 







developed using a ~3:1 anti:syn mixture of racemic diastereomers. We previously determined 
that the (R,R)-diastereomer elutes third.14 
  
Workup procedure A was used and product 2.54 was isolated as a pale yellow oil (82% 
yield, 98:2 dr). 1H NMR (300 MHz, CDCl3) δ 7.26 – 7.18 (m, 2H), 7.00 – 6.79 (m, 2H), 6.03 – 
5.79 (m, 1H), 5.23 – 5.01 (m, 2H), 4.45 (s, 2H), 3.80 (s, 3H), 3.65 – 3.52 (m, 2H), 3.46 (dd, J = 
9.2, 7.1 Hz, 1H), 3.24 (bs, 1H), 2.43 – 2.27 (m, 1H), 2.26 – 2.10 (m, 1H), 1.96 – 1.79 (m, 1H), 
0.91 (d, J = 7.0 Hz, 3H). The 1H NMR spectroscopic data is in agreement with data reported in 




























































Workup procedure A was used and product 2.55 was isolated as a pale yellow oil (80% 
yield, 98:2 dr). 1H NMR (400 MHz, CDCl3) δ 7.26 – 7.22 (m, 2H), 6.90 – 6.85 (m, 2H), 5.84 
(ddt, J = 17.2, 10.1, 7.0 Hz, 1H), 5.16 – 5.02 (m, 2H), 4.44 (s, 2H), 3.84 – 3.79 (m, 1H), 3.81 (s, 
3H), 3.49 (d, J = 5.4 Hz, 2H), 2.52 (d, J = 3.8 Hz, 1H), 2.29 – 2.15 (m, 2H), 1.94 – 1.81 (m, 1H), 
0.95 (d, J = 7.1 Hz, 3H). The 1H NMR spectroscopic data is in agreement with data reported in 






























































Workup procedure B was used and product 2.56 was isolated as a colorless oil (87% 
yield, 96:4 dr). 1H NMR (500 MHz, CDCl3) δ 5.91 – 5.75 (m, 1H), 5.20 – 5.10 (m, 2H), 4.37 – 
4.28 (m, 1H), 4.09 (dd, J = 7.9, 6.0 Hz, 1H), 3.94 – 3.86 (m, 1H), 3.53 (t, J = 8.1 Hz, 1H), 2.36 – 
2.20 (m, 3H), 1.78 (ddd, J = 14.2, 7.4, 3.0 Hz, 1H), 1.72 – 1.67 (m, 1H), 1.67 – 1.59 (m, 4H), 
0.90 (td, J = 7.5, 3.0 Hz, 6H). The 1H NMR spectroscopic data is in agreement with data reported 
in literature and comparison of the optical rotation to the literature value of the enantiomer 
verifies the absolute configuration of 2.56: [α]D21 +8.0° (CHCl3, c 2.0); lit: [α]D20 -6.8° (CHCl3, c 


































































Workup procedure A was used and product 2.57 was isolated as a pale yellow oil (82% 
yield, 92:8 dr. 1H NMR (500 MHz, CDCl3) δ 7.26 – 7.20 (m, 2H), 6.95 – 6.79 (m, 2H), 5.85 
(ddd, J = 17.5, 10.5, 7.3 Hz, 1H), 5.10 – 4.97 (m, 2H), 4.44 (s, 2H), 3.80 (s, 3H), 3.63 (dd, J = 
9.1, 4.1 Hz, 1H), 3.46 (dd, J = 9.1, 6.4 Hz, 1H), 3.39 (t, J = 5.7 Hz, 1H), 3.22 (bs, 1H), 2.39 – 
2.24 (m, 1H), 1.99 – 1.85 (m, 1H), 1.04 (d, J = 6.7 Hz, 3H), 0.95 (d, J = 7.0 Hz, 3H). The 1H 
NMR spectroscopic data is in agreement with data reported in literature.61 The diastereomer ratio 





































































































Workup procedure A was used and product 2.58 was isolated as a pale yellow oil (80% 
yield, 93:7 dr). 1H NMR (500 MHz, CDCl3) δ 7.26 – 7.22 (m, 2H), 6.90 – 6.85 (m, 2H), 5.90 
(ddd, J = 16.6, 11.0, 8.4 Hz, 1H), 5.10 – 5.00 (m, 2H), 4.44 (s, 2H), 3.80 (s, 3H), 3.55 (dd, J = 
9.2, 4.3 Hz, 1H), 3.48 (dd, J = 9.2, 7.6 Hz, 1H), 3.39 (bs, 1H), 3.35 (dd, J = 8.0, 3.7 Hz, 1H), 
2.41 – 2.29 (m, 1H), 1.97 – 1.84 (m, 1H), 1.10 (d, J = 6.9 Hz, 3H), 0.87 (d, J = 6.9 Hz, 3H). The 
1H NMR spectroscopic data is in agreement with data reported in literature.62 The diastereomer 






































































Workup procedure A was used and product 2.59 was isolated as a pale yellow oil (80% 
yield, 94:6 dr). 1H NMR (500 MHz, CDCl3) δ 7.26 – 7.20 (m, 2H), 6.90 – 6.85 (m, 2H), 5.63 
(ddd, J = 17.2, 10.3, 8.7 Hz, 1H), 5.10 – 4.92 (m, 2H), 4.49 – 4.39 (m, 2H), 3.81 (s, 3H), 3.57 – 
3.46 (m, 3H), 2.62 (bs, 1H), 2.29 (ddt, J = 15.5, 8.8, 6.6 Hz, 1H), 1.92 (ddt, J = 7.0, 4.8, 2.4 Hz, 
1H), 1.09 (d, J = 6.6 Hz, 3H), 0.95 (d, J = 7.0 Hz, 3H). The 1H NMR spectroscopic data is in 
agreement with data reported in literature.63 The diastereomer ratio was determined by 1H NMR 





































































Workup procedure A was used and product 2.60 was isolated as a pale yellow oil (80% 
yield, 95:5 dr). 1H NMR (500 MHz, CDCl3) δ 7.26 – 7.23 (m, 2H), 6.91 – 6.84 (m, 2H), 5.79 
(ddd, J = 17.3, 10.3, 8.4 Hz, 1H), 5.14 – 5.05 (m, 2H), 4.45 (s, 2H), 3.80 (s, 3H), 3.59 – 3.42 (m, 
3H), 2.33 – 2.19 (m, 2H), 2.01 – 1.88 (m, 1H), 1.00 – 0.93 (m, 6H). The 1H NMR spectroscopic 
data is in agreement with data reported in literature.64 The diastereomer ratio was determined by 









































































2.6. HPLC data 
 
>99% ee 















96% ee, 98:2dr 





















97% ee, 94:6 dr 
OD-H column, 98:2 hexanes:iPrOH, 1 mL/min, 254 nm. 






















93% ee, >99:1 dr 
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Chapter 3: Synthesis of a spongistatin CD fragment analog 
3.1. Introduction 
Among several obstacles encountered in synthesis of spongistatin 1 (3.1) are the 
challenges of preparing the singly anomeric CD spiroketal. Due to the contra-thermodynamic 
conformation of the CD spiroketal, there are significant challenges of spiroketalization selec-
tivity and acid sensitivity when preparing the CD fragment. However, previous SAR studies 
have suggested that the CD fragment might not be involved in tubulin binding and serves to 
scaffold spongistatin 1 into the conformation required for potent activity. This proposal was 
recently supported by Smith and coworkers who prepared a diminutive analog of spongistatin 1 
(3.2), in which the entire C12-C28 region was replaced with a simple alkyl strap (Figure 3.1).1 
Compared to other analogs with substantial simplifications, 3.2 boasts the most potent activity 
with GI50 values of 80-300 nM. Despite the extensive computational studies to determine the 
solution structure of spongistatin 1 and design 3.2 with a similar ABEF solution structure, 3.2 is 
about three orders of magnitude less potent than spongistatin 1, suggesting a CD fragment analog 
should contain more structural rigidity. Taking these considerations into account, this chapter 
will describe our design and synthesis of a novel analog for spongistatin 1’s CD fragment. 
 
























































3.1.1. Design of CD* 
In designing an analog of the CD fragment (CD*)a, we were interested in addressing the 
inherent sensitivity of a singly anomeric spiroketal in order to devise a more scalable synthesis of 
spongistatin. Since the overall shape of the CD fragment is crucial for correctly scaffolding the 
conformation of spongistatin for potent activity, we propose that a suitable analog will be a 
similar spiroketal. Thus, if the D-ring in the natural CD-spiroketal 3.3 is reconfigured by moving 
its ketal oxygen to the C24 position and removing the C25 hydroxyl, then the resulting spiroketal 
3.4 is doubly anomeric and the same overall shape as the natural CD spiroketal 3.3 (Figure 3.2). 
A CD spiroketal analog like 3.4 will serve the same scaffolding purpose as 3.3 without the 
spiroketalization selectivity and acid sensitivity issues associated with 3.3, which should result in 
a more scalable synthesis. 
 
Figure 3.2. Design of CD spiroketal analog 
Insertion of our proposed analog into the spongistatin 1 framework gives 3.5 as the 
overall target for the Leighton Group spongistatin research program (Scheme 3.1). For the 
synthesis of 3.5, we plan to follow the major disconnections as shown in Scheme 3.1, which 
were previously discussed in Chapter 1. We expect our AB-CD coupling by crotylation strategy 
(described in Chapter 1) will be amenable to coupling AB diene 3.6 to CD* aldehyde 3.7. In 
accordance with our goal to devise a scalable synthesis of 3.5, the following will detail our work 
on a robust and step-economical synthesis of CD* 3.7. 
                                                
a (*) will refer to things specific to the analog. For example, in carbon number where C#* refers to number specific 
















Scheme 3.1. Retrosynthesis of proposed spongistatin analog 3.5 
 
3.1.2. Retrosynthesis of CD* 
 It is possible that we may need to prepare multiple CD* analogs in order to identify one 
that retains bioactivity, and as such it would be advantageous to devise a synthesis of 3.7 that 
will enable facile access to various analogs. We envisioned preparing 3.7 through an acid 
mediated spiroketalization of ketone 3.9 (Scheme 3.2), in which the C21-22 bond could be 
formed through an aldol reaction between ketone 3.10 and aldehyde 3.11. Targeting 3.10 and 
3.11, with roughly similar sizes, would allow for a convergent synthesis, offering opportunities 
to easily prepare other D ring analogs as needed by simply changing the methyl ketone subunit.  
 
Scheme 3.2. CD* retrosynthesis 
Our protecting group strategy also deserves comment. Due to our proposed acid mediated 

































































































protecting group must be orthogonal to the C19 and C27* protecting groups to prevent the 
formation of a 5,6-spiroketal, but the C17 protecting group in 3.9 doesn’t necessarily need to be 
acid stable since the 6,8-spiroketal will most likely be disfavored relative to the alternative 6,6-
spiroketal. In the case of both the C28* and C17 protecting groups in the final CD* aldehyde 3.7, 
they must be fluoride labile to fit into our downstream, post AB-CD coupling, deprotection 
strategy, described in Chapter 4. The selection of the specific protecting groups will be discussed 
as needed along with the synthesis of each fragment. 
 
3.2. Preparation of methyl ketone subunit 3.12 
 
Scheme 3.3. Retrosynthesis of CD* ketone subunit 3.12 
According to our previously discussed protecting group and spiroketalization strategy, 
the C27* and C28* protecting groups must have differential stability in the presence of acid. 
Accordingly, we chose TBS and TBDPS protecting groups for C27* and C28*, respectively, to 
give 3.12 as our target for the methyl ketone subunit (Scheme 3.3). We planned to install the 
methyl ketone by alkene oxidation and set the C25* all carbon stereocenter through a Myers 
asymmetric alkylation.2 
To install the chiral auxiliary for the Myers alkylation, lactone opening of 3.15 with 
(R,R)-pseudoephedrine occurred smoothly to afford amide 3.17 in 78% yield (Scheme 3.4). After 
TBS protection, amide 3.14 was alkylated, providing 3.19 in 88% yield and >20:1 dr. The 
observed selectivity of this alkylation was proposed to be a result of bottom face alkylation of the 



































the secondary lithium alkoxide and associated solvent molecules.2 Conversion of amide 3.19 to 
primary alcohol 3.20 was achieved in 87% yield by reduction with lithium amido borane, which 
was previously established to be selective for the alcohol product over the amine product.2 
Alcohol 3.20 was subsequently TBDPS protected, providing 3.21 in 97% yield.  
 
Scheme 3.4. Preparation of alkene 3.21 towards synthesis of CD* ketone subunit 3.12 
 
Scheme 3.5. Ozonolysis of alkene 3.21 
The preparation of 3.21 positioned us to install the methyl ketone by oxidative cleavage 
of the 1,1-disubstituted olefin (Scheme 3.5). Initial efforts using an ozonolysis only afforded 
product 3.12 in 65% yield, with the majority of the remaining mass isolated as a side product 
whose NMR was consistent with an α-hydroxy ketone, presumably 3.22. Using a mixed solvent 
system of 5:1 CH2Cl2:MeOH effectively eliminated the production of 3.22, but we could not effi-
ciently isolate the 3.12 from the excess PPh3 used to ensure complete reduction of the ozonide. 
Several tedious column chromatographies were required to isolate pure 3.12 in 79% yield with 
another 14% of the product still contaminated with PPh3. We were not satisfied with this ozono-
lysis since in the long run, this difficulty in purification would lessen the scalability of our route 













































































5:1 CH2Cl2:MeOH: 79% yield
3.21 3.12 3.22
95 
Other ongoing work in our group at the time was utilizing the Sigman modified Wacker 
oxidation to convert terminal olefins to methyl ketones.3 We gravitated toward this strategy for 
the installation of the methyl ketone in 3.12 because allylbromide is significantly less expensive 
relative to methallylbromide and we have previously found this Wacker oxidation to be highly 
robust and selective. Thus, we quickly prepared 3.25, the allyl derivative of 3.21, through a 
similar synthetic route (Scheme 3.6) to test the Wacker oxidation. To our delight, alkene 3.25 
smoothly underwent the Wacker oxidation to afford the desired methyl ketone 3.12 in a 94% 
yield (Scheme 3.7). Additionally, alkene 3.25 can also be subjected to the oxidation conditions as 
a crude oil without affecting the efficiency of the reaction to give 3.12 in 88% yield over 2 steps 
from 3.24. Through this route, 3.12 was accessed in 60% overall yield over a longest linear 
sequence of 6 steps and with high enantiopurity, which was verified by Mosher’s ester analysis 
of 3.24. This route was highly scalable, and has been used to prepare over 40 grams of 3.12. 
 
Scheme 3.6. Optimized route for the preparation of Wacker oxidation substrate, alkene 3.25 
 





























































OTBDPS 4 mol% Pd(Quinox)Cl2, 
10 mol % AgSbF6, TBHP





3.3. Preparation of aldehyde subunit 3.29 
 
Scheme 3.8. Diastereochemical outcome of Mukaiyama aldol reactions 
In considering the preparation of the aldehyde subunit 3.11, we were aware of the impli-
cations its β-protecting group could have on the selectivity of the proposed aldol reaction to join 
3.10 and 3.11 (Scheme 3.2). Mukaiyama aldol reactions are known to favor 1,3-anti products if 
the aldehyde possesses a polar β-substituent (alkoxy- or halo-), and this outcome is independent 
of the stereochemistry of the ketone reactant (Scheme 3.8).4 Protecting groups that traditionally 
enforce high 1,3-anti selectivity, including the benzyl and PMB protecting groups,4-5 were not 
compatible with the protecting group strategy as discussed in section 3.1.2. In contrast, silyl 
protecting groups, which are compatible, generally do not display very high 1,3-anti selectivity 
due to their steric bulk. Based on these protecting group generalizations, we considered adjusting 
our strategy to utilize a PMB protecting group. However, a model aldol reaction of ketone 3.12, 
via silylenol ether 3.27, using β-PMB protected aldehyde 3.26 revealed only a modest 3.7:1 dr 
for this system (Scheme 3.9). 
 
Scheme 3.9. Model Mukaiyama aldol reaction  
Despite the discouraging results from the model reaction, we chose a ketal protecting 
group for the aldehyde subunit for its acid sensitivity, as well as literature precedent for high 1,3-
anti selectivity in Mukaiyama aldol reactions.6 With a ketal protecting group, our aldehyde subu-
nit target is 3.29 (Scheme 3.10). Sober about the possibility that our proposed aldol reaction with 






































to investigate the proposed aldol reaction. This was achieved through a highly reliable iterative 
crotylation-oxidation process (Scheme 3.10), utilizing our groups strained silane methodology. 
 
Scheme 3.10. Retrosynthesis of CD* aldehyde subunit 3.29 
The route to prepare aldehyde subunit 3.29 started with an allylation of known PMB 
protected aldehyde 3.31 using the one-pot allylation protocol developed in Chapter 2 to afford 
the product in 75% yield and 97% ee (Scheme 3.11).7 As was mentioned in Chapter 2, this 
allylation required the one-pot protocol since the alternative first-generation allylsilane/Sc(OTf)3 
protocol promoted PMB deprotection, leading to eroded yields. 3.32 was easily converted to 
aldehyde 3.30 via TES protection and oxidative cleavage of the terminal olefin. OsO4 was used 
to oxidize the terminal olefin since the alternative ozonolysis procedure was incompatible with 
PMB protecting groups. It should be noted, however, we found that the yield varied with the 
source of the OsO4 catalyst: OsO4 from Strem gave a better yield of 87% compared to 69% when 
OsO4 from Aldrich was used. Aldehyde 3.30 was crotylated, again using the one pot crotylation  
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protocol, and subsequent quench with excess TBAF allowed for concomitant TES deprotection 
affording the product in 95% yield and 15:1 dr. The resulting diol 3.34 was protected as an 
acetonide and the PMB group was removed with DDQ to provide primary alcohol 3.36 in 95% 
yield over 2 steps. Oxidation of 3.36 under Swern oxidation conditions cleanly provided 3.29, 
which was used in the aldol reaction without further purification. 
Minimal optimization was required to improve this route that accessed 3.29 in 59% 
overall yield with a longest linear sequence of 7 steps. Notably, this route utilized the newly 
developed one-pot allylation/crotylation protocol twice to set all three stereocenters and the 
chiral diaminophenol (S,S)-3.37 was recovered in the process. This route offers a robust and 
scalable way to rapidly prepare multi-gram quantities of 3.29. 
 
3.4. Anti-aldol and elaboration to final CD* aldehyde 3.43 
To evaluate the aldol reaction, ketone 3.12 was converted to its TMS enol ether 3.27, 
which was purified by triturating with pentane to remove the iPr2NH•HCl salts (Scheme 3.12). A 
solution of the resulting TMS enol ether 3.27 and aldehyde 3.29 was treated with BF3•OEt2 to 
provide 3.38 in 78% yield as a 7:1 mixture of diastereomers. Slow addition of freshly distilled 
BF3•OEt2 was essential for an efficient and selective reaction. The C21 secondary alcohol was 
subsequently converted to the corresponding methylether by treatment with the Meerwein salt 
(Me3OBF4) in the presence of proton sponge, affording the product (3.39) in 93% yield. 
 




















3.38: R = H








Having prepared ketone 3.39, we were ready to try the spiroketalization reaction, which 
we were confident would selectively afford the doubly anomeric spiroketal. Our main concern 
was with identifying conditions that would not also remove the TBDPS protecting group. 
TBDPS protecting groups are significantly more stable to acid than are TBS groups,8 and we 
were optimistic that this would allow us to identify suitable conditions. A number of acid 
conditions were screened as shown in Table 3.1. Several conditions (entries 1, 8, 9, 11, and 12) 
were too strong, leading to TBDPS deprotection, while others (entries 5, 7, and 13) gave a slow 
or no reaction. As for entries 3, 4, and 10, the reaction conditions resulted in decomposition, 
where several compounds did not converge on product over time. CSA/EtOH conditions (entry 
2) did not deprotect the TBDPS group, affording the product in a 65% yield; however, a 
significant portion of the remaining mass was isolated as C21-OMe eliminated products. 
PPTS/MeOH was identified as the best conditions to effect spiroketalization (entry 6), without 
side reactions, to provide the desired spiroketal in 78% yield. Also, at this stage the minor 
diastereomer from the aldol reaction was removed by column chromatography.  
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CSA/EtOH: 65% yield3.39 3.40
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The stereochemistry of the spiroketal product was verified by NOESY experiments on 
the acetylated spiroketal 3.41 (Figure 3.3). Acetylation of C17 and C21 alcohols were required to 
enable differentiation between the various carbinol protons by NMR, and this change is incon- 
sequential to the stereochemistry at C21 and the outcome of the spiroketalization. Based on these 
assumptions, the observed nOe correlations for 3.41 support the assigned stereochemistry of 
C21, set in the aldol reaction, and C23, set in the spiroketalization, as depicted in Figure 3.3. 
 
Figure 3.3. nOe correlations assigning stereochemistry of CD spiroketal 3.41 
Final conversion of the spiroketalization product 3.40 to the fully elaborated CD* alde-
hyde 3.43 required 2 additional steps. Homoallylic alcohol 3.40 was TES protected in 93% yield 
and ozonolysis of the terminal olefin provided the final CD aldehyde 3.43 in 94% yield. The 
synthesis of 3.43 was achieved in a longest linear sequence of 12 steps from 3.31 in 30% overall 
yield. More importantly, this route enabled the preparation of multi-gram quantities of 3.43 ready 
to be coupled with the AB fragment. Due to the propensity of aldehydes to oxidize to carboxylic 
acids, we also stockpiled 5 g of 3.40 and 3 g of 3.42 to be brought forward as needed. 
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3.5. Summary and outlook 
In this chapter, we disclosed our proposal for a novel analog of the CD spiroketal of 
spongistatin 1. We believe designing a doubly-anomeric analog of the CD spiroketal that closely 
mimics the same overall shape as the natural CD spiroketal will impart acid stability while also 
serving to scaffold the rest of the spongistatin into the conformation required to retain potent 
bioactivity. The high demonstrated overall yield is a testament to the robustness and efficiency of 
the synthetic route, which was enabled by the use of the newly developed one-pot crotylation 
methodology. This route facilitated the rapid synthesis of several grams of 3.40, 3.42 and 3.43, 
which is a sufficient amount of material to complete the synthesis and test this spongistatin 
analog against tumor cells. If in fact our spongistatin analog is biologically active, we will have 
opportunities in the future to improve this synthesis of 3.43. Nonetheless, having established a 
viable route to 3.43, we were prepared to tackle the AB-CD coupling reaction. 
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3.6. Experimental procedures 
General Information. All reactions were carried out under an atmosphere of nitrogen in flame-
dried glassware with magnetic stirring unless otherwise indicated. Degassed solvents were 
purified by passage through an activated alumina column. Thin-layer chromatography (TLC) 
was carried out on glass backed silica gel TLC plates (250 mm) from Silicycle; visualization by 
UV light and/or phosphomolybdic acid (PMA). HPLC analysis was carried out on an Agilent 
1200 Series using either a Chiralpak AD-H (250 x 4.5 mm ID) column or Chiralcel OD-H 
(250x4.5 mm ID) column. 1H NMR spectra were recorded on a Bruker AVIII 300 (300 MHz), 
AVIII 400 (400 MHz), AVIII 500 (500 MHz) or AVIII 500 Ascend (500 MHz) spectrometer and 
are reported in ppm, relative to residual protonated solvent peak (CDCl3, 7.26 ppm; C6D6, 7.16 
ppm). Data are reported as follows: (bs= broad singlet, s = singlet, d = doublet, t = triplet, m = 
multiplet, dd = doublet of doublets, ddd = doublet of doublet of doublets, ddt = doublet of 
doublet of triplets, td = triplet of doublets; coupling constant(s) in Hz; integration). Proton 
decoupled 13C NMR spectra were recorded on a Bruker AVIII 400 (100 MHz), AVIII 500 (126 
MHz) or AVIII 500 Ascend (126 MHz) spectrometer and are reported in ppm from CDCl3 
internal standard (77.16 ppm). 29Si NMR spectra were recorded on a Bruker AVIII 400 (79 
MHz) or AVIII 500 (100 MHz) and are reported in ppm relative to TMS (0.00 ppm) internal 
standard. 19F NMR spectra were recorded on a Bruker AVIII 400 (376 MHz) and are reported in 
ppm relative to α,α,α-trifluorotoluene (-63.72 ppm) internal standard. Infrared spectra were 
recorded on a Nicolet Avatar 370DTGS FT-IR. Optical rotations were recorded on a Jasco DIP-
1000 digital polarimeter. (APCI)-MS was conducted on a JMS-LCmate LCMS (JEOL). Melting 
points were determined using a Stanford Research Systems DigiMelt apparatus. 
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3.6.1. Preparation of methyl ketone subunit 3.12 
  
Amide 3.17 was prepared using a modified procedure.2 To a cooled mixture of (R,R)-
pseudoephedrine 3.16 (33.0 g, 200 mmol) and LiCl (25.4 g, 600 mmol) in THF (800 mL) at 0 ºC 
was added n-BuLi (40.0 mL, 100 mmol, 2.5 M in hexanes). The resulting mixture was stirred at 
0 ºC for 30 min. γ-Butyrolactone 3.15 (30.5 mL, 400 mmol) was added slowly and warmed to 
room temperature to stir for 4 h. Aqueous NaOH (1 M, 300 mL) was added and the resulting 
mixture was stirred for 1 h. THF was removed in vacuo and the resulting mixture was extracted 
with 1:9 MeOH:CH2Cl2 (7 x 100 mL). The combined organic layers were washed with water (1 
x 200 mL), dried over Na2SO4, filtered, and concentrated in vacuo. The crude product was 
purified by silica gel column chromatography eluting with 6:94 MeOH:CH2Cl2 to give pure 3.17 
was a pale yellow oil (39.2 g, 156 mmol, 78% yield). The product is a 3:1 mixture of rotamers 
about the amide bond. (*) is used to indicate the minor rotamer peaks. 1H NMR (500 MHz, 
CDCl3) δ 7.40 – 7.19 (m, 5H), 4.55 (m, 1H), 4.13* (s, 1H), 4.05* (m, 1H), 3.77 – 3.59 (m, 2H), 
3.56 (s, 1H)*, 3.13 (s, 1H), 2.91* (s, 3H), 2.85 (s, 3H), 2.73* (ddd, J = 15.9, 8.2, 5.7 Hz, 1H), 
2.56 – 2.32 (m, 2H), 1.99 – 1.78* (m, 2H), 1.90 – 1.81* (m, 2H), 1.02 (d, J = 6.3 Hz, 3H), 0.95* 
(d, J = 6.8 Hz, 3H). 13C NMR (101 MHz, CDCl3) δ 175.63, 174.78*, 142.25, 141.51*, 128.81*, 
128.53, 128.43*, 127.91, 127.05*, 126.70, 76.37, 75.50*, 62.44, 62.41, 58.65, 57.67*, 32.23*, 
31.63, 30.70*, 27.93*, 27.64, 27.07, 15.58*, 14.53. IR (thin film, cm-1) 3349.91, 2968.16, 




















93.7º (c 1.0, CHCl3). HRMS (FAB+): calculated for C14H22NO3 [M+H]+ 252.1600; found 
252.1595. 
 
To a solution of 3.17 (39.2 g, 156 mmol) in CH2Cl2 (1.5 L) was added Et3N (26.1 mL, 
187 mmol). A solution of TBSCl (24.7 g, 164 mmol) in CH2Cl2 (100 mL) was added via addition 
funnel. DMAP (0.95 g, 7.8 mmol) was added and the resulting solution was stirred for 4 h. The 
reaction mixture was quenched with water (200 mL) and extracted with EtOAc (3 x 200 mL). 
The combined organic layers were dried over Na2SO4, filtered, and concentrated in vacuo to give 
crude 3.14 as a pale yellow oil (56.6 g, 155 mmol, 99% yield) that was used without further 
purification. Purification for a characterization sample was achieved by silica gel column 
chromatography eluting with 5:95 MeOH:CH2Cl2 to give pure 3.14 as a pale yellow oil. The 
product is a 3:1 mixture of rotamers about the amide bond. (*) is used to indicate the minor 
rotamer peaks. 1H NMR (500 MHz, CDCl3) δ 7.39 – 7.27 (m, 5H), 4.63 – 4.51 (m, 1H), 4.51 – 
4.38 (m, 1H), 4.29* (s, 1H), 4.13 – 3.97* (m, 1H), 3.70 – 3.56 (m, 2H), 2.91* (s, 3H), 2.82 (s, 
3H), 2.60 – 2.42* (m, 1H), 2.42 – 2.30 (m, 1H), 1.93 – 1.72 (m, 2H), 1.10 (d, J = 6.9 Hz, 3H), 
0.97* (d, J = 6.7 Hz, 3H), 0.89 (s, 9H), 0.88 (s, 9H), 0.07 – 0.01 (m, 6H). 13C NMR (101 MHz, 
CDCl3) δ 175.51, 174.20*, 142.62, 141.39*, 128.81*, 128.47, 127.75, 127.08*, 126.51, 77.36*, 
76.74, 75.66*, 62.68*, 62.25, 58.72, 58.44*, 32.98*, 30.66, 30.15*, 28.67*, 28.28, 26.82*, 
26.10*, 26.06, 18.42*, 15.43*, 14.59, -5.14*, -5.19. IR (thin film, cm-1) 3411.24, 2961.80, 
1635.96, 1465.17, 1253.93, 1092.13. OR [α]D21 -63.1º (c 1.0, CHCl3). HRMS (FAB+) calculated 






















Alkylation of 3.14 was achieved using a modified procedure.2 To a mixture of iPr2NH 
(27.5 mL, 195 mmol) and LiCl (22.0 g, 519 mmol) in THF (100 mL) at -78 ºC was added n-
BuLi (73.0 mL, 182 mmol, 2.5 M in hexanes). The resulting mixture was stirred at -78 ºC for 15 
min and at room temperature for 5 min before returning to -78 ºC. Crude amide 3.14 (31.6 g, 86 
mmol) was added as a cooled (0 ºC) solution in THF (100 mL), rinsing with THF (20 mL). The 
resulting mixture was stirred for 1 h at -78 ºC, 15 min at 0 ºC, and room temperature for 5 min. 
The reaction mixture was returned to 0 ºC and allylbromide (11.2 mL, 130 mmol) was slowly 
added. After the resulting mixture was stirred at 0 ºC for 1 h, it was quenched with saturated 
NH4Cl (50 mL) and extracted with EtOAc (3 x 150 mL). The combined organic layers were 
dried over Na2SO4, filtered, and concentrated in vacuo. The resulting crude oil was purified by 
silica gel column chromatography eluting with 3:97 à 5:95 MeOH:CH2Cl2 to give pure 3.23 as 
a pale yellow oil (34.3 g, 85 mmol, 98% yield). The product is a 4:1 mixture of rotamers about 
the amide bond. (*) is used to indicate the minor rotamer peaks. 1H NMR (400 MHz, CDCl3) δ 
7.41 – 7.29 (m, 4H), 7.29 – 7.21 (m, 1H), 5.91 – 5.73* (m, 1H), 5.73 – 5.55 (m, 1H), 5.18 – 4.90 
(m, 2H), 4.65 – 4.51 (m, 1H), 4.43 (s, 1H), 4.33 – 4.24* (m, 1H), 3.70 – 3.58 (m, 1H), 3.57 – 
3.49 (m, 1H), 3.49 – 3.42* (m, 1H), 3.18* (p, J = 7.0 Hz, 1H), 3.03 – 2.93 (m, 1H), 2.92* (s, 
3H), 2.90* (s, 3H), 2.53 – 2.39* (m, 1H), 2.39 – 2.19 (m, 1H), 2.19 – 2.08* (m, 1H), 1.90 – 1.71 
(m, 1H), 1.71 – 1.56 (m, 1H), 1.10 (d, J = 7.0 Hz, 3H), 1.00* (d, J = 6.7 Hz, 3H), 0.88 (s, 9H), 
0.83* (s, 9H), 0.04 (d, J = 1.7 Hz, 6H), -0.01* (d, J = 19.9 Hz, 6H). 13C NMR (101 MHz, 
CDCl3) δ 177.97, 176.76*, 142.61, 141.20*, 136.91*, 136.01, 128.82*, 128.45, 127.70, 127.13*, 




















36.93, 36.09*, 35.71, 33.34, 27.26*, 26.06, 18.37, 15.81*, 14.73, -5.21. IR (thin film, cm-1) 
3388.76, 2952.81, 2853.93, 1617.98, 1447.19, 1244.94, 1096.63, 835.96, 701.12. OR [α]D22 -
69.4º (c 1.0, CHCl3). HRMS (FAB+): calculated for C23H40NO3Si [M+H]+ 406.2777; found 
406.2776. 
  
To a solution of iPr2NH (1.51 mL, 10.7 mmol) in THF (10 mL) at -78 ºC was added n-
BuLi (4.0 mL, 9.9 mmol, 2.5 M in hexanes). The resulting solution was stirred at -78 ºC for 10 
min and at 0 ºC for 10 min. BH3•NH3 (0.31 g, 10.2 mmol) was added in 1 portion [CAUTION: 
gas evolution]. The resulting mixture was stirred at 0 ºC for 15 min and at room temperature for 
15 min before cooling back to 0 ºC. Amide 3.23 (1.03 g, 2.5 mmol) was added as a solution in 
THF (6.0 mL) via addition funnel. The resulting mixture was warmed to room temperature and 
stirred for 5 h. The reaction mixture was cooled to 0 ºC, carefully quenched with saturated 
NH4Cl (10 mL) and extracted with Et2O (3 x 5.0 mL). Combined organic layers were dried over 
MgSO4, filtered, and concentrated in vacuo. The resulting crude oil was purified by silica gel 
column chromatography eluting with 8:92 EtOAc:Hexanes to give pure 3.24 was a colorless oil 
(0.58g, 2.4 mmol, 93% yield). [This reaction was also performed on 50 mmol and 100 mmol 
scales with a 91% combined yield.] 1H NMR (400 MHz, CDCl3) δ 5.91 – 5.64 (m, 1H), 5.12 – 
4.93 (m, 2H), 3.77 (ddd, J = 10.4, 6.2, 4.2 Hz, 1H), 3.71 – 3.54 (m, 2H), 3.47 (dd, J = 11.1, 6.5 
Hz, 1H), 3.12 (s, 1H), 2.24 – 1.92 (m, 2H), 1.83 – 1.61 (m, 2H), 1.61 – 1.40 (m, 1H), 0.90 (s, 
9H), 0.08 (s, 6H). 13C NMR (101 MHz, CDCl3) δ 137.05, 116.40, 66.06, 61.97, 39.55, 36.60, 
35.21, 26.04, 26.02, 18.39, -5.30, -5.33. IR (thin film, cm-1) 3415.73, 2925.84, 1640.45, 1469.66, 
















comparison to its literature value: [α]D25 +10.8º (c 1.30, CHCl3).9 HRMS (FAB+): calculated for 
C13H29O2Si [M+H]+ 245.1930; found 245.1937.  
 
 Alcohol 3.24 was converted to its corresponding Mosher ester to determine enantiopurity. 
To a solution of 3.24 (16 mg, 0.064 mmol) in CDCl3 (1.0 mL) were sequentially added (S)-(−)-α-
methoxy-α-(trifluoromethyl)phenylacetic acid (47 mg, 0.2 mmol), DCC (42 mg, 0.2 mmol) and 
DMAP (25 mg, 0.2 mmol). The resulting solution was stirred at room temperature for 1 h and 
filtered through a cotton plug directly into an NMR tube to remove the white solids. 1H NMR 
analysis of the filtrate showed a >20:1 dr for the crude product.  
  
To a solution of alcohol 3.24 (37.2 g, 152 mmol) in CH2Cl2 (1.2 L) was added Et3N (32.0 
mL, 228 mmol), TBDPSCl (50.4 mL, 193 mmol), and DMAP (3.71 g, 30.4 mmol). The resulting 
solution was stirred at room temperature overnight. MeOH (8.0 mL) was added to quench 
unreacted TBDPSCl and the resulting solution was concentrated in vacuo. The resulting residue 
was resuspended in hexanes and the Et3N•HCl salts were removed by filtration. The filtrate was 
washed with water (1 x 200 mL) and saturated NH4Cl (2 x 150 mL), being sure to remove all 
DMAP impurities. The aqueous layer was extracted with EtOAc (3 x 100 mL). The combined 
organic layers were dried over Na2SO4, filtered, and concentrated in vacuo to give crude 3.25 as 
a pale yellow oil (70.6 g, 146 mmol, 96% yield) that was used without further purification. 

























eluting with 2:98 EtOAc:Hexanes to give pure 3.25 as a pale yellow oil.  1H NMR (400 MHz, 
CDCl3) δ 7.75 – 7.59 (m, 4H), 7.51 – 7.31 (m, 6H), 5.87 – 5.65 (m, 1H), 5.12 – 4.90 (m, 2H), 
3.73 – 3.47 (m, 4H), 2.35 – 2.19 (m, 1H), 2.19 – 2.05 (m, 1H), 1.78 (hept, J = 6.0 Hz, 1H), 1.70 
– 1.47 (m, 2H), 1.08 (d, J = 1.0 Hz, 9H), 0.89 (d, J = 0.9 Hz, 9H), 0.03 (dd, J = 2.0, 0.9 Hz, 6H). 
13C NMR (101 MHz, CDCl3) δ 137.27, 135.78, 134.10, 134.08, 129.67, 127.73, 116.11, 66.03, 
61.44, 37.47, 35.74, 34.11, 27.07, 26.12, 19.49, 18.45, -5.14. IR (thin film, cm-1) 2928.72, 
2858.20, 1470.80, 1427.73, 1253.40, 1090.25, 1056.34, 1032.90, 1007.26, 833.37, 775.30, 
701.85, 504.68. OR [α]D18 -5.1º (1.0, CHCl3). HRMS (FAB+) calculated for C29H47O2Si2 
[M+H]+ 483.3115; found 483.3103. 
 
Wacker oxidation of alkene 3.25 was performed using a modified procedure.3 To a 
suspension of AgSbF6 (3.35 g, 9.8 mmol), which was measured into a foil-covered vial in the 
glovebox, in CH2Cl2 (200 mL) was added Pd(Quinox)Cl2 (1.47 g, 3.9 mmol). The resulting 
mixture was stirred for 15 min before diluting with CH2Cl2 (400 mL). 70% aqueous tert-butyl 
hydrogenperoxide (340 mL, 2.3 mol) was added and the resulting mixture was stirred for 10 min. 
The reaction mixture was cooled to 0 ºC and alkene 3.25 (47.1 g, 97.5 mmol) was added as a 
neat oil, rinsing with minimal amounts of CH2Cl2. The resulting mixture was warmed to room 
temperature and stirred for 3 h. The reaction mixture was cooled to 0 ºC and carefully quenched 
with saturated Na2SO3 solution (800 mL). The aqueous layer was separated and extracted with 
hexanes (3 x 200 mL). The combined organic layers were washed with H2O (1 x 500 mL) and 
dried over Na2SO4, filtered, and concentrated in vacuo. The resulting crude oil was purified by 





OTBDPS 4 mol% Pd(Quinox)Cl2, 
10 mol % AgSbF6, TBHP
CH2Cl2, 0 to 23 °C
3.25 3.12
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was a pale yellow oil (44.6 g, 89 mmol, 92% yield). 1H NMR (400 MHz, CDCl3) δ 7.73 – 7.59 
(m, 4H), 7.49 – 7.32 (m, 6H), 3.68 – 3.44 (m, 4H), 2.64 (dd, J = 16.5, 6.9 Hz, 1H), 2.41 (dd, J = 
16.5, 6.3 Hz, 1H), 2.35 – 2.22 (m, 1H), 2.10 (s, 3H), 1.72 – 1.54 (m, 1H), 1.54 – 1.39 (m, 1H), 
1.05 (s, 9H), 0.86 (s, 9H), 0.00 (s, 6H). 13C NMR (101 MHz, CDCl3) δ 208.69, 135.74, 135.72, 
133.79, 129.77, 127.79, 66.29, 61.21, 46.05, 34.39, 34.11, 30.35, 27.05, 26.08, 19.45, 18.40, -
5.22. IR (thin film, cm-1) 2929.58, 2856.76, 1715.73, 1470.92, 1427.38, 1253.71, 1107.31, 
835.12, 775.91, 739.30, 702.57, 613.61, 504.68. OR [α]D22 -2.1º (c 1.0, CHCl3). HRMS (FAB+): 
calculated for C29H45O3Si2 [M-H]- 497.2907; found 497.2917. 
 
3.6.2. Preparation of aldehyde subunit 3.29 
  
Alcohol 3.32 was prepared using a modified literature procdure.7 To a cooled (0 °C) 
solution of (S,S)-3.37 (20.3 g, 70.0 mmol) in CH2Cl2 (250 mL) was added DBU (31.4 mL, 210 
mmol). The allyltrichlorosilane (11.2 mL, 77 mmol) was then added slowly. The ice/water bath 
was removed and after 1 h the mixture was recooled to 0 °C. Aldehyde 3.31 (13.6 g, 70.0 mmol), 
which was prepared according to literature procedure,10 was added and the resulting solution was 
stirred at 0 °C for 1 h.  
 The mixture was concentrated and the residue was suspended in Et2O (250 mL). The 
mixture was stirred vigorously for 20 min to ensure complete precipitation of the DBU•HCl 
salts. The mixture was then filtered through a frit, and the filtrate was treated with TBAF (70.0 
mL, 70.0 mmol, 1 M in THF). After 2.5 h, aqueous 1 M HCl (350 mL, 350 mmol) was added 
O OPMB
H










and the mixture was transferred to a separatory funnel. The layers were separated and the 
aqueous layer was extracted with Et2O (3 x 100 mL). The combined organic layers were washed 
with H2O (2 x 50 mL) and saturated aqueous NaHCO3 (1 x 100 mL), dried over MgSO4, filtered 
and concentrated. The residue was purified by chromatography on silica gel to provide pure 3.32 
as a pale yellow oil (12.3 g, 52.2 mmol, 75% yield, 97% ee). 1H NMR (400 MHz, CDCl3) δ 7.28 
(m, 2H), 7.01 – 6.79 (m, 2H), 5.86 (ddt, J = 17.4, 10.4, 7.1 Hz, 1H), 5.20 – 5.05 (m, 2H), 4.48 (s, 
2H), 3.93 – 3.85 (m, 1H), 3.83 (s, 3H), 3.72 (dt, J = 9.3, 5.3 Hz, 1H), 3.65 (ddd, J = 9.3, 6.7, 5.4 
Hz, 1H), 2.88 (s, 1H), 2.27 (ddt, J = 7.4, 6.3, 1.3 Hz, 2H), 1.84 – 1.67 (m, 2H). The 1H NMR 
spectroscopic data is in agreement with data reported in literature.11 The enantiomeric excess was 
determined by chiral HPLC analysis: OD-H column, 98:2 hexanes:iPrOH, 1 mL/min, 254 nm, 
where the desired R-enantiomer 3.32 has been established to elute second.11  
 To recover (S,S)-3.37, the combined aqueous layers from above are treated with aqueous 
3 M NaOH (240 mL) and extracted with CH2Cl2 (5 x 100 mL). The combined organic layers 
were washed with water (2 x 100 mL), dried over MgSO4, filtered, and concentrated. The residue 
was dissolved in minimal hot 9:1 MeOH:H2O (during the dissolution process the temperature 
should not be allowed to exceed 80 °C, as the ligand may start to undergo decomposition at 
higher temperatures). The hot saturated solution is allowed to cool to room temperature, and 
distilled water (10.0 mL) was added to ensure complete crystallization of 3.37. The white solid is 
collected by filtration through a frit with a cold 1:1 MeOH:H2O rinse and then dried in vacuo at 





 To a solution of 3.32 (17.8 g, 75.2 mmol) in CH2Cl2 (225 mL) at 0 ºC was added Et3N 
(13.6 mL, 97.7 mmol) followed by slow addition of TESCl (12.6 mL, 75.2 mmol) and DMAP 
(0.28 g, 2.2 mmol). The resulting solution was stirred at room temperature for 2 h. MeOH (3.0 
mL) was added to quench unreacted TESCl and the resulting solution was concentrated in vacuo. 
The resulting residue was resuspended in hexanes and the Et3N•HCl salts were removed by 
filtration. The filtrate was concentrated to give crude 3.33 as a pale orange oil (26.6 g, 76 mmol, 
100% yield), which was used without further purification. 1H NMR (500 MHz, CDCl3) δ 7.34 – 
7.24 (m, 2H), 6.95 – 6.84 (m, 2H), 5.84 (ddt, J = 16.3, 11.1, 7.1 Hz, 1H), 5.11 – 5.01 (m, 2H), 
3.92 (m, 1H), 3.83 (s, 3H), 3.61 – 3.46 (m, 2H), 2.38 (s, 1H), 2.25 (m, 2H), 1.81 (m, 1H), 1.71 
(m, 1H), 0.98 (t, J = 8.0 Hz, 9H), 0.62 (q, J = 7.7 Hz, 6H). 
 
 To a solution of crude 3.33 (15.5 g, 44.2 mmol) in dioxane:H2O (330 mL:110 mL) were 
sequentially added 2,6-lutidine (6.7 mL, 57.5 mmol), OsO4 (168 mg, 0.66 mmol), and NaIO4 
(21.7 g, 102 mmol). The resulting reaction mixture was stirred at room temperature for 2.5 h. 
The reaction mixture was cooled to 0 ºC and carefully quenched with saturated Na2S2O3 solution 
(250 mL). The aqueous layer was extracted with Et2O (3 x 100 mL). The combined organic 
layers were dried over MgSO4, filtered and concentrated. The resulting residue was purified by 
silica gel column chromatography eluting with 5:95 à 15:85 EtOAc:Hexanes to give pure 3.30 
was a pale yellow oil (13.5 g, 38.3 mmol, 87% yield). 1H NMR (500 MHz, CDCl3) δ 9.78 (t, J = 
2.3 Hz, 1H), 7.30 – 7.16 (m, 2H), 6.92 – 6.82 (m, 2H), 4.47 – 4.33 (m, 3H), 3.79 (s, 3H), 3.58 – 













3.42 (m, 2H), 2.63 – 2.45 (m, 2H), 1.93 – 1.73 (m, 1H), 0.94 (t, J = 8.0 Hz, 9H), 0.60 (q, J = 8.0 
Hz, 6H). 13C NMR (126 MHz, CDCl3) δ 201.98, 159.30, 130.47, 129.36, 113.86, 72.77, 66.15, 
65.70, 55.33, 51.27, 37.87, 6.91, 5.02. IR (thin film, cm-1) 2953.35, 2875.97, 1724.20, 1612.12, 
1512.76, 1460.61, 1366.01, 1246.54, 1173.87, 1093.77, 1026.86, 820.20, 741.84. OR [α]D19 -6.1º 
(c 1.0, CHCl3). HRMS (FAB+): calculated for C19H31O4Si 351.1992 [M+H]+; found 351.1994. 
  
Diol 3.34 was prepared using a modified literature procdure.7 To a cooled (0 °C) solution 
of (S,S)-3.37 (8.02 g, 27.6 mmol) in CH2Cl2 (100 mL) was added DBU (12.4 mL, 82.8 mmol). 
The cis-crotyltrichlorosilane (4.6 mL, 30.4 mmol) was then added slowly. The ice/water bath 
was removed and after 1 h the mixture was recooled to 0 °C. Aldehyde 3.38 (9.13 g, 25.9 mmol) 
was added and the resulting solution is stirred at 0 °C for 1 h.  
 The mixture was concentrated and the residue was resuspended in Et2O (100 mL). The 
mixture was stirred vigorously for 20 min to ensure complete precipitation of the DBU•HCl 
salts. The mixture was then filtered through a frit, and the filtrate was treated with TBAF (52.0 
mL, 52.0 mmol, 1 M in THF). After 2.5 h, aqueous 1 M HCl (140 mL, 140 mmol) was added 
and the mixture was transferred to a separatory funnel. The layers were separated and the 
aqueous layer was extracted with Et2O (3 x 50 mL). The combined organic layers were washed 
with H2O (2 x 25 mL) and saturated aqueous NaHCO3 (1 x 50 mL), dried over MgSO4, filtered, 
and concentrated. The residue was purified by chromatography on silica gel to provide pure 3.34 
as a pale yellow oil (7.24 g, 24.6 mmol, 95% yield, 15:1 dr). 1H NMR (500 MHz, CDCl3) δ 7.28 
– 7.19 (m, 2H), 6.95 – 6.80 (m, 2H), 5.78 (ddd, J = 17.1, 10.6, 7.5 Hz, 1H), 5.09 – 4.98 (m, 2H), 
















4.44 (s, 2H), 4.09 – 3.98 (m, 1H), 3.88 – 3.81 (m, 1H), 3.80 (s, 3H), 3.75 – 3.69 (m, 1H), 3.69 – 
3.64 (m, 1H), 3.64 – 3.54 (m, 2H), 2.35 – 2.15 (m, 1H), 1.86 – 1.65 (m, 2H), 1.58 (dt, J = 14.3, 
2.3 Hz, 1H), 1.48 (dt, J = 14.4, 10.1 Hz, 1H), 1.03 (d, J = 6.9 Hz, 3H). 13C NMR (126 MHz, 
CDCl3) δ 159.43, 141.00, 130.02, 129.45, 115.08, 113.99, 75.76, 73.10, 72.74, 68.51, 55.37, 
44.16, 40.03, 37.09, 15.03. IR (thin film, cm-1) 3377.75, 2938.45, 2862.90, 1611.94, 1512.52, 
1420.55, 1301.43, 1246.34, 1174.40, 1089.12, 1034.69, 914.93, 820.25, 569.55. OR [α]D19 -6.1º 
(c 1.0, CHCl3). HRMS (FAB+): calculated for C17H27O4 295.1909 [M+H]+; found 295.1911. 
To recover (S,S)-3.37, see procedure described following preparation of alcohol 3.32. 
  
 To a solution of 3.34 (9.27 g, 31.5 mmol) in dimethoxypropane (210 mL) was added 
CSA (0.37 g, 1.6 mmol). The resulting solution was stirred at room temperature for 1 h. 
Saturated NaHCO3 (75 mL) was added. The aqueous layer was extracted with EtOAc (3 x 50 
mL). The combined organic layers were washed with H2O (1 x 75 mL), dried over Na2SO4, 
filtered, and concentrated to give crude 3.35 as a pale yellow oil (10.4 g, 31.2 mmol, 99% yield) 
that was used without further purification. Purification for a characterization sample was 
achieved by silica gel column chromatography eluting with 0:100 à 10:90 EtOAc:Hexanes to 
give pure 3.35 as a pale yellow oil.  1H NMR (400 MHz, CDCl3) δ 7.31 – 7.20 (m, 2H), 6.93 – 
6.80 (m, 2H), 5.72 (ddd, J = 17.1, 10.4, 7.7 Hz, 1H), 5.11 – 4.95 (m, 2H), 4.42 (s, 2H), 4.04 – 
3.91 (m, 1H), 3.80 (s, 3H), 3.64 – 3.42 (m, 3H), 2.24 – 2.10 (m, 1H), 1.82 – 1.60 (m, 2H), 1.46 
(dt, J = 12.9, 2.5 Hz, 1H), 1.41 (s, 3H), 1.37 (s, 3H), 1.11 (dt, J = 12.6, 11.5 Hz, 1H), 1.02 (d, J = 
6.7 Hz, 3H). 13C NMR (101 MHz, CDCl3) δ 159.28, 140.36, 130.84, 129.35, 114.98, 113.89, 












cm-1) 2859.39, 1612.08, 1512.49, 1460.63, 1378.20, 1300.69, 1247.24, 1199.51, 1174.41, 
1096.76, 1035.17, 915.21, 872.23, 817.36, 522.38. OR [α]D21 -16.3º (1.0, CHCl3). HRMS 
(FAB+) calculated for C20H29O4 [M+H]+ 333.2066; found 333.2060. 
 
To a solution of crude PMB ether 3.35 (4.00 g, 12.0 mmol) in CH2Cl2 (106 mL) was 
added pH 7 buffer solution (14 mL). The resulting mixture was cooled to 0 ºC. DDQ (4.07 g, 
17.9 mmol) was added in 3 portions at a rate of 1 portion per 3 min. The resulting mixture was 
stirred at 0 ºC for 5 min and at room temperature for 1 h. The reaction mixture was filtered 
through celite, on to pH 7 buffer solution (100 mL), rinsing with CH2Cl2. The aqueous layer was 
extracted with CH2Cl2 (3 x 50 mL). The combined organic layers were washed with saturated 
NaHCO3 solution (1 x 100 mL) and H2O (1 x 100 mL), dried over Na2SO4, filtered, and 
concentrated in vacuo. The resulting crude oil was purified by pH 7 buffered silica gel column 
chromatography eluting with 10:90 à 30:70 EtOAc:Hexanes to give pure 3.36 was a pale 
yellow oil (2.46 g, 11.4 mmol, 96%). 1H NMR (400 MHz, CDCl3) δ 5.70 (ddd, J = 17.2, 10.4, 
7.8 Hz, 1H), 5.08 – 4.94 (m, 2H), 4.05 (dddd, J = 11.7, 7.3, 4.6, 2.6 Hz, 1H), 3.83 – 3.66 (m, 
2H), 3.59 (ddd, J = 11.6, 7.3, 2.4 Hz, 1H), 2.60 (s, 1H), 2.24 – 2.08 (m, 1H), 1.80 – 1.62 (m, 2H), 
1.48 – 1.40 (m, 1H), 1.43 (s, 3H), 1.37 (s, 3H), 1.23 (dt, J = 13.0, 11.5 Hz, 1H), 1.01 (d, J = 6.7 
Hz, 3H). 13C NMR (101 MHz, CDCl3) δ 140.13, 115.19, 98.72, 72.42, 69.60, 61.04, 43.45, 
38.30, 34.47, 30.32, 19.93, 15.82. IR (thin film, cm-1) 3418.36, 2945.88, 1379.29, 1257.10, 
1199.52, 1099.69, 1052.76, 997.58, 964.52, 915.60, 874.11. OR [α]D21 -27.7º (c 1.0, CHCl3). 
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To a solution of oxalyl chloride (4.4 mL, 52.4 mmol) in CH2Cl2 (175 mL) at -78 ºC was 
added DMSO (7.4 mL, 105 mmol). The resulting mixture was stirred for 20 min at -78 ºC. A 
solution of solution of 3.36 (5.61 g, 26.2 mmol) in CH2Cl2 (90 mL) was added slowly and the 
resulting mixture was stirred for 20 min. Et3N (24.5 mL, 175 mmol) was added dropwise. The 
resulting thick white mixture was stirred at room temperature for 30 min. The reaction mixture 
was quenched with water (100 mL) and all volatiles were removed in vacuo. The resulting 
residue was extracted with Et2O (3 x 100 mL). The combined ether layers were washed with 
water (1 x 100 mL), dried over Na2SO4, filtered, and concentrated to give crude 3.29 as a pale 
yellow oil (5.6 g, 26 mmol, 100% yield), which was used without further purification. 1H NMR 
(400 MHz, CDCl3) δ 9.77 (dd, J = 2.3, 1.7 Hz, 1H), 5.70 (ddd, J = 17.1, 10.4, 7.8 Hz, 1H), 5.11 – 
4.95 (m, 2H), 4.35 (dddd, J = 12.0, 7.4, 5.0, 2.6 Hz, 1H), 3.62 (ddd, J = 11.5, 7.3, 2.4 Hz, 1H), 
2.60 (ddd, J = 16.6, 7.3, 2.3 Hz, 1H), 2.45 (ddd, J = 16.6, 5.0, 1.8 Hz, 1H), 2.25 – 2.12 (m, 1H), 
1.55 (dt, J = 12.9, 2.5 Hz, 1H), 1.44 (s, 3H), 1.37 (s, 3H), 1.18 (dt, J = 12.8, 11.5 Hz, 1H), 1.02 
(d, J = 6.8 Hz, 3H). 13C NMR (101 MHz, CDCl3) δ 201.18, 140.00, 115.36, 98.93, 72.28, 64.94, 
50.09, 43.48, 34.48, 30.16, 19.81, 15.84. IR (thin film, cm-1) 2924.38, 2854.11, 1717.25, 
1380.14, 1259.40, 1200.84, 1101.76, 964.50, 917.34, 770.72. OR [α]D22 -18.1º (0.8, CHCl3). 
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3.6.3. Anti-aldol and elaboration to final CD* aldehyde 3.43 
 
To a solution of iPr2NH (4.5 mL, 32.1 mmol) in THF (170 mL) at -78 ºC was added n-
BuLi (11.1 mL, 27.8 mmol, 2.5 M in hexanes). The resulting solution was stirred at -78 ºC for 5 
min and at 0 ºC for 10 min before cooling back to -78 ºC. A solution of 3.12 (10.7 g, 21.4 mmol) 
in THF (25 mL) was added slowly, rinsing with THF (15 mL), and stirred 20 min. TMSCl (4.6 
mL, 36.4 mmol) was added slowly and stirred for 1 h. The resulting reaction mixture was 
warmed to room temperature and concentrated in vacuo via rotary evaporation to give a thick 
cloudy oil. [CAUTION: over concentration will result in isomerization of the enol ether product]. 
The resulting residue was resuspended in pentane and the iPr2NH•HCl salts were removed by 
filtration. The filtrate was concentrated in vacuo to give the enol ether as a pale yellow oil that is 
used without further purification. 
To a solution of enol ether 3.27 and crude aldehyde 3.29 (4.13 g, 19.5 mmol) in CH2Cl2 
(200 mL) at -78 ºC was added BF3•Et2O (2.52 mL, 20.4 mmol) over 20 min via syringe pump. 
The resulting solution was stirred for 1 h at -78 ºC and then quenched with saturated NaHCO3 
(100 mL). The aqueous layer was extracted with CH2Cl2 (3 x 50 mL), dried over Na2SO4, 
filtered, and concentrated to give the crude product is a 7:1 dr. The crude material was purified 
by silica gel column chromatography eluting with 5:95 à 20:80 EtOAc:Hexanes to give 3.38 as 
a colorless oil in 7:1 dr (10.8 g, 15.2 mmol, 78% yield). 1H NMR (400 MHz, CDCl3) δ 7.71 – 
7.54 (m, 4H), 7.48 – 7.29 (m, 6H), 5.72 (ddd, J = 17.7, 10.4, 7.7 Hz, 1H), 5.13 – 4.94 (m, 2H), 
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J = 16.8, 6.8 Hz, 1H), 2.58 – 2.45 (m, 2H), 2.40 (dd, J = 16.8, 6.3 Hz, 1H), 2.34 – 2.23 (m, 1H), 
2.18 (hept, J = 6.8, 6.4 Hz, 1H), 1.68 – 1.44 (m, 5H), 1.43 (s, 3H), 1.38 (s, 3H), 1.27 – 1.13 (m, 
1H), 1.05 (s, 9H), 1.03 (d, J = 6.7 Hz, 3H), 0.85 (s, 9H), -0.01 (d, J = 1.6 Hz, 6H). 13C NMR 
(101 MHz, CDCl3) δ 211.42, 140.25, 135.73, 135.70, 133.74, 129.81, 127.81, 115.12, 98.75, 
72.59, 66.39, 66.03, 64.50, 61.20, 49.90, 45.73, 43.46, 42.66, 34.68, 34.36, 33.71, 30.37, 27.07, 
26.09, 19.94, 19.45, 18.40, 15.86, -5.21. IR (thin film, cm-1) 2952.20, 2930.10, 2856.94, 
1705.56, 1470.41, 1427.47, 1379.52, 1254.26, 1199.79, 1102.87, 998.57, 916.69, 834.37, 776.39, 
703.07, 504.85. OR [α]D19 -4.7º (c 1.0, CHCl3). HRMS (FAB+): calculated for C41H66O6Si2Na 
[M+Na]+ 733.4296; found 733.4267. 
 
 To a solution of 3.38 (10.8 g, 15.2 mmol) in CH2Cl2 (150 mL) was added 4 Å MS (11.0 
g), proton sponge (32.6 g, 152 mmol) and BF4•Me3O (18.1 g, 122 mmol), sequentially. The 
resulting mixture was stirred at room temperature for 5 h and then filtered through celite, rinsing 
with EtOAc. The filtrate was washed with aqueous 1 M AcOH (1 x 500 mL), saturated NaHCO3 
(1 x 300 mL), dried over MgSO4, filtered, and concentrated. The resulting residue was purified 
by silica gel column chromatography eluting with 5:95 à 20:80 EtOAc: Hexanes to give 3.39 as 
a colorless oil in 7:1 dr (10.20 g, 14.1 mmol, 93% yield). 1H NMR (400 MHz, CDCl3) δ 7.71 – 
7.52 (m, 4H), 7.49 – 7.31 (m, 6H), 5.72 (ddd, J = 17.3, 10.4, 7.7 Hz, 1H), 5.12 – 4.93 (m, 2H), 
4.02 – 3.91 (m, 1H), 3.91 – 3.81 (m, 1H), 3.68 – 3.47 (m, 5H), 3.32 (s, 3H), 2.64 (ddd, J = 24.3, 
16.4, 7.0 Hz, 2H), 2.49 – 2.35 (m, 2H), 2.28 (h, J = 6.1 Hz, 1H), 2.18 (h, J = 7.0 Hz, 1H), 1.68 – 
1.45 (m, 4H), 1.45 – 1.39 (m, 1H), 1.41 (s, 3H), 1.37 (s, 3H), 1.17 – 1.07 (m, 1H), 1.06 (s, 9H), 


















209.00, 140.34, 135.74, 135.73, 133.83, 129.76, 127.79, 115.02, 98.60, 73.98, 72.57, 66.10, 
65.72, 61.31, 58.18, 48.83, 46.10, 43.46, 42.57, 35.13, 34.46, 33.70, 30.40, 27.08, 26.09, 19.97, 
19.47, 18.40, 15.83, -5.19. IR (thin film, cm-1) 2929.77, 2855.34, 1713.08, 1469.87, 1378.42, 
1252.55, 1199.29, 1090.35, 834.87, 703.04, 505.08. OR [α]D19 -8.4º (c 1.0, CHCl3). HRMS 
(FAB+): calculated for C42H68O6Si2Na [M+Na]+ 747.4452; found 747.4445. 
  
To a solution of ketone 3.39 (70 mg, 0.1 mmol) in MeOH (1.0 mL) was added PPTS (25 
mg, 0.1 mmol). The resulting mixture was stirred for 20 h at which time additional PPTS (25 mg, 
0.1 mmol) was added and stirred for another 2 h. The reaction mixture was quenched by addition 
of saturated NaHCO3 (3.0 mL). The resulting mixture was extracted with CH2Cl2 (3 x 2.0 mL). 
The combined organic layers were dried over MgSO4, filtered, and concentrated in vacuo to give 
the crude product as a colorless oil which was purified by silica gel column chromatography 
eluting with 5:95 à 20:80 EtOAc:Hexanes. The product 3.40 was isolated as a colorless oil (42 
mg, 0.075 mmol, 78% yield). 1H NMR (500 MHz, CDCl3) δ 7.74 – 7.57 (m, 4H), 7.48 – 7.29 
(m, 6H), 5.84 (ddd, J = 17.6, 10.4, 7.6 Hz, 1H), 5.12 – 5.02 (m, 2H), 3.92 – 3.80 (m, 1H), 3.76 – 
3.59 (m, 5H), 3.48 (dd, J = 10.0, 5.2 Hz, 1H), 3.42 (dd, J = 10.0, 5.7 Hz, 1H), 3.33 (s, 3H), 2.28 
(h, J = 6.9 Hz, 1H), 2.14 – 2.07 (m, 1H), 2.07 – 1.96 (m, 2H), 1.74 – 1.55 (m, 4H), 1.45 – 1.35 
(m, 1H), 1.35 – 1.22 (m, 2H), 1.18 (q, J = 11.7 Hz, 1H), 1.08 (d, J = 6.8 Hz, 3H), 1.05 (s, 9H). 
13C NMR (126 MHz, CDCl3) δ 141.15, 135.75, 133.77, 129.73, 127.77, 114.96, 98.31, 75.54, 
72.67, 70.31, 68.33, 60.43, 55.64, 44.10, 41.74, 39.60, 38.22, 37.96, 33.00, 28.07, 27.05, 19.47, 
15.26. IR (thin film, cm-1) 3501.12, 3060.67, 2925.84, 2858.43, 1635.96, 1420.22, 1379.78, 
Me
















1105.62, 710.11. OR [α]D22 +32.4º (c 1.8, CHCl3). HRMS (FAB+): calculated for C33H48O5SiNa 
[M+Na]+ 575.3169; found 575.3161. 
 
 To a cooled solution of 3.40 (4.79 g, 8.7 mmol) in CH2Cl2 (90 mL) at 0 ºC was 
sequentially added Et3N (2.66 mL, 19.1 mmol), TESCl (2.91 mL, 17.3 mmol), and DMAP (0.21 
g, 1.7 mmol). The resulting mixture was warmed to room temperature and stirred 15 h. Excess 
TESCl was quenched by the addition of MeOH (0.80 mL) and the reaction mixture was 
concentrated. The resulting residue was resuspended in hexanes and the Et3N•HCl salts were 
removed by filtration. The filtrate was concentrated and purified by silica gel column 
chromatography eluting with 5:95 EtOAc:Hexanes to give 3.42 as a colorless oil (5.38 g, 8.1 
mmol, 93% yield). 1H NMR (400 MHz, CDCl3) δ 7.72 – 7.56 (m, 4H), 7.51 – 7.28 (m, 6H), 6.02 
– 5.80 (m, 1H), 5.13 – 4.92 (m, 2H), 3.88 – 3.71 (m, 2H), 3.70 – 3.58 (m, 3H), 3.50 (dd, J = 9.9, 
5.3 Hz, 1H), 3.42 (dd, J = 9.8, 6.3 Hz, 1H), 3.35 (s, 3H), 2.50 – 2.35 (m, 1H), 2.28 – 2.14 (m, 
1H), 2.13 – 1.99 (m, 2H), 1.81 – 1.53 (m, 4H), 1.34 (qd, J = 12.2, 6.3 Hz, 1H), 1.24 (dd, J = 
12.9, 11.6 Hz, 2H), 1.06 (s, 9H), 1.10 – 1.02 (m, 1H), 1.02 – 0.92 (m, 12H), 0.62 (q, J = 7.9 Hz, 
6H). 13C NMR (101 MHz, CDCl3) δ 141.52, 135.74, 133.96, 133.93, 129.70, 127.75, 114.38, 
97.65, 73.38, 72.82, 68.69, 65.44, 60.30, 55.61, 43.06, 41.85, 40.59, 38.78, 37.50, 32.98, 28.69, 
27.00, 19.47, 14.56, 7.13, 5.36. IR (thin film, cm-1) 3071.31, 2953.46, 2931.51, 2876.11, 
1639.26, 1460.81, 1384.58, 1238.87, 1092.22, 1004.32, 823.54, 738.91, 702.51, 613.64, 504.68. 
OR [α]D18 +21.5º (c 1.0, CHCl3). HRMS (ESI+): calculated for C39H62O5Si2Na [M+Na]+ 

























 A solution of 3.42 (1.15 g, 1.7 mmol) in CH2Cl2 (17 mL) was cooled to -78 ºC while 
flushing with O2 over 5 min. The reaction solution was flushed with O3 until the solution turned 
blue (8 min.). The resulting solution was flushed with O2 for 5 min to give and cloudy white 
mixture. PPh3 (0.54 g, 2.1 mmol) was added at -78 ºC and the resulting mixture was warmed to 
room temperature. After stirring for 12h, all volatiles were removed in vacuo. The resulting 
residue was resuspended in hexanes and OPPh3 was removed by filtration. The filtrate was 
concentrated and purified by silica gel column chromatography eluting with 5:95 à 15:85 
EtOAc:Hexanes to give 3.43 as a colorless oil (1.07 g, 1.6 mmol, 94% yield). 1H NMR (400 
MHz, CDCl3) δ 9.78 (d, J = 1.0 Hz, 1H), 7.75 – 7.56 (m, 4H), 7.51 – 7.30 (m, 6H), 4.52 – 4.40 
(m, 1H), 3.72 – 3.52 (m, 4H), 3.52 – 3.39 (m, 2H), 3.34 (s, 3H), 2.61 – 2.51 (m, 1H), 2.25 – 2.12 
(m, 1H), 2.09 (ddd, J = 12.5, 4.7, 1.7 Hz, 1H), 2.05 – 1.95 (m, 1H), 1.85 – 1.57 (m, 4H), 1.42 – 
1.29 (m, 1H), 1.29 – 1.18 (m, 2H), 1.11 (d, J = 6.9 Hz, 3H), 1.16 – 1.08 (m, 1H) 1.05 (s, 9H), 
0.95 (t, J = 7.9 Hz, 9H), 0.67 – 0.53 (m, 6H). 13C NMR (101 MHz, CDCl3) δ 205.09, 135.73, 
133.90, 129.74, 127.75, 97.77, 73.14, 68.62, 68.51, 65.17, 60.47, 55.66, 51.15, 41.80, 41.23, 
38.86, 37.53, 33.12, 28.55, 27.00, 19.47, 7.62, 6.98, 5.23. IR (thin film, cm-1) 2930.27, 2876.13, 
1726.84,1589.43,1460.95, 1385.02, 1239.55, 1103.61, 821.61, 703.05, 613.63, 504.98. OR 




   -78 °C
ii) PPh3























3.7. HPLC Data  
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Chapter 4: AB-CD* coupling and elaboration to final ABCD* 
4.1. Introduction 
 
Scheme 4.1. Retrosynthesis of ABCD* 
With the AB diene (4.2)1 and CD* aldehyde (4.3) in hand (Scheme 4.1), we were excited 
to complete this synthesis of ABCD* 4.1. As discussed in Chapter 1, the foundation for the 
proposed coupling of 4.2 and 4.3 by crotylation was established by Dr. Samuel Reznik, a former 
graduate student of our group. In his report, he demonstrated the efficient coupling of various 
complex dienes with chiral aldehydes,2 and this methodology was subsequently extended to the 
coupling of AB diene 4.2 to a model chiral aldehyde 4.7 to access the product 4.8 in 59% yield 
and 10:1 dr (Scheme 4.2).1  
 
























































































   CH2Cl2, 0 to 23 °C
ii. concentrate, remove



















Having prepared CD* aldehyde 4.3 (Chapter 3), we were able to apply these previously 
reported conditions to the real system (Scheme 4.3). Thus, AB-silane 4.6 was formed by hydro-
silylation of AB-diene 4.2 and subsequent treatment of the resulting product with diamine (R,R)-
4.5 and DBU. Upon removal of the DBU•HCl salts, AB-silane 4.6 was reacted with CD* 4.3 in 
the presence of 10 mol% Sc(OTf)3 to provide the desired product (4.9) in 77% yield and >15:1 
dr. Despite achieving a high yield in this reaction, we were still concerned about the technically 
challenging procedure employed to isolate the sensitive AB-silane intermediate 4.6, which 
required multiple solvent switches and a filtration under strictly anhydrous conditions. This 
considerable amount of manipulation of 4.6 increases the opportunity to introduce water into the 
reaction, which would ultimately result in the hydrolysis of 4.6. The moisture sensitivity of 4.6 
manifests itself in the requirement of 1.3 equivalents of AB-diene 4.2 to fully consume CD* 
aldehyde 4.3 and the variability of the yield of 4.9 (50-77% yield) in other runs of this coupling 
reaction. We were uncomfortable with potential risk of hydrolyzing 4.6 on larger scales and were 
interested in a more practical AB-CD coupling protocol that minimizes the manipulation of 4.6. 
 
Scheme 4.3. First generation AB-CD coupling: preparation of ABCD* couple product 4.9 
Consequently, we developed a one-pot crotylation protocol (Chapter 2) that does not 

















































1. 1 mol% Pd(PPh3)4,
    HSiCl3, C6H6, 70 °C
2. i) (R,R)-4.5, 
       DBU, CH2Cl2
    ii) concentrate, remove




new crotylation methodology for the AB-CD coupling. The following chapter will describe the 
challenges faced in applying the one-pot crotylation methodology to the AB-CD coupling and 
the steps taken to transform ABCD* coupled product to its fully elaborated form in preparation 
for coupling to the EF fragment.  
 
4.2. Preliminary results for model one-pot coupling reactions 
At the outset, we planned to investigate the implementation of a one-pot coupling proce-
dure using model diene 4.10 in order to compare our results to those reported for the first genera-
tion crotylation-based coupling model studies.2 Hydrosilylation of 4.10 with HSiCl3 and catalytic 
Pd(PPh3)4 afforded the corresponding crotyltrichlorosilane 4.11, as expected. Silane 4.11 was 
subsequently reacted with diaminophenol 4.12 and DBU to access silane 4.13, but the reaction 
was very messy and resulted in two major products as a 4:1 mixture (Scheme 4.4). Due to the 
sensitivity of these silanes, isolation and separation to identify the products was not feasible. 
 
Scheme 4.4. Complexation of model crotyltrichlorosilane 4.11 with diaminophenol 4.12 
We previously had not observed the diaminosilane reagent forming as a mixture during 
the development of the one-pot crotylation methodology using simple crotyltrichlorosilanes 
(Chapter 2). As a result, we wondered if we were observing a slow complexation due to the 

































chlorosilane. Based on this hypothesis, we tried forcing the reaction by heating to 50 °C, but this 
resulted in the formation of a third compound (Scheme 4.4). According to 1H NMR and mass 
spectrometry of the isolated product, the structure of the new compound was assigned as 4.14, 
which could have been formed by an intramolecular reaction of the silane with the neighboring 
acetate group (4.13 to 4.14, Scheme 4.4).   
Concerned that our one-pot crotylation methodology was not compatible with the C5 
acetate group on AB-diene 4.2, we went ahead and attempted the complexation of diamino-
phenol 4.12 with silane 4.4, which was formed by hydrosilylation of AB-diene 4.2 (Scheme 4.5). 
As was observed for the model system, this reaction did not progress cleanly, affording two 
major products in a 4:1 mixture. However, heating the mixture neither led to decomposition nor 
significant improvements in the product ratio. These results suggested that acetate groups could 
be compatible with this chemistry if they are not in close proximity to the silicon. In addition, the 
mixture of products that we observed may not be due to incomplete complexation, since we 
would expect the product ratio to change with increasing temperature if that were the case. 
Alternatively, decomposition of silane 4.15 or its precursor 4.4 could also potentially account for 
the observed mixture of products. After establishing these results, we returned to a model system 
to determine why the desired diaminosilane was not forming cleanly. 
 
Scheme 4.5. Complexation of AB-crotyltrichlorosilane 4.4 with diaminophenol 4.12 
To avoid the side reaction experienced when using an acetate protecting group, we pre-


































4.6). Benzylation of known alcohol 4.162 was achieved by treatment with BnBr, NaH, and 
catalytic TBAI, but this reaction also always yielded ~5-10% dibenzylether that was inseparable 
from the desired product 4.17. Fortunately, dibenzylether was inert and could be carried through 
subsequent reactions without affecting the results.  
 
Scheme 4.6. Preparation of benzyl protected diene 4.17  
Similar to previous diene substrates, hydrosilylation of diene 4.17 proceeded cleanly, 
then reaction of the resulting product 4.18 with diaminophenol 4.12 and DBU afforded a 3:1 
mixture of major products (Scheme 4.7). While varying the reaction conditions of the complexa-
tion in hopes of identifying possible decomposition pathways, 4.18 was found to be unstable to 
both 4.12 and DBU when applied on their own. To ensure complete consumption of these amine 
reagents, we modified the stoichiometry to use 0.2 equivalents excess of 4.17 relative to 4.12, 
which gratifyingly gave complete and clean conversion to the desired product 4.19 (Scheme 4.7). 
These results suggested that the observed messy reaction progress and formation of a mixture of 
products can be attributed to the decomposition of 4.18 and the excess diaminophenol 4.12 or 
DBU may be acting as Lewis bases and attacking any 4.19 that does form. After further 
optimization, we found that using 1.1 equivalents of 4.17 along with inverse addition of reagents 
allowed for clean formation of the desired silane 4.19 with minimal 4.18 remaining. 
 

























1.0 equiv. 4.17: 3:1 product mixture
1.2 equiv. 4.17: complete clean conversion
 165 
With an optimized and reliable complexation procedure in place, we were finally able to 
attempt the crotylation of aldehydes with silane 4.19. Using the above optimized conditions, 4.19 
was formed and, without its isolation, hydrocinnamaldehyde (4.20) was added directly to the 
reaction mixture (Scheme 4.8). Upon quenching by the addition of TBAF, the desired product 
4.21 was afforded in 73% yield and 10:1 dr.  
 
Scheme 4.8. Proof of concept reaction using one-pot crotylation protocol 
 
Scheme 4.9. Preparation of model chiral aldehyde 4.7 
 Excited by these results, we prepared aldehyde 4.7 (Scheme 4.9), with the α and β stereo-
centers set in the same configuration as our CD* aldehyde 4.3 (Scheme 4.1). Straightforward 
preparation of aldehyde 4.7 was achieved through cis-crotylation of hydrocinnamaldehyde (4.20) 
TES protection of the resulting secondary alcohol 4.22, and ozonolysis of the terminal olefin of 
4.23 to provide 4.7 in 62% yield over 3 steps. Aldehyde 4.7 was evaluated in a model coupling 
reaction as described by Scheme 4.10, but surprisingly, silane 4.19 was unreactive towards 4.7, 
and provided only trace product.  
 
Scheme 4.10. Model one-pot coupling reaction with α,β-chiral aldehyde 4.7 
Ph
OBn
1. 2 mol% 
    Pd(PPh3)4,
    HSiCl3,
    C6H6, 80 °C
2. (R,R)-4.12, 





































i) O3, -78 °C
   CH2Cl2
ii) PPh3
   -78 to 23 °C
4.20 4.22 4.23 4.780%, 94% ee
91% 4.12 recov. 83% 93%
Ph
OBn
1. 2 mol% 
    Pd(PPh3)4,
    HSiCl3,
    C6H6, 80 °C
2. (R,R)-4.12, 




















4.17 4.19 4.24trace product
4.7
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This lack in reactivity was especially unexpected since the first generation crotylsilane 
reagents are able to undergo this reaction efficiently (Scheme 4.2). In our efforts to explain the 
observed breakdown in reactivity, we analyzed the transition state for this reaction (Scheme 
4.11). Based on first-order assumptions and theoretical studies for our first generation 
crotylsilane reagents,3 we propose the transition state as depicted in 4.25, wherein crotylsilane 
4.19 reacts with aldehyde 4.7 through a closed Zimmerman-Traxler type transition state with the 
aldehyde substituent in the equatorial position to minimize A-1,3 strain. The diastereochemical 
outcome for similar addition of enolates and crotylmetal reagents to chiral aldehydes has been 
extensively studied, notably by the Evans group as well as others.4-8 Specifically, it has been 
demonstrated that Z-crotylmetal reagents and Z-enolates preferentially add to the anti-Felkin face 
of α-chiral aldehydes to minimize syn-pentane and gauche-pentane strain between the aldehyde’s 
α-substituents and the crotylmetal’s axial methyl group. These interactions are also present in our 
system, and therefore, we propose that 4.19 also adds to the anti-Felkin face of aldehyde 4.7. The 
stereochemical outcome afforded by a transition state such as 4.25 for the analogous cis-
crotylation of simple aldehydes is consistent with experimentally observed results. Based on this 
analysis, 4.25 revealed a possible steric clash between the β-TES protecting group on 4.7 and the 
tert-butyl group on the phenol ring of 4.19. If our proposed transition state were correct, then 
reducing the size of the tert-butylphenol or the β-protecting group could lead to a more efficient 
reaction. 
 






























Since crotyltrichlorosilane 4.18 must be freshly prepared each time it is used, we chose to 
investigate our hypothesis using cis-crotyltrichlorosilane (4.28) instead, which should provide 
representative results. Starting with diaminophenol 4.12 (R = t-Bu), cis-crotylation of 4.7 afford-
ed the product in a low 45% yield and 1:1.4 dr (Scheme 4.12), in agreement with the poor results 
observed for the model coupling reaction in Scheme 4.10. But indeed, reducing the size of the 
substituent on the phenol of 4.12 from tert-butyl to methyl (4.26) resulted in improved yield and 
diastereoselectivity. The dr improved minimally to 2.3:1 for the cis-crotylation using 
diaminophenol 4.27 when R = H, which afforded the product in 64% yield. 
 
Scheme 4.12. Effects of diaminophenol sterics of the cis-crotylation of model aldehyde 4.7 
We then sought to reduce the size of the aldehyde β-hydroxyl protecting group. A [2-
(trimethylsilyl)ethoxy]methylacetal (SEM) protecting group was chosen as an alternative to TES 
for its size and fluoride sensitivity, to fit into our overall protecting group strategy for 
spongistatin. Aldehyde 4.30 was prepared similarly to 4.7 (Scheme 4.9), and evaluated in cis-
crotylation reactions (Scheme 4.13). While minimizing the size of the β-hydroxyl protecting 
group on the aldehyde did not improve the yields, there was a significant improvement in dr, 
where 4.26 gave the best results with 52% yield and 10:1 dr.  
 
Scheme 4.13. cis-Crotylation of model SEM aldehyde 4.30: effects of β-hydroxyl protecting group  
In these preliminary reactions described in Scheme 4.13 (as well as Scheme 4.12), excess 



















(R,R)-4.12: R = t-Bu
(R,R)-4.26: R = Me
(R,R)-4.27: R = H
R = t-Bu: 45%, 1:1.4 dr
R = Me: 66%, 2.0:1 dr






















R = t-Bu: 32% (10:1 dr)*, 1:1.3 dr
R = Me: 52% (10:1 dr)*, 5.9:1 dr
R = H: 50% (8:1 dr)*, 10:1 dr4.29
4.28
4.30
(R,R)-4.12: R = t-Bu
(R,R)-4.26: R = Me
(R,R)-4.27: R = H
* dr of isolated product
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and selectivity. However, our protecting group strategy for the synthesis of spongistatin requires 
the analogous protecting group on the CD* aldehyde to stay on during the AB-CD coupling reac-
tion. Therefore, we proceeded to optimize the TBAF work-up conditions for the cis-crotylation 
of 4.30 using diaminophenol 4.26 to minimize the undesired concomitant deprotection of the 
SEM group. But, it was determined that the SEM groups were too labile and deprotected even in 
the absence of TBAF. This was also true for the crotylation of 4.30 using our first generation 
crotylsilane reagents. Consequently, β-SEM protecting groups are not compatible with our 
crotylation methodology or our protecting group strategy for spongistatin. 
At this point, given the limited options for protecting groups that fit our criteria, we were 
extremely concerned that we would not be able to implement our proposed one-pot AB-CD 
coupling reaction. After reanalyzing our synthetic strategy for the preparation of ABCD* 4.1, we 
ultimately realized that the stereochemistry of the β-hydroxyl group (C17) on CD* aldehyde 4.3 
is inconsequential and eventually oxidized to a ketone in the fully elaborated ABCD* fragment 
4.1 (Scheme 4.1). Based on our transition state analysis, changing the β-stereocenter from S to R 
should resolve our selectivity issue if ‘R2’ is sufficiently small (Scheme 4.14).  
 
Scheme 4.14. Proposed transition state for one-pot coupling with anti-aldehyde 4.31 
Accordingly, anti-aldehyde 4.31 was prepared similarly to aldehyde 4.7 (Scheme 4.9). 
Evaluation of 4.31 in cis-crotylation reactions demonstrated an effective reaction using diamino-






























tected 4.33 and TES deprotected 4.34 compounds in a quantitative combined yield and 6:1 dr.a 
The diastereoselectivity improved to >20:1 by decreasing the size of the tert-butyl substituent on 
the diaminophenol; using 4.26 (R = Me) afforded the desired products in 84% combined yield. 
 
Scheme 4.15. cis-crotylation of 4.31; reported yields and dr are for combined 4.33 and 4.34 
Satisfied with the efficiency observed in this cis-crotylation reaction, we attempted the 
model coupling between diene 4.17 and anti-aldehyde 4.31 using diaminophenol 4.26. Similar to 
the cis-crotylation reaction, the model coupling reaction afforded the fully TES deprotected 
product 4.36 in 81% yield and 14:1 dr (Scheme 4.16). Adjusting the workup conditions by 
adding only 1.0 equivalent of TBAF•3H2O at 0 °C to retain TES protecting group on 4.37 led to 
a slight decrease in yield to 67%, but this did not raise too much concern since the reaction 
quench should be more efficient on scale. As an added precaution before moving to the fully 
elaborated system, AB-diene 4.2 was coupled with 4.31, affording product 4.39 in a consistent 
69% yield and >15:1 dr (Scheme 4.17). 
 
Scheme 4.16. Model coupling between diene 4.17 and model anti-aldehyde 4.31 
                                                
a It was our intention to quench this reaction with excess TBAF to remove the TES group in order to accurately 



















(R,R)-4.12: R = t-Bu
(R,R)-4.26: R = Me
R = t-Bu: 100%, 6:1 dr
R = Me: 84%, >20:1 dr4.33: R
1 = TES





1. 2 mol% 
    Pd(PPh3)4,
    HSiCl3,
    C6H6, 80 °C
2. (R,R)-4.26, 





















4.36: R = H; 81%, 14:1 dr




Scheme 4.17. Model coupling between AB-diene 4.2 and model anti-aldehyde 4.31 
The stereochemistry of the new C7 stereocenter installed by this coupling reaction on 
4.37 was verified by analyzing the corresponding acetonide 4.40 using Rychnovsky’s method.9 
The 13C NMR chemical shifts indicated in Scheme 4.18 are suggestive of a 1,3-syn acetonide. 
The assigned stereochemistry was further confirmed by the nOe correlations depicted in 4.40b. 
 
Scheme 4.18. Formation of acetonide 4.40a to verify the stereochemical outcome of one-pot coupling reaction 
Through these experiments, we have learned a great deal about the limitations of our one-
pot crotylation methodology. Compared to our first generation crotylation methodology, the 
newly developed one-pot crotylation methodology has a slightly narrower substrate scope in 
regards to complex chiral aldehydes. Based on our results, the active silane reagent formed from 
diaminophenol 4.12 seems to have a higher steric demand, given they are not able to efficiently 
cis-crotylate α,β-syn aldehydes with bulky β-hydroxyl protecting groups, unlike the first genera-
tion crotyl silane reagents. Additional studies will be required to further map out what types of 











































1. 2 mol% Pd(PPh3)4,
    HSiCl3, C6H6, 80 °C
2. (R,R)-4.26, 






























    (MeO)2CMe2
4.37 4.40a 4.40b
C1 = 19.6 ppm
C2 = 31.3 ppm




Despite this, we were still able to identify a system that would allow us to apply the one-pot 
crotylation methodology to the AB-CD coupling, which would improve the practicality of a 
sensitive late-stage reaction. 
 
4.3. One-pot AB-CD coupling 
The experiments described in Section 4.2 revealed that the one-pot crotylation method-
ology could not be used for cis-crotylation of α,β-syn aldehydes, which we initially planned for 
our ABCD* synthesis (Scheme 4.1), and instead required an α,β-anti CD* aldehyde. Makeda 
Tekle-Smith, a current group member, has demonstrated that the required α,β-anti CD* aldehyde 
can be prepared through a route analogous to the one used to prepare α,β-syn CD* 4.3 (described 
in Chapter 3), but using a trans-crotylation to install the α,β-anti stereochemistry. Nonetheless, 
the several grams of CD* spiroketal 4.41 that we had on hand bore the incorrect stereochemistry 
at C17. Attempts to convert syn-CD* 4.41 to anti-CD* 4.42 by hydroxyl inversion using Mitsu-
nobu chemistry were ineffective since elimination readily occurs for homoallylic alcohols. The 
small amount of desired product that did form was inseparable from the reaction byproducts.  
 
Scheme 4.19. Conversion of syn-CD* 4.41 to anti-CD* 4.42 
We found that 4.41 could be converted to 4.42 by a sequence of DMP oxidation and 










































































2 cycles: 42% yield





conditions showed that the best set of conditions was DIBAL in toluene, which provided the 
product as a 1:1.7 mixture, with DIBAL in CH2Cl2 as a close second at 1:2.0 dr. Starting from 
4.5 g of 4.41, two cycles of DMP oxidation and DIBAL/CH2Cl2 reduction produced 1.9 g of 4.42 
and 1.9 g of 4.41 was recovered (Scheme 4.19). This oxidation/reduction sequence enabled reli-
able access to 4.42 with 85% mass recovery over four steps. Final conversion of 4.42 to the CD* 
aldehyde 4.44 was achieved by TES protection of the secondary alcohol and oxidative cleavage 
of the terminal olefin (Scheme 4.20). 
 
Scheme 4.20. Preparation of anti-CD* aldehyde 4.44 
With plenty of 4.44 available as well as over 30 grams of AB diene 4.2 that was prepared 
by Dr. Samuel Reznik,1 we were well positioned to attempt the one-pot coupling reaction on the 
real system. AB diene 4.2 was hydrosilylated, as previously described, and the resulting AB-
crotyltrichlorosilane was treated with a solution of (R,R)-4.26 and DBU to access intermediate 
4.38. Without isolating 4.38, a solution of CD* aldehyde 4.44 was added directly to the reaction 
vessel. Only minor adjustments were required to obtain the optimal stoichiometry. Ultimately, 
using a stoichiometric ratio of 1.15:1 AB diene 4.2 to CD* aldehyde 4.44, provided the coupled 
product 4.45 in 81% yield and >20:1 dr. This reaction has been used to prepare 1.3 g of 4.45 in 
one pass, without obvious impediments to larger scales. The ability to add the aldehyde substrate 
directly to an in-situ formed reagent allowed for an immensely straightforward procedure that is 









1. TESCl, Et3N, DMAP
    CH2Cl2 (94%)
2. i)O3, CH2Cl2, -78 °C
    ii)PPh3, -78 to 23 °C















Scheme 4.21. One-pot AB-CD coupling 
 
4.4. ABCD* endgame chemistry: final elaboration 
At this point, we were 5 short steps from completing the synthesis of ABCD* 4.1, with 
the remaining steps summarized in Scheme 4.22. Acetylation of 4.45 (C15) proceeded cleanly, 
providing 4.46 in 88 % yield (Scheme 4.23). The previously mentioned requirement for fluoride 
labile protecting groups at C17 and C28* was due to our plan for a global deprotection (Step 2, 
Scheme 4.22) to minimize the number of steps needed for protecting group manipulation. In 
approaching this global deprotection, our biggest concern was the potential technical issues that 
can be associated with isolating and purifying a fairly polar compound, since removing the pro-
tecting groups at C1, C9, C17, and C28* would significantly increase the polarity of the product. 
 














































1. 2 mol% Pd(PPh3)4,
    HSiCl3, C6H6, 80 °C
2. 1.1 equiv. (R,R)-4.26, 



























2) global deprotection (C1, C9, C17, C28*)
3) TIPS protection (C1)
4) double oxidation (C17, C28*)



























After initial global deprotection experiments, we determined that the product could be 
isolated and purified reasonably well. However, two very similar, completely deprotected 
products were generated from this global deprotection reaction (Scheme 4.23). NMR and mass 
spectrometry analysis indicated acetate migration from C15 to C17 may have occurred to afford 
a mixture of 4.47 and 4.48. To test this theory, the two products were individually subjected to 
K2CO3/MeOH acetate deprotection conditions, which afforded identical products, presumably 
4.49. This result suggested that the two compounds differed in the position of the acetates, which 
further supports the hypothesis of a C15 to C17 acetate migration. The 1H NMR spectra of 4.47 
and 4.48 were too complex to distinguish which compound was in fact the desired C15-acetate 
product 4.47 by COSY experiments; however, we were able to observe which set of peaks grew 
in with longer reaction times, prompting the assignment of the associated compound as the 
undesired product 4.48.  
 
Scheme 4.23. Acetylation of 4.45 and preliminary results revealing acetate migration side reaction 
Once acetate migration occurs, 4.48 is nearly impossible to salvage since any acetate 
manipulation reactions will also affect the C5 acetate; consequently, avoiding the observed 




































4.47: R1 = Ac, R2 = H



























4.45: R1 = H





myriad of deprotection conditions were tested to adjust the pH and/or fluoride strength, most of 
which provided complex mixtures of partially deprotected intermediates in addition to 4.47 and 
4.48. TASF/pH 7 buffer conditions gave the highest 4.47 to 4.48 ratio (3:1) with minimal partial 
deprotection intermediates (Scheme 4.24). Nonetheless, evidence suggested 4.47 can isomerize 
to 4.48 during purification by silica gel column chromatography. 
 
Scheme 4.24. Best conditions for global deprotection of 4.46 
During these experiments, we determined that the C28* TBDPS group was removed last, 
providing time for the C15 acetate to migrate to the free hydroxyl group at C17 during the course 
of the reaction. As a result, we proposed that if we could modify the protecting groups such that 
the C17 hydroxyl would be deprotected last, then perhaps the reaction could be stopped prior to 
acetate migration. Accordingly, the C17 TBS derivative 4.50 was prepared and subjected to 
global deprotection conditions (Scheme 4.25). The TBS group was last to deprotect, as expected. 
However, due to the forcing conditions that were required to remove the severely hindered TBS 
group, acetate migration occurred even more readily. 
 




































4.47: R1 = Ac, R2 = H


















































As a comparison, 4.9 (C14-C17 syn, anti, syn stereochemistry), derived from the first-
generation AB-CD coupling (Scheme 4.3), was also acetylated and the resulting product 4.51 
was evaluated in global deprotection reactions (Scheme 4.26). In contrast to 4.46 (C14-C17 syn, 
anti, anti stereochemistry), during the global deprotection of 4.51, the C17 TES protecting group 
was last to be removed, requiring heat. Acetate migration did occur during the deprotection of 
4.51, but much more slowly than we observed for 4.46. Thus for 4.51, the deprotection 
conditions must convert partial deprotection product 4.53 to the desired product 4.52 without the 
formation of the acetate migrated product 4.54 (Scheme 4.26). Upon screening several 
deprotection conditions, we were able to identify TASF as a fluoride source that minimized 
acetate migration. After adding water as a buffer and optimizing temperature and reaction time, 
we were able to stop the reaction before substantial acetate migration occurred. 
 
Scheme 4.26. Acetylation of 4.9 and subsequent global deprotection of 4.51 
These experimental observations can be explained through an analysis of the transition 
state for the acetate migration process (Scheme 4.27). For 4.47, the 1,3-syn relationship aligns 
the C15 acetate and C17 hydroxyl into a chair-like transition state with RCD and C16-Me substi-
tuents in the equatorial position (4.47b). Therefore, the acetate is well situated to migrate to the 
less sterically hindered C17 hydroxyl. Conversely, 4.52, with the 1,3-anti relationship between 
C15 and C17, requires a bond rotation from the lowest energy structure 4.52b to form the 




































4.52: R1 = Ac, R2 = H
4.53: R1 = Ac, R2 = TES





17 : 0.5 : 1
4.52 : 4.53 : 4.54
88%
4.9: R1 = H





Because of this preference for 4.52b conformer, we were able to minimize acetate migration in 
the case of 4.52.   
 
Scheme 4.27. Analysis of transition states for acetate migration process 
Despite our best effort to utilize the one-pot crotylation reaction for the AB-CD coupling, 
it seemed highly unlikely that we would be able to efficiently progress 4.46 forward to synthe-
size the fully elaborated ABCD* 4.1. More extensive experiments to fine-tune our protecting 
group strategy would be required to prevent the facile acetate migration that occurs for 4.46. 
However, given our ultimate goal is to prepare a spongistatin analog equipped with a linker for 
conjugation with an antibody (ADC), perhaps the one-pot coupling protocol still has utility in 
our synthesis; this proposal will be revisited in Section 4.5.2. Regardless, it was imperative to 
establish a viable route to prepare 4.1 in order to test the corresponding spongistatin 1 analog. 
We therefore pressed ahead with 4.52, derived from the first generation AB-CD coupling. Accor-
dingly, 4.52 was protected as a TIPS ester, which also allowed for removal of minor products 
(4.53 and 4.54) from the global deprotection (Scheme 4.28). The C17 and C28* alcohols were 




































































Scheme 4.28. Conversion of 4.52 to 4.56 
Finally, the last step was a TES protection of the C9 tertiary hydroxyl, which is severely 
hindered due to its axial configuration, requiring the use of TESOTf, a highly reactive silylating 
reagent (Scheme 4.29). The key issue that we foresaw with using TESOTf was the possible 
epimerization of the C25* stereocenter due to the enolization of the C28* aldehyde (4.57). In 
addition, our group has previously observed that TESOTf is capable of silylating the α position 
of the C5 acetate (4.68), raising concern of this potential side reaction.10 Keeping these two 
possible side reactions in mind, we focused on more hindered amine bases. Hunig’s base, i-
Pr2NEt, was not hindered enough, promoting both acetate silylation and enolization. Initially, 
2,6-lutidine appeared to perform well, providing only a single product, but upon closer 
inspection, the crude product contained two different compounds that converged into a single 
product upon purification. NMR evidence suggests the minor product to be the silyl enol ether. It 
is likely that the silyl enol ether cleaved to give the desired stereochemistry due to axial 
protonation of the enol, resulting in equatorial substitution. Despite this, we were uncomfortable 
with the fact that enolization was occurring. To that end, we found that 2,6-di-tert-butylpyridine 





































































Scheme 4.29. TES protection of 4.56 C9 hydroxyl 
Overall, the synthesis of ABCD* 4.1 was achieved in 12% yield over a longest linear 
sequence of 18 steps. The demonstrated high overall yield can be attributed to the efficiency and 
step-economy of this route. Furthermore, 0.5 g of intermediate 4.51 has been stockpiled in 
preparation for coupling to the EF fragment.  
 
4.5. Preliminary studies for future directions 
4.5.1. Model Wittig olefination for ABCD-EF coupling 
Currently, we are working hard to prepare the EF fragment in order to complete this 
synthesis of our spongistatin analog. In the meantime we felt it would be prudent to model the 
ABCD-EF Wittig coupling to determine the best conditions to achieve high Z-selectivity. Tradi-
tionally, the Wittig olefination to join the natural ABCD fragment and the EF ylide is 60-65% 
yielding and highly selective for the Z-alkene when using MeLi•LiBr or LiHMDS/HMPA to 
form the EF ylide.11 However, given the electronic difference of the ABCD* aldehyde 4.1, an α-
alkyl branched aldehyde, compared to the natural ABCD aldehyde 4.59, an α-alkoxy aldehyde 





































































Figure 4.1. Comparison of natural ABCD fragment 4.59 to analog ABCD* fragment 4.1 
Since effectively modeling the Wittig reaction using the fully elaborated ABCD* alde-
hyde 4.1 would require several milligrams of 4.1 and the resulting NMR could be too complex 
and difficult to analyze and determine the E/Z selectivity, we prepared aldehyde 4.63 as a model 
for the Wittig reaction using the route shown in Scheme 4.30. The terminal alkene in 4.60 was 
reduced with Wilkinson’s catalyst to lessen the possibility of deprotonation at C16 during the 
proposed Wittig reaction of model aldehyde 4.63, since side reactions related to this functionality 
would not be relevant to our real system. TBAF deprotection of the silyl groups in 4.61 was 
followed by an oxidation of the resulting diol to afford 4.63 in 53% yield over three steps. 
 
Scheme 4.30. Preparation of model Wittig substrate 4.63 
Aldehyde 4.63 was subjected to the two most common conditions reported for the ABCD 
-EF Wittig coupling reaction (Scheme 4.31). When the model ylide was formed by deprotonation 
of 4.65 using MeLi•LiBr complex, the reaction provided a mixture of 3 alkene products, with a 







































































cosolvent in THF resulted in a Wittig reaction that provided a single alkene product with a 
coupling constant of 10.5 Hz, indicative of Z-geometry, in 82% yield. 
 
Scheme 4.31. Model Wittig reaction between aldehyde 4.63 and Wittig salt 4.65 
Bolstered by these promising results, we subjected the fully elaborated aldehyde 4.1 to 
the same conditions, affording the desired product as a single isomer, assumed to be the Z-alkene 
by extension from the model reactions (Scheme 4.32). The desired product 4.66 was isolated in a 
low 42% yield with a significant portion (25%) of the remaining mass isolated as the free acid 
4.67. Since the TIPS deprotection likely occurred as a result of hydroxide produced from residual 
water, we were able to minimize the formation of 4.67 with careful drying of all glassware and 
reagents, but not completely eliminate it. When we are able to move forward with the fully 
elaborated EF fragment, we expect that re-protection of any free acid side product would be 
straightforward and proceed under mild conditions, given our experience with the TIPS protec-
tion of 4.52 (Scheme 4.28). Conversely, we may also choose to allow the TIPS deprotection to 
occur during this Wittig reaction since the next step in the reaction sequence is a silyl deprotec-
tion including the TIPS group. Regardless, we are excited about the results of this model Wittig 
reaction: it is selective for the desired Z-isomer and the yield is on par with literature yields. 
 
























THF, -78 to 0 °C
MeLi • LiBr: 60% mass recovery, 3 alkene products












































-78 to 0 °C
n-Bu
4.66: R = TIPS




4.5.2. Preparation of C15-linker analogs 
Though the complete preparation of ABCD* 4.1 was a significant accomplishment, it is 
only the first step toward completing this synthesis of our proposed spongistatin analog and 
toward our long-term goal of investigating the potential of spongistatin to serve as an effective 
drug in an ADC context. As discussed in Chapter 1, we believe that a robust synthesis along with 
an ADC-targeted drug delivery strategy will provide the best opportunity to realize spongistatin 
1, or an analog thereof, as a useful chemotherapy. In approaching the development of 
spongistatin as the drug cargo for an ADC, our initial investigations were centered on the linker 
strategy to conjugate spongistatin to an antibody without interfering with its ability to bind to 
tubulin. The most common strategy for functionalizing molecules with linkers is through 
hydroxyl modification. However, caution should be taken to not perturb a molecule’s electronics 
when modifying free hydroxyl groups with linkers as they may be involved in crucial hydrogen 
bonding interactions with the protein binding site.  
Recently, Smith and coworkers reported the preparation of a diminutive analog of 
spongistatin 1 that replaced the C12-C28 region of spongistatin with a simple alkyl strap while 
retaining modest bioactivity (Figure 4.2A).12 This study suggests that the C12-C28 region may 
not be necessary for tubulin binding, and consequently, there is a good likelihood that this region 
can accommodate a linker without affecting the bioactivity of spongistatin. Within the C12-C28 
region, the C15 acetate and C21 methyl ether stood out as possible sites for linker attachment 
(Figure 4.2B). Complex ether formation at C21 could be difficult, and therefore in these prelim-
inary experiments, we focused on derivatizing the C15 acetate, which should be synthetically 
straightforward through acylation reactions. Furthermore, modifying the C15 acetate with 
extended ester linkers should very minimally perturb the local electronics of the molecule. 
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Figure 4.2. A) Smith diminutive analog of spongistatin 1; B) Leighton group proposed analog of spongistatin 1 
Another important factor that must be taken into consideration is the type of bond made 
between the linker and the C15 hydroxyl. In order for ADCs to be effective, the drug molecule 
must be released from the antibody only when the ADC has reached its tumor target. Therefore, 
the C15 hydroxyl to linker bond must be hydrolytically stable and resist nonspecific metabolic 
degradation. Therefore in these initial investigations, we targeted sterically hindered esters at 
C15, which are more stable than the C15 acetate. 
Since we were interested in introducing a hindered ester at C15, we were optimistic that 
we might be able to utilize the material with C14-C17 syn, anti, anti stereochemistry (4.45), 
which was derived from the one-pot AB-CD coupling reaction (Scheme 4.21). We propose that 
an ester more hindered than an acetate at C15 could potentially impede the acyl migration that 
occurs during the global deprotection (Scheme 4.23). The ability to use our one-pot coupling 
protocol would enable more facile and rapid access to our desired linker analogs. To test our 
theory, we prepared C15-benzoate 4.68 and C15-tert-butylacetate 4.69 analogs and subsequently 
subjected them to TASF deprotection conditions (Scheme 4.33). While the micromolar scale of 
these reactions did not allow us to determine yields of 4.70 and 4.71, we were able to observe 
that 4.68 and 4.69 were well behaved in the global deprotection reaction: a single product was 


























































Scheme 4.33. Preparation and global deprotection of ABCD* analogs 4.68 and 4.69 
Satisfied with these results, we were interested in further functionalizing C15 to include 
an azide, which could serve as a chemical handle for conjugation to an antibody. 4-(2-azido 
ethyl)benzoic acid (AEB acid) 4.73 and 5-azido-3,3-dimethylpentanoic acid (ADP acid) 4.77 
were prepared as described in Scheme 4.34. Formation of 4.73 by a SN2 reaction between NaN3 
and chloroacid 4.72 was straightforward and achieved in 79% yield (Scheme 4.34A). Azidoacid 
4.77 was prepared starting from anhydride 4.74 (Scheme 4.34B). While lactone 4.75 was easily 
converted to bromoacid 4.76, the conditions required to install the azide readily converted 4.76 
back to lactone 4.75 via intramolecular SN2. To circumvent this issue, lactone 4.75 was 
converted to methyl ester 4.78, which cleanly underwent SN2 to afford azide 4.79. Saponification 
of the methyl ester afforded our desired azidoacid 4.77 in 50% yield over four steps.  
 



























































4.68: R = Ph
4.69: R = CH2t-Bu
4.70: R = Ph




























































50% over 4 steps
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With 4.73 and 4.77 in hand, each was reacted with 2,4,6-trichlorobenzoyl chloride to 
form its mixed anhydride, which were then used for the acylation of 4.45 to provide the corres-
ponding esters 4.80 and 4.81 in 84% and 98% yields, respectively (Scheme 4.35). Subjecting 
both 4.80 and 4.81 to TASF/pH 7 buffer deprotection conditions resulted in clean conversion to 
the desired products in 83% and 86% yields, respectively, without evidence of acetate migration. 
TIPS protection and DMP oxidation using our previously established conditions smoothly 
converted 4.82 and 4.83 to 4.86 and 4.87, respectively. 
 





































4.80: R = AEB; 84%



















4.82: R = AEB; 83%



















4.84: R = AEB; 97%



















4.86: R = AEB; 92% crude



















4.88: R = AEB; 52%






















We had not yet determined that 2,6-di-tert-butylpyridine was the optimal base for the C9 
hydroxyl TES protection at the time of these experiments, so the 2,6-lutidine/TESOTf conditions 
were used to protect 4.86 and 4.87, affording 4.88 and 4.89 in 52% and 74% yield, respectively. 
There was NMR evidence of silyl enol ether formation, as was previously experienced for the 
parent compound 4.56 (Scheme 4.29); however, extensive NMR studies on 4.88 allowed for the 
assignment of all relevant protons and the observed nOe correlation (specifically HD-HC) depic-
ted in Figure 4.3 is consistent only with the desired stereochemistry at C25* as assigned. Despite 
possible enolization at C25*, we are confident that the isolated product has the correct stereo-
chemistry. Additional experiments using 2,6-di-tert-butylpyridine will be necessary to confirm 
our conclusion. 
 
Figure 4.3. Determination of the stereochemistry at C25* for ABCD* linker analog 4.88 
Linker analogs 4.88 and 4.89 were prepared in an unoptimized 36% and 58%, respec-
tively, over five steps from a common intermediate 4.45. Further optimization of the isolation 
and purification conditions to account for the increased polarity of compounds 4.80-4.89, and 
optimization of the final TES protection step will improve the overall yield of this route.  
Nonetheless, the ability to prepare 4.88 and 4.89 in high yields is a testament to the adaptability 
of established route to parent compound 4.1 is amendable to analog synthesis. With ABCD* 
linker analogs 4.88 and 4.89 in hand, we are well equipped to synthesize the corresponding 
spongistatin analogs and learn whether a C15 linker is tolerated and if so, which functional 















































4.6. Summary, conclusions and outlook 
Herein, we have described the development of a one-pot AB-CD coupling protocol, 
which we were able to apply to the coupling of the AB and CD* fragments. Despite not being 
able to efficiently progress the product from the one-pot AB-CD coupling past the global depro-
tection step, we were able utilize the first generation coupling strategy to establish a route to 
access the final ABCD* fragment 4.1 in 12% overall yield in a longest linear sequence of 18 
steps. Furthermore, we were able to model the subsequent Wittig coupling of 4.1 to a model EF 
ylide and demonstrate high Z-alkene selectivity, which we require for our synthesis. Current 
work to prepare the EF fragment is currently being pursued by Dr. Kevin Williamson and Josh 
Infantine. Upon preparation of the EF fragment, we project being only 4 steps away from com-
pleting this synthesis of our spongistatin analogs. 
In efforts toward our ultimate goal of synthesizing spongistatin as a ‘warhead’ for an 
ADC, we prepared ABCD*-linker analogs 4.88 and 4.89. The rapid synthesis of these linker 
analogs was facilitated by our robust one-pot AB-CD coupling protocol and established route to 
4.1. Upon completion of spongistatin analogs containing fragments 4.1, 4.88, and 4.89, we plan 
to evaluate their efficacy in biological studies. Whether or not these particular analogs exhibit 
our desired level of activity, the tools developed here will enable quick preparation of additional 
compounds to identify a potent analog of spongistatin 1. 
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4.7. Experimental procedures 
General Information. All reactions were carried out under an atmosphere of nitrogen in flame-
dried glassware with magnetic stirring unless otherwise indicated. Degassed solvents were 
purified by passage through an activated alumina column. Thin-layer chromatography (TLC) 
was carried out on glass backed silica gel TLC plates (250 mm) from Silicycle; visualization by 
UV light and/or phosphomolybdic acid (PMA). HPLC analysis was carried out on an Agilent 
1200 Series using either a Chiralpak AD-H (250 x 4.5 mm ID) column or Chiralcel OD-H 
(250x4.5 mm ID) column. 1H NMR spectra were recorded on a Bruker AVIII 300 (300 MHz), 
AVIII 400 (400 MHz), AVIII 500 (500 MHz) or AVIII 500 Ascend (500 MHz) spectrometer and 
are reported in ppm, relative to residual protonated solvent peak (CDCl3, 7.26 ppm; C6D6, 7.16 
ppm). Data are reported as follows: (bs= broad singlet, s = singlet, d = doublet, t = triplet, m = 
multiplet, dd = doublet of doublets, ddd = doublet of doublet of doublets, ddt = doublet of 
doublet of triplets, td = triplet of doublets; coupling constant(s) in Hz; integration). Proton 
decoupled 13C NMR spectra were recorded on a Bruker AVIII 400 (100 MHz), AVIII 500 (126 
MHz) or AVIII 500 Ascend (126 MHz) spectrometer and are reported in ppm from CDCl3 
internal standard (77.16 ppm). 29Si NMR spectra were recorded on a Bruker AVIII 400 (79 
MHz) or AVIII 500 (100 MHz) and are reported in ppm relative to TMS (0.00 ppm) internal 
standard. 19F NMR spectra were recorded on a Bruker AVIII 400 (376 MHz) and are reported in 
ppm relative to α,α,α-trifluorotoluene (-63.72 ppm) internal standard. Infrared spectra were 
recorded on a Nicolet Avatar 370DTGS FT-IR. Optical rotations were recorded on a Jasco DIP-
1000 digital polarimeter. (APCI)-MS was conducted on a JMS-LCmate LCMS (JEOL). Melting 
points were determined using a Stanford Research Systems DigiMelt apparatus. 
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4.7.1. Model one-pot coupling 
  
 Homoallylic alcohol 4.90 was prepared according using a modified literature procedure.13 
To a solution of diaminophenol (R,R)-4.12 (2.00 g, 6.9 mmol) in CH2Cl2 (32.0 mL) at 0 °C was 
added DBU (3.1 mL, 20.6 mmol), followed by dropwise addition of trans-crotyltrichlorosilane 
(1.16 mL, 7.6 mmol). The resulting mixture was warmed to room temperature and stirred for 1 h. 
The reaction mixture was cooled to 0 °C and hydrocinnamaldehyde (0.85 mL, 6.5 mmol) was 
added. Upon stirring for 1 h at 0 °C, TBAF (1 M, 13.0 mL, 13.0 mmol) was added and stirred at 
room temperature for 30 min. The resulting mixture was concentrated in vacuo and filtered 
through a plug of silica. The filtrate was concentrated and the crude product was purified by 
silica gel column chromatography eluting with 0:100 à 20:80 EtOAc:Hexanes to give 4.90 as a 
colorless oil (1.29 g, 6.5 mmol, 98% yield). 1H NMR (500 MHz, CDCl3) δ 7.38 – 7.16 (m, 5H), 
5.77 (ddd, J = 16.6, 10.9, 8.2 Hz, 1H), 5.20 – 5.06 (m, 2H), 3.44 (dddd, J = 9.2, 6.0, 4.4, 3.3 Hz, 
1H), 2.87 (ddd, J = 13.8, 10.2, 5.2 Hz, 1H), 2.70 (ddd, J = 13.7, 9.9, 6.6 Hz, 1H), 2.32 – 2.18 (m, 
1H), 1.90 – 1.79 (m, 1H), 1.79 – 1.62 (m, 2H), 1.05 (d, J = 6.9 Hz, 3H). 13C NMR (126 MHz, 
CDCl3) δ 142.42, 140.31, 128.58, 128.48, 125.88, 116.57, 74.11, 44.45, 36.24, 32.30, 16.35. IR 
(thin film, cm-1) 3382.57, 3064.02, 3025.93, 2961.62, 2928.14, 2865.85, 2333.93, 1944.16, 
1804.51, 1638.15, 1602.77, 1494.73, 1453.63, 1416.74, 1395.38, 1373.70, 1321.38, 1289.72, 
1259.93, 1153.44, 1117.36, 1069.84, 1032.52, 998.54, 963.00, 913.11, 842.57, 802.19, 746.61, 



















 To a solution of 4.90 (1.20 g, 6.3 mmol) in CH2Cl2 (63.0 mL) at 0 ºC was sequentially 
added Et3N (1.32 mL, 9.5 mmol), TESCl (1.27 mL, 7.6 mmol), and DMAP (0.23 mg, 1.9 mmol). 
The resulting mixture was stirred at room temperature for 12 h. Excess TESCl was quenched by 
the addition of MeOH (0.50 mL) and all volatiles were removed in vacuo. The resulting residue 
was resuspended in hexanes and the Et3N•HCl salts were removed by filtration. The filtrate was 
concentrated and purified by silica gel column chromatography eluting with 0:100 à 5:95 
EtOAc:Hexanes to give 4.91 as a pale yellow oil (1.85 g, 6.1 mmol, 96% yield). 1H NMR (400 
MHz, CDCl3) δ 7.35 – 7.24 (m, 2H), 7.23 – 7.14 (m, 3H), 5.89 – 5.76 (m, 1H), 5.09 – 4.98 (m, 
2H), 3.73 – 3.61 (m, 1H), 2.80 – 2.66 (m, 1H), 2.57 (ddd, J = 13.6, 9.6, 7.0 Hz, 1H), 2.44 – 2.31 
(m, 1H), 1.77 – 1.66 (m, 2H), 1.04 (d, J = 6.8 Hz, 3H), 1.00 (t, J = 7.9 Hz, 9H), 0.64 (q, J = 7.9 
Hz, 6H). 13C NMR (101 MHz, CDCl3) δ 142.83, 141.01, 128.48, 128.46, 125.80, 114.61, 75.77, 
43.51, 35.73, 32.53, 15.10, 7.17, 5.42. IR (thin film, cm-1) 3341.08, 3065.77, 3026.71, 2953.59, 
2910.71, 2875.72, 2732.85, 1938.51, 1799.72, 1639.47, 1603.86, 1494.93, 1454.95, 1415.15, 
1374.84, 1237.48, 1182.25, 1089.42, 1057.54, 1037.77, 1004.78, 959.70, 911.80, 845.34, 819.44, 
738.30, 697.90, 589.54, 524.99, 500.28. OR [α]D24 +5.6° (c 1.0, CHCl3). HRMS (ASAP+) 
calculated for C19H33OSi [M+H]+ 305.2301; found 305.2295. 
  
A solution of 4.91 (144 mg, 0.47 mmol) in CH2Cl2 (4.7 mL) was cooled to -78 ºC while 
purging with O2. The reaction solution was purged with O3 until the solution turned blue. The 



















i) O3, -78 °C
   CH2Cl2
ii) PPh3
   -78 to 23 °C
4.314.91
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PPh3 (136 mg, 0.52 mmol) was added at -78 ºC and the resulting mixture was thawed to room 
temperature. After stirring for 12h, all volatiles were removed in vacuo. The resulting residue 
was resuspended in hexanes and OPPh3 was removed by filtration. The filtrate was concentrated 
and purified by pH 7 buffered silica gel column chromatography eluting with 0:100 à 10:90 
EtOAc:Hexanes to give 4.31 as a pale yellow oil (125 mg, 0.41 mmol, 87% yield). 1H NMR 
(400 MHz, CDCl3) δ 9.77 (dd, J = 2.3, 0.9 Hz, 1H), 7.33 – 7.26 (m, 2H), 7.23 – 7.13 (m, 3H), 
4.04 (q, J = 5.5 Hz, 1H), 2.73 – 2.63 (m, 2H), 2.63 – 2.53 (m, 1H), 1.93 – 1.74 (m, 2H), 1.11 (d, 
J = 7.1 Hz, 3H), 0.98 (dd, J = 8.3, 7.5 Hz, 9H), 0.63 (q, J = 8.0 Hz, 6H). 13C NMR (101 MHz, 
CDCl3) δ 204.93, 141.99, 128.61, 128.42, 126.07, 73.10, 51.52, 36.92, 31.42, 10.40, 7.05, 5.27. 
IR (thin film, cm-1) 3085.08, 3062.40, 3026.57, 2953.08, 2911.24, 2876.02, 2727.35, 1942.42, 
1723.61, 1602.89, 1495.25, 1455.22, 1413.46, 1375.76, 1237.83, 1180.15, 1092.99, 1067.07, 
1039.27, 1006.40, 959.95, 925.20, 809.99, 739.99, 698.89, 589.16, 520.47. OR [α]D24 -22.4° (c 
1.0, CHCl3). HRMS (ESI+) calculated for C18H30O2SiNa [M+Na]+ 329.1913; found 329.1906. 
 
 Boc diamine 4.92 was prepared as described in Chapter 2 and converted to imine 4.94 
using a modified literature procedure.13 To a solution of compound 4.92 (7.00 g, 32.7 mmol) in 
MeOH (100 mL), was added aldehyde 4.93 (3.6 mL, 29.7 mmol). The mixture was stirred at 
room temperature for 5 h. The mixture was concentrated in vacuo and the resulting residue was 
recrystallized from minimal boiling MeOH to give imine 4.94 as yellow crystals (8.82 g, 26.5 














1H), 7.07 (dd, J = 7.8, 1.7 Hz, 1H), 6.76 (t, J = 7.5 Hz, 1H), 4.39 (s, 1H), 3.57 – 3.54 (m, 1H), 
3.08 (s, 1H), 2.26 (s, 3H), 2.12 – 2.03 (m, 1H), 1.92 – 1.83 (m, 1H), 1.77 (ddq, J = 19.7, 12.7, 3.5 
Hz, 2H), 1.71 – 1.60 (m, 1H), 1.47 – 1.29 (m, 4H), 1.29 (s, 9H). 13C NMR (126 MHz, CDCl3) δ 
164.37, 159.61, 155.29, 133.21, 129.04, 126.07, 118.11, 118.02, 79.40, 72.26, 54.41, 33.38, 
31.53, 28.27, 24.83, 24.08, 15.63. IR (thin film, cm-1) 3351.22, 2936.47, 2857.57, 1684.52, 
1627.71, 1524.99, 1442.05, 1366.16, 1315.57, 1270.74, 1171.42, 1013.81, 846.32, 746.30. OR 
[α]D26 -111.14º (c 1.0, CHCl3). HRMS (ASAP+) calculated for C19H29N2O3 [M+H]+ 333.2178; 
found 333.2181.  
 
Diaminophenol 4.26 was prepared using a modified literature procedure.13 A 500 mL 
roundbottom flask equipped with an addition funnel was charged with LiAlH4 (5.03 g, 133 
mmol) and THF (100 mL) and the resulting mixture was cooled to 0 °C. A solution of 4.94 (8.82 
g, 26.5 mmol) in THF (100 mL) was added slowly via the addition funnel, with THF rinses (3 x 
20.0 mL). The mixture was warmed to room temperature and stirred for 2 h. The addition funnel 
was replaced with a reflux condenser and the mixture was heated to reflux for 12 h. The mixture 
was cooled to 0 °C, and the reaction was quenched by the CAREFUL and SLOW sequential 
addition of water (5.0 mL), 15% aq. NaOH (5.0 mL) and additional water (15.0 mL). The 
resulting mixture was stirred for 10 min at room temperature. The mixture was dried by stirring 
with excess MgSO4 for an additional 20 min. The fine white solids were removed filtration and 
the filtrate was concentrated in vacuo. The resulting beige solid was purified by recrystallization 











mmol, 93% yield). 1H NMR (400 MHz, CDCl3) δ 7.08 – 6.96 (m, 1H), 6.84 (ddd, J = 7.5, 1.7, 
0.9 Hz, 1H), 6.68 (t, J = 7.4 Hz, 1H), 4.02 (d, J = 13.6 Hz, 1H), 3.82 (d, J = 13.6 Hz, 1H), 2.40 
(s, 3H), 2.24 (s, 3H), 2.22 – 2.09 (m, 4H), 1.82 – 1.65 (m, 2H), 1.31 – 1.13 (m, 3H), 1.02 – 0.88 
(m, 1H). 13C NMR (101 MHz, CDCl3) δ 156.54, 129.68, 125.57, 125.28, 123.34, 118.41, 62.53, 
62.17, 50.49, 33.53, 31.22, 31.11, 25.30, 24.77, 15.85. IR (thin film, cm-1) 3311.63, 3235.44, 
2924.45, 2850.58, 2795.74, 1595.23, 1466.50, 1448.89, 1359.49, 1267.88, 1230.39, 1110.90, 
1081.83, 975.23, 853.77, 765.55, 741.91. OR [a]D24 -137.3º (c 1.0, CHCl3). HRMS (ESI+) 
calculated for C15H25N2O [M+H]+ 249.1967; found 249.1967.  
  
Alcohol 4.16 is a known compound and was prepared according to literature procedure.2 
To a solution of alcohol 4.16 (0.95 g, 4.7 mmol) in THF (16 mL) at 0 °C was added NaH (0.34 g, 
8.4 mmol). The resulting mixture was warmed to room temperature and stirred for 1 h. The 
reaction mixture was returned to 0 °C, and benzyl bromide (0.59 mL, 4.9 mmol) and TBAI (0.19 
g, 0.5 mmol) were added. The resulting mixture was stirred for 12 h while the ice bath expired. 
Excess NaH was quenched by slow addition of saturated NH4Cl solution (10.0 mL). The aqueous 
layer was extracted with CH2Cl2 (3 x 5.0 mL), dried over MgSO4, filtered, and concentrated in 
vacuo. The crude benzyl ether product was purified by silica gel column chromatography eluting 
with 0:100 à 20:80 EtOAc:Hexanes to give 4.17 as a colorless oil (1.20 g, 4.0 mmol, 87% 
yield). 1H NMR (500 MHz, CDCl3) δ 7.39 – 7.32 (m, 4H), 7.31 – 7.24 (m, 3H), 7.20 – 7.14 (m, 
3H), 6.38 (dd, J = 17.6, 11.0 Hz, 1H), 5.21 (d, J = 17.6 Hz, 1H), 5.15 – 5.02 (m, 3H), 4.61 (d, J = 
11.4 Hz, 1H), 4.57 (s, 0H), 4.50 (d, J = 11.4 Hz, 1H), 3.64 (qd, J = 6.7, 4.4 Hz, 1H), 2.83 (ddd, J 








2H). 13C NMR (101 MHz, CDCl3) δ 143.34, 142.50, 139.08, 138.94, 128.53, 128.48, 128.46, 
128.01, 127.68, 125.84, 118.49, 113.79, 77.27, 71.56, 36.90, 36.25, 31.83, 1.18. IR (thin film, 
cm-1) 3084.75, 3061.96, 3026.69, 2922.26, 2858.69, 1945.33, 1805.27, 1729.79, 1593.53, 
1494.64, 1453.35, 1389.68, 1348.52, 1260.62, 1205.22, 1155.00, 1091.32, 1066.89, 1028.12, 
991.86, 898.60, 805.64, 736.31, 697.30, 606.52, 475.99. OR [α]D22 +23.7° (c 1.0, CHCl3). 
HRMS (ASAP+) calculated for C21H25O [M+H]+ 293.1905; found 293.1903. 
 
General procedure 1 for coupling by crotylation using the one-pot protocol: 
To a solution of the diene starting material (1.1 equiv.) in C6H6 (0.1 M) in a septum-
adapted scintillation was added Pd(PPh3)4 (2.0 mol%). The resulting solution was pumped on 
and back-filled with N2 (3x). HSiCl3 (2.0 equiv.) was added and the reaction vessel was sealed 
with a teflon lined screw cap and heated to 80 °C for 12 h. The reaction mixture was carefully 
cooled to room temperature. The reaction vessel was attached to a vacuum line equipped with a 
manometer and a -78 °C cold finger, and then placed in a warm (~35 °C) water bath. All 
volatiles were carefully evaporated by application of vacuum until a viscous oil remained.  
The resulting hydrosilylated product was retaken in CDCl3 (0.15 M) and cooled to 0 °C. 
CH2Cl2 can be used in place of CDCl3, which was used to facilitate monitoring reactions by 
NMR. A solution of diaminophenol (R,R)-4.12 or (R,R)-4.26 (1.0 equiv.) and DBU (3.0 equiv.) 
in CDCl3 was added, rinsing with enough CDCl3 to dilute the concentration of the reaction 
mixture to 0.1 M. The reaction mixture was warmed to room temperature and stirred for 1 h. The 
reaction mixture was returned to 0 °C and the aldehyde substrate (1.0 equiv.) was added by 
microsyringe. The resulting mixture was stirred for 12 h while the ice bath thawed to room 
temperature. The reaction was quenched by addition of TBAF. For complete TES deprotection 
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of the product, 1 M TBAF solution in THF (2.0 equiv.) was added and stirred for 1 h. For mild 
cleavage of the diaminosilane reagent from the product, the reaction mixture was cooled to 0 °C 
and TBAF•3H2O (1.0 equiv.) was added and stirred for 20 min. In both cases, the reaction 
mixture was filtered through a plug of the silica and the filtrate was concentrated in vacuo. The 
crude coupled product was purified by silica gel column chromatography. 
  
Diene 4.17 (50 mg, 0.17 mmol) was coupled with hydrocinnamaldehyde (20 µL, 0.15 
mmol) according to general procedure 1, utilizing diaminophenol (R,R)-4.12. The crude product 
was purified by silica gel column chromatography eluting with 0:100 à 30:70 EtOAc:Hexanes 
to give 4.21 as a colorless oil (44 mg, 0.10 mmol, 10:1 dr, 73% yield). 1H NMR (400 MHz, 
CDCl3) δ 7.39 – 7.25 (m, 9H), 7.23 – 7.13 (m, 6H), 4.99 (d, J = 1.4 Hz, 1H), 4.93 (d, J = 1.3 Hz, 
1H), 4.51 (s, 2H), 3.67 – 3.52 (m, 2H), 2.87 – 2.57 (m, 4H), 2.38 (dd, J = 14.7, 7.1 Hz, 1H), 2.30 
– 2.18 (m, 2H), 1.96 – 1.64 (m, 5H), 1.05 (d, J = 6.9 Hz, 3H). 13C NMR (101 MHz, CDCl3) δ 
149.14, 142.25, 138.63, 128.57, 128.52, 128.50, 128.01, 127.75, 125.95, 125.93, 112.98, 77.18, 
71.17, 71.14, 44.57, 40.45, 36.28, 35.87, 32.89, 31.81, 12.70. IR (thin film, cm-1) 3444.93, 
3083.70, 3062.18, 3026.20, 2926.25, 2861.27, 1639.08, 1602.48, 1494.72, 1453.35, 1348.23, 
1208.44, 1064.27, 1028.93, 898.37, 804.44, 743.62, 696.71, 495.58. OR [α]D22 +41.3° (c 1.0, 
CHCl3). HRMS (ESI+) calculated for C30H36O2Na [M+Na]+ 451.2613; found 451.2617. 
 
1. 2 mol% Pd(PPh3)4,
    HSiCl3, C6H6, 80 °C
2. (R,R)-4.12, DBU





















Diene 4.17 (75 mg, 0.26 mmol) was coupled with aldehyde 4.31 (72 mg, 0.23 mmol) 
according to general procedure 1, utilizing diaminophenol (R,R)-4.26. The crude product was 
purified by silica gel column chromatography eluting with 0:100 à 15:85 EtOAc:Hexanes to 
give 4.38 as a colorless oil (92 mg, 0.15 mmol, >10:1 dr, 67% yield).1H NMR (500 MHz, 
CDCl3) δ 7.38 – 7.09 (m, 15H), 5.05 (s, 1H), 4.99 (s, 1H), 4.50 (s, 2H), 4.13 (ddd, J = 9.0, 4.3, 
2.9 Hz, 1H), 3.60 – 3.51 (m, 1H), 3.33 (d, J = 9.9 Hz, 1H), 2.92 – 2.81 (m, 1H), 2.70 (dddd, J = 
39.4, 13.8, 9.7, 6.1 Hz, 2H), 2.54 (ddd, J = 13.5, 11.6, 5.2 Hz, 1H), 2.36 (tt, J = 13.9, 7.1 Hz, 
2H), 2.27 (dd, J = 14.5, 4.8 Hz, 1H), 2.01 – 1.96 (m, 1H), 1.96 – 1.78 (m, 3H), 1.77 – 1.60 (m, 
2H), 1.04 – 0.97 (m, 12H), 0.77 (d, J = 6.9 Hz, 3H), 0.66 (q, J = 7.9 Hz, 6H). 13C NMR (126 
MHz, CDCl3) δ 149.31, 143.25, 142.19, 138.61, 128.55, 128.52, 128.49, 128.48, 128.44, 128.01, 
127.73, 125.95, 125.76, 113.47, 77.13, 73.54, 71.88, 71.21, 41.44, 40.84, 40.46, 35.84, 33.91, 
33.10, 31.86, 10.28, 10.25, 7.13, 5.32. IR (thin film, cm-1) 3026.47, 2949.63, 2874.98, 1603.10, 
1495.09, 1454.17, 1379.40, 1237.77, 1063.48, 1006.04, 974.82, 820.59, 738.76, 697.96. OR 
[α]D25 +44.3 (c 1.0, CHCl3). HRMS (ASAP+) calculated for C39H57O3Si [M+Na]+ 601.4077; 



















1. 2 mol% Pd(PPh3)4,
    HSiCl3, C6H6, 80 °C
2. (R,R)-4.26, DBU








Diene 4.2 (56 mg, 0.1 mmol) was coupled with aldehyde 4.31 (28 mg, 0.09 mmol) 
according to general procedure 1, utilizing diaminophenol (R,R)-4.26. The crude product was 
purified by silica gel column chromatography eluting with 0:100 à 50:50 EtOAc:Hexanes to 
give 4.39 as a colorless oil (55 mg, 0.063 mmol, >15:1 dr, 69% yield). 1H NMR (500 MHz, 
CDCl3) δ 7.28 (d, J = 7.6 Hz, 2H), 7.23 – 7.15 (m, 3H), 5.19 (s, 1H), 5.06 – 4.99 (m, 2H), 4.37 – 
4.27 (m, 2H), 4.19 – 4.06 (m, 3H), 3.40 – 3.32 (m, 1H), 2.90 – 2.80 (m, 2H), 2.57 – 2.42 (m, 
3H), 2.33 (dd, J = 14.6, 8.8 Hz, 1H), 2.25 (dd, J = 16.5, 6.9 Hz, 1H), 2.19 (dd, J = 14.5, 4.5 Hz, 
1H), 2.14 – 2.08 (m, 1H), 2.01 (s, 3H), 2.01 – 1.98 (m, 1H), 1.95 – 1.82 (m, 2H), 1.81 – 1.75 (m, 
1H), 1.75 – 1.64 (m, 2H), 1.60 (dd, J = 15.1, 4.4 Hz, 1H), 1.54 – 1.44 (m, 1H), 1.52, (s, 3H) 1.37 
(d, J = 15.2 Hz, 1H), 1.33 – 1.24 (m, 1H), 1.04 (d, J = 6.9 Hz, 3H), 0.98 (dt, J = 20.0, 8.2 Hz, 
11H), 0.85 (d, J = 6.9 Hz, 3H), 0.65 (q, J = 7.9 Hz, 6H), 0.04 (s, 9H). 13C NMR (126 MHz, 
CDCl3) δ 171.02, 170.61, 156.59, 156.26, 148.18, 143.27, 128.52, 128.44, 125.78, 115.56, 
113.75, 113.28, 96.80, 84.20, 73.68, 72.16, 66.48, 63.53, 62.64, 61.40, 42.64, 41.73, 41.46, 
41.08, 40.15, 39.90, 37.68, 34.00, 33.78, 33.05, 26.46, 21.59, 17.39, 10.23, 10.21, 7.13, 5.55, 
5.31, -1.43. IR (thin film, cm-1) 2953.55, 1777.20, 1733.83, 1377.43, 1247.27, 1214.60, 1162.36, 
1059.46, 977.21, 743.71. OR [α]D25 -36.0° (c 1.0, CHCl3). HRMS (ASAP+) calculated for 





























1. 2 mol% Pd(PPh3)4,
    HSiCl3, C6H6, 80 °C
2. (R,R)-4.26, DBU








To a solution of 4.37 (118 mg, 0.20 mmol) in CH2Cl2 (2.0 mL) was added TBAF (1 M in 
THF, 0.60 mL, 0.60 mmol). The resulting reaction mixture was stirred at room temperature for 
15 min and then filtered through a plug of silica gel, rinsing with EtOAc. The filtrate was 
concentrated and the resulting residue was purified by silica gel column chromatography eluting 
with 0:100 à 40:60 EtOAc:Hexanes to afford the desired diol product as a colorless oil (95 mg, 
0.19 mmol, 97% yield). 1H NMR (400 MHz, CDCl3) δ 7.37 – 7.10 (m, 15H), 5.07 (d, J = 1.4 
Hz, 1H), 4.98 (d, J = 1.3 Hz, 1H), 4.58 – 4.41 (m, 2H), 4.21 (s, 1H), 3.69 – 3.54 (m, 2H), 3.49 
(dd, J = 9.7, 2.1 Hz, 1H), 2.86 (ddd, J = 13.6, 10.6, 5.0 Hz, 1H), 2.77 – 2.62 (m, 3H), 2.45 – 2.34 
(m, 2H), 2.32 (d, J = 6.2 Hz, 2H), 2.01 – 1.78 (m, 3H), 1.77 – 1.60 (m, 2H), 0.98 (d, J = 6.9 Hz, 
3H), 0.71 (d, J = 6.9 Hz, 3H).  
To a solution of the previously prepared diol (95 mg, 0.19 mmol) in dimethoxypropane 
(2.0 mL) was added catalytic CSA (2.3 mg, 5 mol%). Upon stirring at room temperature for 0.5 
h, Et3N (0.1 mL) was added to quench the CSA and the dimethoxypropane was removed under 
reduced pressure. The resulting crude product was purified by silica gel column chromatography 
eluting with 0:100 à 4:96 EtOAc:Hexanes to afford the desired product 4.40 as a colorless oil 
(93 mg, 0.19 mmol, 96% yield). 1H NMR (400 MHz, CDCl3) δ 7.43 – 7.12 (m, 15H), 5.01 – 
4.95 (m, 1H), 4.87 (d, J = 1.7 Hz, 1H), 4.60 (d, J = 11.5 Hz, 1H), 4.52 (d, J = 11.5 Hz, 1H), 3.62 
– 3.52 (m, 1H), 3.47 (dd, J = 10.3, 1.8 Hz, 1H), 3.36 (td, J = 9.5, 2.4 Hz, 1H), 2.90 – 2.76 (m, 
2H), 2.67 (ddt, J = 16.6, 13.7, 8.2 Hz, 2H), 2.52 (dd, J = 14.6, 6.0 Hz, 1H), 2.35 – 2.22 (m, 2H), 


















    (MeO)2CMe2
4.37 4.40
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(s, 3H), 1.04 (d, J = 7.1 Hz, 3H), 0.62 (d, J = 6.6 Hz, 3H). 13C NMR (101 MHz, CDCl3) δ 
149.38, 142.60, 142.42, 138.95, 128.76, 128.55, 128.46, 128.36, 127.98, 127.65, 125.85, 125.78, 
112.39, 97.79, 76.97, 75.74, 73.18, 70.94, 40.22, 39.38, 35.86, 35.13, 31.84, 31.35, 30.29, 19.65, 
12.16, 12.05. IR (thin film, cm-1) 3025.84, 2986.55, 2933.02, 2860.09, 1640.82, 1602.41, 
1453.61, 1378.19, 1253.73, 1200.25, 1064.42, 1045.46, 899.34, 742.49, 698.10. OR [α]D22 
+47.6° (c 1.0, CHCl3). HRMS (ASAP+) calculated for C36H47O3 [M+Na]+ 527.3525; found 
527.3525.   
 
4.7.2. Synthesis of ABCD* 4.1 and its model Wittig reactions 
 
To a solution of alcohol 4.41 (4.49 g, 8.1 mmol) in CH2Cl2 (160 mL) was added DMP 
(4.83 g, 11.4 mmol) and the resulting solution was stirred at room temperature for 1h. The 
reaction mixture was cooled to 0 °C and slowly quenched with a 1:1 solution of saturated 
aqueous NaHCO3:Na2S2O3 (200 mL). After stirring at room temperature for 1 h, the aqueous 
layer was extracted with CH2Cl2 (3 x 50 mL). The combined organic layers were dried over 
MgSO4, filtered, and concentrated to provide the desired ketone intermediate as a clear and 
colorless oil, which was used without further purification. 1H NMR (500 MHz, CDCl3) δ 7.66 – 
7.60 (m, 4H), 7.45 – 7.34 (m, 6H), 5.80 (ddd, J = 17.2, 10.2, 8.1 Hz, 1H), 5.24 – 5.12 (m, 2H), 
4.13 (tdd, J = 8.9, 4.1, 2.0 Hz, 1H), 3.74 – 3.58 (m, 3H), 3.47 (dd, J = 9.9, 5.4 Hz, 1H), 3.41 (dd, 






















J = 15.6, 4.2 Hz, 1H), 2.13 – 1.97 (m, 3H), 1.69 – 1.56 (m, 2H), 1.35 – 1.26 (m, 1H), 1.26 – 1.16 
(m, 5H), 1.10 (q, J = 11.8 Hz, 1H), 1.04 (s, 9H).  
To a solution of the resulting crude ketone in CH2Cl2 (160 mL) at 0 °C was slowly added 
DIBAL (16.2 mL, 16.2 mmol, 1M in CH2Cl2). The resulting reaction mixture was stirred at 0 °C 
for 20 minutes before quenching by slow addition of a saturated Rochelle’s salt solution (200 
mL). After the reaction mixture became clear (~45 min.), the aqueous layer was extracted with 
CH2Cl2 (3 x 50 mL). The combined organic layers were dried over MgSO4, filtered, and 
concentrated to give the crude product in a 2:1 dr. The diastereomers were separated by silica gel 
column chromatography eluting with 0:100 à 50:50 EtOAc:Hexanes providing anti-4.42 in 
29% yield (1.29 g, 2.3 mmol). Undesired syn-4.41 was recovered in 62% (2.76 g, 5.0 mmol) and 
can be resubjected to the above conditions to access anti-4.42. 1H NMR (400 MHz, CDCl3) δ 
7.71 – 7.59 (m, 4H), 7.49 – 7.33 (m, 6H), 5.82 (ddd, J = 16.7, 10.8, 8.0 Hz, 1H), 5.19 – 5.06 (m, 
2H), 4.04 – 3.92 (m, 1H), 3.81 – 3.77 (m, 1H), 3.76 – 3.61 (m, 3H), 3.52 (dd, J = 9.9, 5.0 Hz, 
1H), 3.43 (dd, J = 9.9, 6.3 Hz, 1H), 3.34 (s, 3H), 2.29 – 2.05 (m, 4H), 1.96 (ddt, J = 12.2, 4.3, 1.9 
Hz, 1H), 1.74 – 1.53 (m, 4H), 1.43 – 1.33 (m, 1H), 1.33 – 1.17 (m, 3H), 1.12 – 1.02 (m, 12H). 
13C NMR (101 MHz, CDCl3) δ 140.49, 135.74, 133.92, 129.73, 127.76, 116.15, 97.72, 73.33, 
71.21, 68.60, 65.53, 60.31, 55.65, 44.60, 41.76, 40.09, 38.66, 37.43, 32.97, 28.58, 27.06, 19.50, 
16.29. IR (thin film, cm-1) 3470.90, 2930.51, 1385.78, 1186.21, 1149.61, 1107.04, 1090.61, 
1058.82, 997.69, 969.65, 916.02, 880.34, 823.09, 808.20, 755.03, 702.75613.19504.71. OR 






To a cooled solution of 4.42 (1.10 g, 2.0 mmol) in CH2Cl2 (20.0 mL) at 0 ºC was 
sequentially added Et3N (0.56 mL, 4.0 mmol), TESCl (0.50 mL, 3.0 mmol), and DMAP (73 mg, 
0.6 mmol). The resulting mixture was warmed to room temperature and stirred 15 h. Excess 
TESCl was quenched by the addition of MeOH (0.30 mL) and all volatiles were removed in 
vacuo. The resulting residue was resuspended in hexanes and the Et3N•HCl salts were removed 
by filtration. The filtrate was concentrated and purified by silica gel column chromatography 
eluting with 0:100 à 10:90 EtOAc:Hexanes to give 4.95 as a colorless oil (1.23 g, 1.8 mmol, 
92% yield). 1H NMR (400 MHz, CDCl3) δ 7.69 – 7.57 (m, 4H), 7.48 – 7.29 (m, 6H), 5.88 – 5.76 
(m, 1H), 5.09 – 4.99 (m, 2H), 3.90 (ddd, J = 6.8, 4.9, 3.1 Hz, 1H), 3.74 – 3.58 (m, 4H), 3.52 (dd, 
J = 9.9, 5.2 Hz, 1H), 3.43 (dd, J = 9.9, 6.4 Hz, 1H), 3.34 (s, 3H), 2.40 (dq, J = 9.9, 7.0, 6.6 Hz, 
1H), 2.24 – 2.11 (m, 1H), 2.07 (ddd, J = 12.5, 4.7, 1.7 Hz, 1H), 2.00 (ddt, J = 12.3, 4.2, 2.0 Hz, 
1H), 1.76 – 1.62 (m, 3H), 1.48 (ddd, J = 14.0, 6.9, 4.6 Hz, 1H), 1.42 – 1.28 (m, 1H), 1.28 – 1.15 
(m, 2H), 1.13 - 1.03 (m, 4H) 1.06 (s, 9H), 0.98 (t, J = 7.9 Hz, 9H), 0.63 (q, J = 7.8 Hz, 6H). 13C 
NMR (101 MHz, CDCl3) δ 140.56, 135.73, 133.98, 129.72, 127.76, 114.96, 97.55, 73.47, 73.35, 
68.71, 65.95, 60.41, 55.62, 43.75, 41.71, 40.63, 38.82, 38.16, 33.04, 28.74, 27.15, 27.02, 19.49, 
15.07, 7.20, 5.59, 5.55. IR (thin film, cm-1) 2954.04, 2932.46, 2875.88, 1460.51,1427.36, 
1382.80, 1306.39, 1238.96, 1186.81, 1091.47, 1004.28, 984.98, 913.96, 880.79, 823.06, 738.39, 
701.90, 613.27, 504.31. OR [α]D26 +40.6º (c 1.0, CHCl3). HRMS (APCI) calculated for 























A solution of 4.95 (1.23 g, 1.8 mmol) in CH2Cl2 (18.0 mL) was cooled to -78 ºC while 
purging with O2 over 5 min. The reaction solution was purged with O3 until the solution turned 
blue (8 min). The resulting solution was purged with O2 for 5 min to give and cloudy white 
mixture. PPh3 (0.52 g, 1.98 mmol) was added at -78 ºC and the resulting mixture was thawed to 
room temperature. After stirring for 12h, all volatiles were removed in vacuo. The resulting 
residue was resuspended in hexanes and OPPh3 was removed by filtration. The filtrate was 
concentrated and purified by pH 7 buffered silica gel column chromatography eluting with 0:100 
à 10:90 EtOAc:Hexanes to give 4.44 as a colorless oil (1.14 g, 1.7 mmol, 94% yield). 1H NMR 
(500 MHz, CDCl3) δ 9.79 (d, J = 1.8 Hz, 1H), 7.72 – 7.57 (m, 4H), 7.49 – 7.32 (m, 6H), 4.19 – 
4.18 (m, 1H), 3.81 – 3.71 (m, 1H), 3.71 – 3.56 (m, 3H), 3.52 (dd, J = 9.9, 5.1 Hz, 1H), 3.42 (dd, 
J = 9.9, 6.4 Hz, 1H), 3.34 (s, 3H), 2.67 – 2.65 (m, 1H), 2.18 – 2.03 (m, 2H), 2.02 – 1.98 (m, 1H), 
1.85 (ddd, J = 14.1, 8.1, 5.8 Hz, 1H), 1.74 – 1.59 (m, 3H), 1.45 – 1.31 (m, 1H), 1.29 – 1.20 (m, 
2H), 1.20 – 1.10 (m, 4H), 1.05 (s, 9H), 0.97 (t, J = 8.0 Hz, 9H), 0.63 (q, J = 8.0 Hz, 6H). 13C 
NMR (126 MHz, CDCl3) δ 204.49, 135.71, 135.70, 133.90, 133.87, 129.73, 127.76, 97.73, 
73.06, 71.94, 68.57, 66.06, 60.46, 55.65, 52.26, 42.36, 41.62, 38.61, 38.11, 33.05, 28.63, 27.00, 
19.47, 10.59, 7.06, 5.35. IR (thin film, cm-1) 2953.56, 2933.18, 2876.32, 1724.36, 1460.62, 
1427.57, 1385.05, 1239.34, 1186.59, 1107.30, 1092.90, 974.83, 821.97, 740.30, 703.34, 505.27. 
OR [α]D25 +27.5º (c 1.0, CHCl3). HRMS (ESI+) calculated for C38H60O6Si2Na [M+Na]+ 









i) O3, CH2Cl2, -78 °C















Diene 4.2 was coupled with aldehyde 4.44 according to a modified version of general 
procedure 1 as follows: To a solution of diene 4.2 (0.84 g, 1.5 mmol) in C6H6 (15 mL) in a 100 
mL-capacity, septum-adapted pressure tube was added Pd(PPh3)4 (34 mg, 0.03 mmol). The 
resulting mixture was pumped on and back-filled with N2 (3x). HSiCl3 (0.40 mL, 3.0 mmol) was 
added and the reaction vessel was sealed with a teflon lined screw cap and heated to 80 °C for 12 
h. The reaction solution was carefully cooled to room temperature. The reaction vessel was 
attached to a vacuum line equipped with a manometer and a -78 °C cold finger, and then placed 
in a warm (~35 °C) water bath. All volatiles were evaporated by application of vacuum until a 
viscous oil remained.  
The resulting hydrosilylated product was retaken in CH2Cl2 (11.0 mL) and cooled to 0 
°C. A solution of diaminophenol (R,R)-4.26 (0.35 g, 1.4 mmol) and DBU (0.63 mL, 4.2 mmol) 
in CH2Cl2 (2.0 mL), rinsing with CH2Cl2 (2 x 1.0 mL). The resulting mixture was warmed to 
room temperature and stirred for 1 h. The reaction mixture was cooled back to 0 °C and aldehyde 
4.44 (0.85 g, 1.3 mmol) was added as a solution in CH2Cl2 (2.0 mL), rinsing with CH2Cl2 (3 x 













































1. 2 mol% Pd(PPh3)4,
    HSiCl3, C6H6, 80 °C
2. 1.1 equiv. (R,R)-4.26, 




















mixture was stirred for 12 h while warming to room temperature. The reaction mixture was 
cooled to 0 °C and treated with TBAF•3H2O (400 mg, 1.3 mmol). Upon stirring for 1.5 h at 0 °C, 
the reaction mixture was filtered through a plug of silica gel, rinsing with EtOAc. The filtrate 
was concentrated in vacuo and the crude product was purified by silica gel column 
chromatography eluting with 0:100 à 60:40 EtOAc:Hexanes to give 4.45 as a beige foam (1.27 
g, 1.03 mmol, >20:1 dr, 81% yield). 1H NMR (500 MHz, CDCl3) δ 7.68 – 7.57 (m, 4H), 7.45 – 
7.33 (m, 6H), 5.15 (d, J = 1.9 Hz, 1H), 5.07 – 5.01 (m, 1H), 5.00 (s, 1H), 4.41 (dt, J = 9.2, 2.8 
Hz, 1H), 4.35 – 4.29 (m, 2H), 4.20 – 4.04 (m, 2H), 3.83 – 3.75 (m, 1H), 3.75 – 3.59 (m, 3H), 
3.50 (dd, J = 9.9, 4.9 Hz, 1H), 3.41 (dd, J = 9.9, 6.1 Hz, 1H), 3.34 (s, 4H), 2.84 (dd, J = 15.2, 2.2 
Hz, 1H), 2.54 – 2.42 (m, 2H), 2.33 (dd, J = 14.3, 8.9 Hz, 1H), 2.29 – 2.15 (m, 3H), 2.14 – 2.04 
(m, 2H), 2.02 (s, 3H), 2.02 – 1.98 (m, 1H), 1.96 – 1.84 (m, 3H), 1.81 – 1.78 (m, 1H), 1.73 – 1.56 
(m, 4H), 1.55 – 1.43 (m, 5H), 1.42 – 1.35 (m, 2H), 1.34 – 1.14 (m, 5H), 1.13- 1.04 (s, 4H), 1.04 
(s, 9H), 1.02 – 0.91 (m, 11H), 0.85 (d, J = 6.9 Hz, 3H), 0.64 (q, J = 7.7 Hz, 6H). 13C NMR (126 
MHz, CDCl3) δ 170.97, 170.51, 156.57, 156.24, 148.26, 135.72, 133.92, 129.67, 127.74, 115.57, 
113.92, 113.29, 97.62, 96.77, 84.20, 73.40, 72.00, 70.97, 68.60, 66.47, 66.39, 63.51, 62.58, 
61.39, 60.45, 55.61, 42.66, 42.09, 41.85, 41.09, 39.90, 39.85, 38.86, 38.75, 38.64, 37.68, 33.76, 
32.76, 28.60, 27.02, 26.49, 21.60, 19.48, 17.38, 10.50, 10.04, 7.18, 5.59, -1.43. IR (thin film, cm-
1) 2953.86, 1777.36, 1734.13, 1378.55, 1246.58, 1214.84, 1162.71, 1134.40, 1093.85, 1059.74, 
998.35, 837.30, 753.04, 703.72, 504.88. OR [α]D26 -4.5º (c 1.0, CHCl3). HRMS (ESI+) 




To a solution of 4.45 (332 mg, 0.27 mmol) in THF (3.0 mL) cooled to 0 °C was added 
Et3N (150 µL, 1.1 mmol), Ac2O (76 µL, 0.80 mmol), and DMAP (66 mg, 0.54 mmol), 
sequentially. The resulting mixture was warmed to room temperature and stirred for 1.5 h. 
Saturated NaHCO3 (5.0 mL) was added and the aqueous layer was extracted with EtOAc (3 x 2.0 
mL). The combined organic layers were dried over MgSO4, filtered, and concentrated in vacuo. 
The resulting residue was purified by silica gel column chromatography eluting with 0:100 à 
50:50 EtOAc:Hexanes to give 4.46 as a beige foam (301 mg, 0.24 mmol, 88% yield). 1H NMR 
(500 MHz, CDCl3) δ 7.67 – 7.60 (m, 4H), 7.44 – 7.33 (m, 6H), 5.04 – 5.02 (m, 1H), 5.00 (m, 
1H), 4.89 – 4.81 (m, 2H), 4.30 – 4.19 (m, 2H), 4.19 – 4.08 (m, 2H), 4.08 – 4.01 (m, 1H), 3.76 – 
3.58 (m, 4H), 3.52 (dd, J = 9.9, 4.5 Hz, 1H), 3.40 – 3.33 (m, 1H), 3.32 (s, 3H), 2.84 (dd, J = 
15.3, 2.2 Hz, 1H), 2.61 (q, J = 7.1, 6.5 Hz, 1H), 2.46 (dd, J = 16.4, 6.0 Hz, 1H), 2.41 – 2.32 (m, 
1H), 2.31 – 2.22 (m, 2H), 2.22 – 2.15 (m, 1H), 2.13 – 2.07 (m, 1H), 2.06 – 1.96 (m, 6H), 1.94 – 
1.91 (m, 1H), 1.91 (s, 3H), 1.82 – 1.78 (m, 1H), 1.75 – 1.69 (m, 1H), 1.63 – 1.54 (m, 3H), 1.53 
(s, 3H), 1.51 – 1.40 (m, 2H), 1.40 – 1.27 (m, 3H), 1.23 – 1.08 (m, 6H), 1.04 (s, 9H), 1.02 – 0.93 
(m, 11H), 0.92 (d, J = 6.9 Hz, 3H), 0.68 – 0.60 (m, 6H). 13C NMR (126 MHz, CDCl3) δ 171.01, 
170.46, 169.63, 156.56, 156.23, 147.03, 135.75, 135.72, 133.83, 133.76, 129.72, 129.70, 127.74, 
115.59, 113.85, 113.31, 97.40, 96.71, 84.33, 73.60, 73.36, 69.77, 68.67, 66.39, 65.73, 63.31, 
62.54, 61.36, 60.30, 55.52, 42.85, 42.28, 41.72, 41.12, 41.03, 39.97, 38.51, 38.45, 38.14, 37.73, 
37.63, 33.77, 32.83, 28.94, 27.01, 26.44, 21.60, 20.77, 19.46, 17.39, 11.32, 9.64, 7.19, 5.69, -



















4.45: R = H




1093.76, 1075.55, 1016.32, 998.82, 977.88, 940.82, 858.45, 837.84, 753.55, 703.97, 505.23. OR 
[α]D25 +7.0º (c 1.0, CHCl3). HRMS (ESI+) calculated for C66H103O15Si3F3Na [M+Na]+ 
1299.6455; found 1299.6448. 
 
 Diene 4.2 was coupled with aldehyde 4.3 according to a modified literature procedure.1-2 
A 100 mL-capacity, septum-adapted pressure tube was charged with Pd(PPh3)4 (24 mg, 0.02 
mmol), evacuated, and then back-filled with N2. A solution of diene 4.2 (1.19 g, 2.1 mmol) in 
benzene (24 mL) was added followed by trichlorosilane (0.43 mL, 4.2 mmol) and the tube was 
tightly sealed. The resulting solution was stirred at 70 °C. After 15 h the oil bath was removed 
and the sealed tube was allowed to cool to room temperature. The resulting light brown solution 
was transferred by cannula into a 250 mL round bottom flask, rinsing with benzene (3 x 5 mL). 
The flask was attached to a vacuum line equipped with a manometer and a -78 °C cold finger, 
and then placed in a warm (~35 °C) water bath. All volatiles were evaporated by application of 
vacuum until a viscous oil remained. 
The resulting hydrosilylated product was dissolved in CH2Cl2 (21.0 mL) and (R,R)-4.5 














































1. 1 mol% Pd(PPh3)4,
    HSiCl3, C6H6, 70 °C
2. i) (R,R)-4.5, 
       DBU, CH2Cl2
    ii) concentrate, remove
        DBU•HCl w/Et2O
20 mol% Sc(OTf)3





















8.4 mmol) was added over 10 min. After 5 min, the mixture was warmed and stir at room 
temperature. After 2 h, the flask was attached to a vacuum line equipped with a manometer and a 
-78 °C coldfinger, and then placed in a room temperature water bath. All volatiles were removed 
by careful application of vacuum, and the residue was treated with Et2O (25.0 mL). The mixture 
was stirred vigorously for 3 h during which time to precipitate the DBU•HCl. The DBU•HCl 
salts were removed by syringe transfer on to an oven-dried, air-free filter frit and filtering into a 
250 mL round bottom flask. The residual DBU•HCl salts were rinsed with Et2O (3 x 5.0 mL) and 
the resulting supernatants were again filtered through the air-free frit into the flask. The flask was 
attached to a vacuum line equipped with a manometer and a -78 °C coldfinger, and then placed 
in a room temperature water bath. All volatiles were removed by careful application of vacuum 
until the resulting yellow oil became opaque and foamy. The residue was dissolved in CH2Cl2 
(11.0 mL) and used without further purification. 
 To the above solution of 4.6 at 0 ºC was added CD aldehyde 4.3 (1.06 g, 1.6 mmol) as a 
solution in CH2Cl2 (5.0 mL) rinsing with CH2Cl2 (2 x 2.5 mL). Sc(OTf)3 (78 mg, 0.16 mmol) 
was added in one portion. The N2 inlet was removed and the septum was parafilmed. The 
reaction solution was stirred for 15 h while the ice bath expired. The reaction solution was 
cooled to 0 ºC and TBAF•3H2O (0.50 g, 1.6 mmol) was added. The resulting solution was stirred 
at 0 ºC for 45 min. before concentrating in vacuo. The resulting crude product (>15:1 dr) was 
purified by silica gel column chromatography eluting with 5:95 à 100:0 EtOAc:Hexanes to give 
pure 4.9 as a beige foam (1.50 g, 1.2 mmol, 77% yield). 1H NMR (400 MHz, CDCl3) δ 7.74 – 
7.56 (m, 4H), 7.51 – 7.31 (m, 6H), 5.17 (s, 1H), 5.08 – 4.98 (m, 2H), 4.38 – 4.27 (m, 2H), 4.27 – 
4.20 (m, 1H), 4.20 – 4.06 (m, 2H), 3.78 – 3.54 (m, 5H), 3.49 (dd, J = 9.8, 5.3 Hz, 1H), 3.42 (dd, 
J = 9.8, 6.2 Hz, 1H), 3.34 (s, 3H), 2.99 – 2.78 (m, 2H), 2.56 – 2.32 (m, 3H), 2.32 – 2.16 (m, 3H), 
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2.13 – 1.99 (m, 2H), 2.03 (s, 3H), 1.99 – 1.74 (m, 4H), 1.74 – 1.56 (m, 4H), 1.56 – 1.43 (m, 1H), 
1.53 (s, 3H), 1.43 – 1.17 (m, 6H), 1.05 (s, 9H), 1.08-1.01 (m, 3H), 0.98 (t, J = 7.8 Hz, 11H), 0.81 
(d, J = 6.9 Hz, 3H), 0.63 (q, J = 7.9 Hz, 6H), 0.04 (s, 10H). 13C NMR (101 MHz, CDCl3) δ 
171.06, 170.58, 156.63, 156.22, 148.12, 135.76, 133.99, 133.94, 129.69, 127.75, 115.88, 113.72, 
113.04, 97.68, 96.82, 84.25, 73.37, 71.69, 71.19, 68.68, 66.48, 65.35, 63.51, 62.62, 61.50, 60.24, 
55.64, 42.66, 41.86, 41.62, 41.08, 40.09, 40.03, 39.89, 39.51, 38.78, 37.69, 37.41, 33.80, 32.76, 
28.66, 27.02, 26.50, 21.61, 19.49, 17.44, 10.86, 10.24, 7.07, 5.22, -1.40. IR (thin film, cm-1) 
2953.37, 2931.97, 1778.46, 1735.64, 1378.90, 1247.05, 1215.68, 1164.68, 1107.14, 999.91, 
858.54, 740.98, 703.76. OR [α]D19 -13.5º (c 1.0, CHCl3). HRMS (ESI+) calculated for 
C64H101O14Si3F3Na [M+Na]+ 1257.6349; found 1257.6316. 
 
 To a solution of 4.9 (1.08 g, 0.87 mmol) in THF (9.0 mL) at 0 ºC was added Et3N (1.22 
mL, 8.73 mmol), Ac2O (0.50 mL, 5.24 mmol), and DMAP (0.32 g, 2.62 mmol), sequentially. 
The resulting mixture was warmed to room temperature and stirred for 15 h. Saturated NaHCO3 
was added and the aqueous layer was extracted with EtOAc (3 x 10 mL). The combined organic 
layers were washed with H2O (1 x 20 mL), dried over Na2SO4, filtered, and concentrated in 
vacuo. The resulting residue was purified by silica gel column chromatography eluting with 5:95 
à 30:70 EtOAc:Hexanes to give 4.51 as a beige foam (1.07 g, 0.83 mmol, 96% yield). 1H NMR 
(400 MHz, CDCl3) δ 7.69 – 7.56 (m, 4H), 7.49 – 7.29 (m, 6H), 5.20 – 5.12 (m, 1H), 5.08 – 4.99 
(m, 1H), 4.97 (s, 1H), 4.82 (s, 1H), 4.30 – 4.18 (m, 2H), 4.18 – 4.10 (m, 2H), 4.10 – 4.03 (m, 



















4.9: R = H




3H), 2.85 (dd, J = 15.2, 2.2 Hz, 1H), 2.68 – 2.56 (m, 1H), 2.56 – 2.40 (m, 2H), 2.34 – 2.22 (m, 
2H), 2.22 – 2.11 (m, 1H), 2.11 – 2.03 (m, 1H), 2.02 (s, 3H), 1.99 – 1.86 (m, 3H), 1.89 (s, 3H), 
1.85 – 1.55 (m, 6H), 1.53 (s, 3H), 1.51 – 1.41 (m, 1H), 1.41 – 1.11 (m, 6H), 1.08 (d, J = 6.8 Hz, 
3H), 1.03 (s, 9H), 0.97 (t, J = 8.0 Hz, 14H), 0.89 (d, J = 6.8 Hz, 3H), 0.60 (q, J = 7.9 Hz, 6H), 
0.04 (s, 9H). 13C NMR (101 MHz, CDCl3) δ 171.06, 170.56, 169.97, 156.62, 156.21, 147.81, 
135.71, 135.68, 133.76, 133.71, 129.79, 129.76, 127.77, 115.91, 113.50, 113.06, 97.60, 96.75, 
84.26, 73.75, 73.08, 68.72, 67.55, 66.33, 65.29, 63.31, 62.63, 61.55, 60.07, 55.60, 42.91, 42.25, 
41.93, 41.88, 41.00, 40.10, 38.97, 38.20, 37.73, 37.39, 33.75, 33.02, 28.91, 26.97, 26.45, 21.59, 
20.96, 19.42, 17.46, 10.83, 8.42, 7.16, 5.55, -1.38. IR (thin film, cm-1) 2953.09, 2882.06, 
1778.54, 1735.18, 1378.70, 1245.60, 1216.43, 1164.69, 1100.04, 999.42, 859.15, 837.62, 703.93. 
OR [α]D20 -2.1º (c 1.0, CHCl3). HRMS (ESI+) calculated for C66H103O15SiF3Na [M+Na]+ 
1299.6455; found 1299.6426.  
 
To a solution of ABCD 4.51 (426 mg, 0.33 mmol) in DMF (4.0 mL) was added distilled 
H2O (192 µL) and TASF (1.01 g, 3.7 mmol), and the sides of the reaction vessel was rinsed with 
DMF (2.0 mL). The resulting mixture was stirred at 50 °C for 10h, when TLC analysis indicated 
complete conversion to product. The reaction mixture was cooled to room temperature and the 
excess TASF was quenched with pH 7 buffer (8.0 mL). The resulting reaction mixture was 
extracted with EtOAc (5 x 3.0 mL). The combined organic layers were wash with distilled H2O 
(1 x 3.0 mL), dried over Na2SO4, filtered, and concentrated. The resulting residue was purified 










































a beige foam (211 mg, 0.29 mmol, 88% yield). 1H NMR (500 MHz, CDCl3) δ 5.06 – 4.99 (m, 
2H), 4.94 (d, J = 1.7 Hz, 1H), 4.84 (d, J = 1.7 Hz, 1H), 4.42 – 4.32 (m, 1H), 4.16 (tdd, J = 9.2, 
6.7, 2.0 Hz, 1H), 3.97 (dt, J = 9.0, 2.3 Hz, 1H), 3.84 (ddt, J = 12.1, 9.9, 2.6 Hz, 1H), 3.73 – 3.60 
(m, 2H), 3.53 (ddd, J = 13.1, 11.3, 2.2 Hz, 1H), 3.47 – 3.36 (m, 1H), 3.36 – 3.28 (m, 1H), 3.32 
(s, 3H), 2.61 (qd, J = 7.0, 2.4 Hz, 1H), 2.48 – 2.37 (m, 2H), 2.36 – 2.27 (m, 1H), 2.21 (dd, J = 
13.8, 6.6 Hz, 1H), 2.12 – 2.06 (m, 1H), 2.04 (s, 3H), 2.02 (s, 3H), 2.06 – 1.94 (m, 4H), 1.91 – 
1.82 (m, 1H), 1.82 – 1.70 (m, 6H), 1.70 – 1.63 (m, 1H), 1.63 – 1.49 (m, 3H), 1.39 (d, J = 13.9 
Hz, 1H), 1.28 – 1.09 (m, 13H), 0.98 (d, J = 7.1 Hz, 3H). 
 
 To a solution of acid 4.52 (211 mg, 0.29 mmol) in CH2Cl2 (3.0 mL) was added Et3N (60 
µL, 0.43 mmol) and TIPSCl (68 µL, 0.32 mmol). After stirring at room temperature for 20 min, 
saturated NaHCO3 (3.0 mL) was added. The aqueous layer was extracted with CH2Cl2 (3 x 1.0 
mL). The combined organic layers were dried over Na2SO4, filtered, and concentrated. The 
resulting residue was purified by silica gel column chromatography eluting with 0:100 à 5:95 
MeOH:CH2Cl2 to give 4.55 as a beige foam (212 mg, 0.24 mmol, 83% yield [73% yield over 2 
steps]). 1H NMR (400 MHz, CDCl3) δ 5.09 – 5.02 (m, 2H), 5.00 (dd, J = 9.8, 2.6 Hz, 1H), 4.86 
(s, 1H), 4.41 – 4.22 (m, 2H), 4.03 (s, 1H), 3.87 – 3.72 (m, 2H), 3.72 – 3.54 (m, 3H), 3.52 – 3.36 
(m, 2H), 3.33 (s, 3H), 2.97 (d, J = 2.5 Hz, 1H), 2.66 – 2.52 (m, 2H), 2.46 (dd, J = 17.2, 4.7 Hz, 
1H), 2.35 (dd, J = 14.4, 8.1 Hz, 1H), 2.21 – 2.07 (m, 2H), 2.07 – 1.98 (m, 2H), 2.05 (s, 3H), 2.01 
(s, 3H), 1.98 – 1.91 (m, 1H), 1.90 – 1.69 (m, 5H), 1.69 – 1.61 (m, 3H), 1.61 – 1.56 (m, 1H), 1.56 









































(d, J = 7.5 Hz, 18H), 0.99 – 0.85 (m, 1H), 0.95 (d, 3H). 13C NMR (101 MHz, CDCl3) δ 171.41, 
171.10, 170.35, 147.54, 113.25, 98.27, 97.85, 75.21, 72.95, 68.66, 68.13, 67.77, 66.20, 65.01, 
61.41, 60.19, 55.64, 46.28, 43.87, 42.34, 41.63, 41.54, 40.67, 39.68, 38.77, 38.52, 37.70, 34.08, 
33.23, 30.13, 28.29, 21.65, 20.93, 17.94, 17.92, 12.03, 11.93, 9.39. IR (thin film, cm-1) 3529.62, 
2944.98, 2870.04, 1718.21, 1462.33, 1370.42, 1244.91, 1183.06, 1091.95, 1019.86, 991.45, 
958.31, 884.76, 752.89. OR [α]D20 +16.4º (1.0, CHCl3). HRMS (FAB+) calculated for 
C46H81O14Si [M+H]+ 885.5396; found 885.5422. 
 
To a solution of 4.55 (102 mg, 0.12 mmol) in CH2Cl2 (7.7 mL) was added DMP (147 mg, 
0.35 mmol) and the resulting mixture was stirred at room temperature for 1.5 h. The reaction 
mixture was cooled to 0 °C and a 1:1 solution of saturated NaHCO3 to saturated Na2S2O3 (10.0 
mL) was added. Upon stirring for 0.5 h at room temperature, the aqueous layer was extracted 
with CH2Cl2 (3 x 5.0 mL) and the combined organic layers were dried over MgSO4, filtered, and 
concentrated. Typically, crude 4.56 is sufficiently pure to use without purification, but here 
purification was achieved by pH 7 buffered silica gel column chromatography eluting with 0:100 
à 70:30 EtOAc:Hexanes to give 4.56 as a beige foam (88 mg, 0.10 mmol, 86% yield). 1H NMR 
(400 MHz, CDCl3) δ 9.59 (s, 1H), 5.27 (dd, J = 9.5, 3.1 Hz, 1H), 5.09 – 5.00 (m, 2H), 4.85 (s, 
1H), 4.30 (dq, J = 12.6, 6.8, 5.3 Hz, 2H), 4.21 – 4.12 (m, 1H), 4.00 (s, 1H), 3.88 – 3.75 (m, 1H), 
3.74 – 3.62 (m, 2H), 3.33 (s, 3H), 2.93 – 2.78 (m, 2H), 2.73 (tt, J = 12.8, 3.7 Hz, 1H), 2.62 – 2.50 









































(m, 2H), 1.92 (s, 3H), 1.90 – 1.75 (m, 3H), 1.73 – 1.61 (m, 3H), 1.61 – 1.39 (m, 5H), 1.33 – 1.19 
(m, 7H), 1.15 (s, 3H), 1.11 (d, J = 7.1 Hz, 3H), 1.05 (d, J = 7.4 Hz, 22H). 
 
 To a solution of 4.56 (61 mg, 0.069 mmol) in CH2Cl2 (1.4 mL) was added 2,6-di-tert-
butylpyridine (155 µL, 0.69 mmol). The resulting mixture was cooled to -78 ºC and TESOTf (78 
µL, 0.35 mmol) was added slowly. Upon stirring at -78 °C for 2h, excess TESOTf was quenched 
with the addition of saturated aqueous NaHCO3 (3.0 mL) and warmed to room temperature over 
10 minutes. The aqueous layer was extracted with CH2Cl2 (3 x 2.0 mL) and the combined 
organic layers were dried over MgSO4, filtered, and concentrated. The resulting crude product 
was purified by pH 7 buffered silica gel column chromatography eluting with 0:100 à 60:40 
EtOAc:Hexanes to give 4.1 as a beige foam (58 mg, 0.058 mmol, 84% yield). 1H NMR (400 
MHz, CDCl3) δ 9.57 (s, 1H), 5.29 (dd, J = 9.7, 2.9 Hz, 1H), 5.06 – 5.01 (m, 1H), 4.99 (s, 1H), 
4.84 (s, 1H), 4.29 – 4.09 (m, 3H), 3.88 – 3.76 (m, 1H), 3.74 – 3.62 (m, 2H), 3.33 (s, 3H), 2.94 – 
2.76 (m, 2H), 2.76 – 2.61 (m, 2H), 2.53 – 2.34 (m, 3H), 2.33 – 2.24 (m, 2H), 2.16 – 2.07 (m, 
1H), 2.06 – 1.94 (m, 2H), 2.01 (s, 3H), 1.92 (s, 3H), 1.90 – 1.79 (m, 3H), 1.79 – 1.69 (m, 1H), 
1.63 – 1.37 (m, 56H), 1.37 – 1.15 (m, 8H), 1.20 (s, 3H), 1.13 – 1.00 (m, 25H), 0.93 (t, J = 7.9 
Hz, 9H), 0.55 (qd, J = 7.9, 2.1 Hz, 6H). 13C NMR (101 MHz, CDCl3) δ 209.16, 202.95, 171.09, 
170.65, 169.61, 147.16, 113.88, 97.11, 97.03, 73.75, 72.79, 70.55, 66.84, 64.42, 64.21, 61.29, 
59.56, 55.77, 48.72, 48.46, 47.83, 45.38, 43.43, 42.40, 42.19, 41.27, 38.68, 37.95, 36.96, 35.01, 




















4.56: R = H
4.1: R = TES
Nt-Bu t-Bu
TESOTf, CH2Cl2, -78 °C
 213 
1) 2946.02, 2871.81, 1725.31, 1460.33, 1370.55, 1234.87, 1182.01, 1145.61, 1061.66, 1004.60, 
885.04, 739.67, 673.43, 491.87. OR [α]D20 +13.3º (1.0, CHCl3). HRMS (ESI+) calculated for 
C52H90O14Si2Na [M+Na]+ 1017.5767; found 1017.5761. 
 
**The following precautions were taken to minimize presence of water: (1) phosphonium salt 
4.65 was dried under vacuum at 50 °C for 12 h prior to use; (2) aldehyde 4.63 was dissolved in 
C6H6 and concentrated in vacuo (3x); (3) THF was freshly distilled from LiAlH4. 
 To a suspension of phosphonium salt 4.65 (54 mg, 0.12 mmol) in THF (0.45 mL) was 
added HMPA (0.15 mL) and the resulting mixture was cooled to -78 °C. LiHMDS (120 µL, 0.12 
mmol, 1 M in THF) was added dropwise and stirred for 40 min, over which time the reaction 
mixture turned bright orange. Aldehyde 4.63 (30 mg, 0.096 mmol) was added as a solution in 
THF (0.10 mL), rinsing with THF (2 x 0.10 mL). Upon addition of 4.63, the resulting mixture, 
which faded to pale yellow, was stirred at -78 °C for 15 min and at 0 °C for 20 min, during 
which time the reaction mixture turned bright red-orange. The reaction mixture was quenched by 
addition of saturated NH4Cl (1.0 mL) and Na2S2O3 (1.0 mL), and extracted with Et2O (3 x 2.0 
mL). The combined organic layers were washed with saturated NaHCO3 (2.0 mL) and brine (2.0 
mL), and then dried over MgSO4, filtered, and concentrated in vacuo. The resulting residue was 
purified by silica gel column chromatography eluting with 0:100 à 20:80 EtOAc:Hexanes to 
give 4.64 as a pale yellow oil (29 mg, 0.079 mmol, 82% yield). 1H NMR (500 MHz, CDCl3) δ 
5.27 (dt, J = 10.8, 7.3 Hz, 1H), 5.04 (ddt, J = 10.8, 9.3, 1.6 Hz, 1H), 4.22 – 4.13 (m, 1H), 3.74 – 






























2.80 – 2.67 (m, 1H), 2.51 (h, J = 6.8 Hz, 1H), 2.32 (dd, J = 15.6, 3.4 Hz, 1H), 2.10 – 1.92 (m, 
4H), 1.77 – 1.66 (m, 1H), 1.47 – 1.34 (m, 2H), 1.33 – 1.20 (m, 6H), 1.20 – 1.11 (m, 2H), 1.10 (d, 
J = 6.9 Hz, 3H), 0.92 – 0.84 (m, 6H). 13C NMR (126 MHz, CDCl3) δ 212.90, 133.99, 129.62, 
97.42, 73.04, 65.21, 60.10, 55.69, 49.30, 46.96, 41.95, 41.43, 37.22, 32.20, 31.74, 28.71, 27.27, 
25.54, 22.47, 15.32, 14.12, 11.78. IR (thin film, cm-1) 2958.31, 2928.17, 2874.51, 1711.69, 
1458.87, 1383.74, 1257.09, 1179.65, 1089.16, 1039.14, 981.55, 955.27, 808.28, 749.15. OR 
[α]D22 +82.0° (c 1.0, CHCl3). HRMS (ESI+) calculated for C22H38O4Na [M+Na]+ 389.2668; 
found 389.2661. 
 
**The following precautions were taken to minimize presence of water: (1) phosphonium salt 
4.65 was dried under vacuum at 50 °C for 12 h prior to use; (2) aldehyde 4.1 was dissolved in 
C6H6 and concentrated in vacuo (3x); (3) THF was freshly distilled from LiAlH4. 
 To a suspension of phosphonium salt 4.65 (40 mg, 0.090 mmol) in THF (0.42 mL) was 
added HMPA (0.14 mL) and the resulting mixture was cooled to -78 °C. LiHMDS (90 µL, 0.090 
mmol, 1 M in THF) was added dropwise and stirred for 30 min, over which time the reaction 
mixture turned bright orange. Aldehyde 4.1 (72 mg, 0.072 mmol) was added as a solution in 
THF (0.10 mL), rinsing with THF (3 x 0.05 mL). Upon addition of 4.1, the resulting mixture, 
which faded to beige, was stirred at -78 °C for 20 min and at 0 °C for 20 min, during which time 
the reaction mixture turned bright red-orange. The reaction mixture was quenched by addition of 
saturated NH4Cl (1.0 mL) and Na2S2O3 (1.0 mL), and extracted with Et2O (3 x 2.0 mL). The 









































-78 to 0 °C
n-Bu
4.66: R = TIPS
4.67: R = H
4.1
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then dried over Na2SO4, filtered, and concentrated in vacuo. The resulting residue was purified 
by silica gel column chromatography eluting with 0:100 à 50:50 EtOAc:Hexanes to give TIPS 
deprotected product 4.67 (17 mg, 0.019 mmol, 26% yield) and the desired product 4.66 as a pale 
yellow oil (30 mg, 0.030 mmol, 42% yield). Spectral data for 4.66 is as follows: 1H NMR (500 
MHz, CDCl3) δ 5.32 – 5.23 (m, 2H), 5.14 – 5.02 (m, 2H), 5.01 (s, 1H), 4.86 (s, 1H), 4.32 – 4.22 
(m, 1H), 4.22 – 4.07 (m, 2H), 3.78 – 3.64 (m, 2H), 3.56 (dd, J = 11.5, 4.5 Hz, 1H), 3.32 (s, 3H), 
2.98 – 2.90 (m, 1H), 2.86 (dd, J = 16.8, 8.7 Hz, 1H), 2.79 – 2.63 (m, 2H), 2.48 – 2.34 (m, 3H), 
2.29 (dd, J = 14.5, 8.7 Hz, 1H), 2.21 (dd, J = 14.4, 4.3 Hz, 1H), 2.09 – 2.04 (m, 1H), 2.02 (s, 
3H), 2.01 – 1.95 (m, 4H), 1.93 (s, 3H), 1.88 – 1.81 (m, 1H), 1.78 – 1.71 (m, 1H), 1.64 – 1.50 (m, 
6H), 1.50 – 1.40 (m, 2H), 1.35 – 1.13 (m, 19H), 1.12 – 1.01 (m, 26H), 0.94 (t, J = 7.9 Hz, 10H), 
0.91 – 0.82 (m, 4H), 0.56 (qd, J = 7.7, 4.0 Hz, 6H). 13C NMR (126 MHz, CDCl3) δ 209.56, 
171.12, 170.70, 169.60, 147.21, 134.09, 129.56, 113.87, 97.46, 97.04, 74.14, 73.00, 70.57, 66.90, 
64.80, 64.23, 61.29, 60.20, 55.72, 49.06, 48.71, 47.83, 45.32, 42.38, 42.08, 41.98, 41.49, 38.67, 
37.06, 34.15, 32.17, 32.13, 31.73, 28.70, 27.23, 22.41, 21.69, 20.94, 17.95, 17.94, 14.16, 12.76, 
12.47, 12.07, 7.47, 7.04. IR (thin film, cm-1) 2947.37, 2871.50, 1722.08, 1461.03, 1370.20, 
1233.06, 1181.10, 1144.70, 1065.71, 1020.06, 996.12, 884.22, 753.38, 667.75, 490.80. OR 
[α]D22 +13.4° (c 1.0, CHCl3). HRMS (ESI+) calculated for C57H100O13Si2Na [M+Na]+ 







4.7.3. Preparation of ABCD*-linker analogs 4.88 and 4.89 
 
To a solution of 4.72 (3.00 g, 16.3 mmol) in DMF (50.0 mL) was added NaN3 (2.11 g, 
32.5 mmol). The resulting mixture was stirred at 80 °C for 12 h and the cooled to room 
temperature. Water (30.0 mL) was added to the reaction vessel and the mixture was extracted 
with EtOAc (3 x 20 mL). The combined organic layers were dried over MgSO4, filtered, and 
concentrated. The crude product was purified by silica gel column chromatography eluting with 
0:100 à 70:30 EtOAc:Hexanes to afford the desired product 4.73 as a pale yellow solid (2.37 g, 
79% yield). 1H NMR (300 MHz, CDCl3) δ 8.15 – 7.99 (m, 1H), 7.41 – 7.28 (m, 1H), 3.56 (t, J = 
7.1 Hz, 1H), 2.97 (t, J = 7.1 Hz, 1H). The 1H NMR spectroscopic data is in agreement with data 
reported in literature.14 
 
To a solution of 3,3-dimethylglutaric anhydride 4.74 (5.00 g, 35.0 mmol) in THF (175 
mL) cooled to -20 °C was added a LiAlH4 (0.80 g, 21 mmol) in 3 equal portions in 5 min 
increments. The reaction mixture was slowly warmed to 0 °C and stirred for 1 h. Excess LiAlH4 
was quenched by slow addition of 6 M HCl (45.0 mL) and stirring at room temperature for 20 
min. The aqueous layer was extracted with EtOAc (3 x 50 mL) and the combined organic layers 
were dried over MgSO4, filtered, and concentrated to provide crude 4.75, which was used 
without additional purification. 1H NMR (500 MHz, CDCl3) δ 4.40 – 4.32 (m, 2H), 2.32 (s, 2H), 
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A mixture of lactone 4.75 (205 mg, 1.6 mmol) and 33% HBr in AcOH (0.46 mL) was 
stirred at 75 °C for 1 h. Upon cooling to room temperature, MeOH (0.60 mL) was added and the 
resulting mixture was stirred for 48 h. All volatiles were removed in vacuo and the resulting 
residue was dissolved in EtOAc (5.0 mL) and washed with saturated NaHCO3 (3 x 2.0 mL). The 
organic layer was dried over Mg2SO4, filtered, and concentrate to afford crude 4.78 as a colorless 
oil. NMR analysis of the crude indicated an 85:15 mixture of product 4.78 to side products (4.75 
and bromoacid) that was used without further purification. 1H NMR (400 MHz, CDCl3) δ 3.67 
(s, 3H), 3.46 – 3.36 (m, 2H), 2.22 (s, 2H), 2.01 – 1.91 (m, 2H), 1.03 (s, 6H). 
To a solution of crude 4.78 in DMF (4.0 mL) was added NaN3 (210 mg, 3.2 mmol) and 
the resulting mixture was stirred at 70 °C for 2 h. The reaction mixture was quenched by the 
addition of H2O (4.0 mL) and extracted with EtOAc (3 x 2.0 mL). The combined organic layers 
were dried over MgSO4, filtered, and concentrated to provide the crude product 4.79, which was 
used without further purification. 1H NMR (400 MHz, CDCl3) δ 3.65 (s, 3H), 3.35 – 3.23 (m, 
2H), 2.23 (s, 2H), 1.71 – 1.61 (m, 2H), 1.02 (s, 6H). 
To a solution of crude 4.79 in MeOH (0.4 mL) was added 1 M NaOH (2.4 mL, 2.4 
mmol). The resulting reaction mixture was stirred at room temperature for 12 h. The reaction 
mixture was concentrated in vacuo and the resulting residue was treated with 1 M HCl until pH 
1. The product was extracted with EtOAc (3 x 2.0 mL) and the combined organic layers were 
dried over MgSO4, filtered, and concentrated. The crude product was purified by silica gel 
column chromatography eluting with 0:100 à 50:50 EtOAc:Hexanes to afford the desired 
product 4.77 as a colorless oil (138 mg, 50% yield over 4 steps). 1H NMR (400 MHz, CDCl3) δ 
3.40 – 3.24 (m, 2H), 2.28 (s, 2H), 1.78 – 1.66 (m, 2H), 1.08 (s, 6H). 13C NMR (101 MHz, 
CDCl3) δ 177.71, 47.69, 45.77, 39.84, 32.58, 27.55. IR (thin film, cm-1) 2962.92, 2091.79, 
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1702.18, 1471.83, 1408.92, 1249.27, 1249.27, 898.09, 669.92. HRMS (APCI-) calculated for 
C7H12N3O2 [M-H]- 170.0930; found 170.0923. 
 
To a solution of alcohol 4.45 (400 mg, 0.32 mmol) in toluene (6.5 mL) cooled to 0 °C 
was sequentially added benzoic acid 4.73 (309 mg, 1.6 mmol), Et3N (0.27 mL, 1.9 mmol), 
DMAP (198 mg, 1.6 mmol), and 2,4,6-trichlorobenzoyl chloride (278 µL, 1.8 mmol). The 
reaction mixture immediately becomes thick and cloudy upon addition of 2,4,6-trichlorobenzoyl 
chloride. The resulting reaction mixture was stirred at room temperature for 12 h and then 
quenched by treatment with saturated aqueous NaHCO3 solution (10.0 mL). The product was 
extract with EtOAc (3 x 3.0 mL) and the combined organic layers were dried over MgSO4, 
filtered, and concentrated. The crude product was purified by silica gel column chromatography 
eluting with 0:100 à 50:50 EtOAc:Hexanes to afford the desired product 4.80 as a beige foam 
(378 mg, 0.27 mmol, 84% yield). 1H NMR (400 MHz, CDCl3) δ 7.91 – 7.78 (m, 2H), 7.73 – 
7.59 (m, 4H), 7.52 – 7.34 (m, 6H), 7.00 (d, J = 8.1 Hz, 2H), 5.19 – 5.07 (m, 1H), 5.07 – 4.96 (m, 
1H), 4.87 (s, 1H), 4.72 (s, 1H), 4.34 – 4.21 (m, 2H), 4.19 – 4.06 (m, 2H), 4.03 (dd, J = 10.3, 2.5 
Hz, 1H), 3.67 – 3.52 (m, 2H), 3.44 – 3.37 (m, 2H), 3.35 – 3.26 (m, 2H), 3.31 (s, 3H), 3.21 (d, J = 
4.2 Hz, 2H), 2.90 – 2.77 (m, 1H), 2.72 (q, J = 7.6 Hz, 1H), 2.65 (td, J = 7.1, 2.7 Hz, 2H), 2.53 – 
2.38 (m, 2H), 2.34 – 2.18 (m, 3H), 2.13 – 1.95 (m, 4H), 1.95 – 1.84 (m, 1H), 1.91 (s, 3H), 1.83 – 
1.67 (m, 3H), 1.58 (dd, J = 15.0, 4.2 Hz, 2H), 1.53 (s, 3H), 1.50 – 1.14 (m, 14H), 1.14 – 1.06 (m, 
1H), 1.06 – 1.01 (m, 1H), 1.04 (s, 9H), 1.00 – 0.83 (m, 16H), 0.64 – 0.55 (m, 6H), 0.04 (s, 9H). 



















4.45: R = H








135.78, 135.72, 133.97, 133.90, 129.82, 129.77, 129.72, 129.00, 128.75, 127.81, 127.77, 115.89, 
114.44, 113.04, 97.54, 96.73, 84.32, 77.36, 74.49, 73.48, 70.54, 68.10, 66.42, 66.36, 63.30, 
62.56, 61.39, 60.06, 55.54, 51.92, 42.88, 42.18, 41.81, 41.55, 41.01, 40.00, 38.64, 38.37, 38.08, 
37.90, 37.71, 35.20, 33.77, 32.20, 28.06, 26.99, 26.45, 21.54, 19.53, 17.40, 11.52, 9.73, 7.17, 
5.60, -1.43. IR (thin film, cm-1) 2954.29, 2096.78, 1776.74, 1733.16, 1428.13, 1378.04, 1247.96, 
1215.06, 113.84, 1097.88, 998.59, 752.18, 666.97, 504.50. OR [α]D24 +1.6 (c 1.0, CHCl3). 
HRMS (ESI+) calculated for C73H108N3O15F3Si3Na [M+Na]+ 1430.6938; found 1430.6936.  
 
To a solution of alcohol 4.45 (400 mg, 0.32 mmol) in toluene (6.5 mL) cooled to 0 °C 
was sequentially added acid 4.77 (166 mg, 0.97 mmol), Et3N (180 µL, 1.3 mmol), DMAP (119 
mg, 0.97 mmol), and 2,4,6-trichlorobenzoyl chloride (167 µL, 1.1 mmol). The reaction mixture 
immediately becomes thick and cloudy upon addition of 2,4,6-trichlorobenzoyl chloride. The 
resulting reaction mixture was stirred at room temperature for 1.5 h and then quenched by 
treatment with saturated aqueous NaHCO3 solution (10.0 mL). The product was extract with 
EtOAc (3 x 3.0 mL) and the combined organic layers were dried over MgSO4, filtered, and 
concentrated. The crude product was purified by silica gel column chromatography eluting with 
0:100 à 50:50 EtOAc:Hexanes to afford the desired product 4.81 as a beige foam (439 mg, 0.32 
mmol, 98% yield). 1H NMR (500 MHz, CDCl3) δ 7.68 – 7.58 (m, 4H), 7.46 – 7.31 (m, 6H), 5.06 
– 4.97 (m, 2H), 4.97 – 4.90 (m, 1H), 4.86 (s, 1H), 4.30 – 4.19 (m, 2H), 4.18 – 4.04 (m, 2H), 3.97 
(d, J = 10.2 Hz, 1H), 3.72 – 3.57 (m, 4H), 3.54 (dd, J = 10.0, 4.2 Hz, 1H), 3.39 (dd, J = 9.9, 6.5 
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(ddd, J = 19.6, 15.8, 4.2 Hz, 2H), 2.33 – 2.22 (m, 2H), 2.21 – 1.85 (m, 12H), 1.83 – 1.76 (m, 
1H), 1.73 – 1.16 (m, 20H), 1.11 (d, J = 6.9 Hz, 3H), 1.08 – 1.03 (m, 2H), 1.05 (s, 9H), 1.02 – 
0.89 (m, 21H), 0.62 (q, J = 7.9 Hz, 6H), 0.04 (s, 9H). 13C NMR (126 MHz, CDCl3) δ 171.04, 
170.51, 170.48, 156.57, 156.25, 146.74, 135.79, 135.76, 133.90, 133.79, 129.75, 129.72, 127.76, 
115.60, 114.29, 113.32, 97.54, 96.74, 84.34, 73.99, 73.34, 70.31, 68.54, 66.62, 66.39, 63.24, 
62.57, 61.40, 60.25, 55.58, 47.69, 45.85, 42.93, 42.02, 41.92, 41.23, 40.99, 40.00, 39.60, 38.63, 
38.47, 37.86, 37.74, 37.61, 36.79, 33.78, 32.76, 32.02, 28.71, 27.71, 27.33, 27.05, 26.44, 24.84, 
23.49, 21.62, 19.51, 17.41, 11.33, 10.19, 7.21, 5.61, -1.42. IR (thin film, cm-1) 2655.03, 2095.01, 
1777.47, 1733.82,1377.89, 1247.75, 1214.64, 1162.56, 1105.62, 1073.92, 999.04, 976.77, 
837.81, 741.81, 702.26, 504.58. OR [α]D23 +14.4 (c 1.0, CHCl3). HRMS (ESI+) calculated for 
C71H112N3O15F3Si3Na [M+Na]+ 1410.7251; found 1410.7235. 
 
To a solution of 4.80 (45 mg, 0.032 mmol) in DMF (0.64 mL) was added pH 7 buffer (17 
µL) followed by TASF (88 mg, 0.32 mmol). The resulting reaction solution was stirred at room 
temperature for 20 h and quenched by the addition of pH 7 buffer (1.0 mL). The product was 
extract with EtOAc (5 x 1.0 mL) and the combined organic layers were dried over MgSO4, 
filtered, and concentrated. The resulting residue was purified by preparative TLC (1000 µm, 
glass back silica gel plate), developing with 10:90 MeOH:CH2Cl2 to afford the desired product 
4.82 as a beige foam (23 mg, 0.026 mmol, 83% yield). 1H NMR (500 MHz, CDCl3) δ 8.01 (dd, J 














































4.92 (s, 1H), 4.57 – 4.29 (m, 2H), 4.29 – 4.21 (m, 1H), 4.21 – 4.12 (m, 1H), 4.07 – 3.96 (m, 1H), 
3.77 – 3.59 (m, 3H), 3.55 (dd, J = 7.9, 6.3 Hz, 2H), 3.44 – 3.36 (m, 1H), 3.36 – 3.26 (m, 1H), 
3.32 (s, 3H), 2.99 – 2.87 (m, 3H), 2.47 – 2.27 (m, 4H), 2.19 – 1.94 (m, 4H), 2.01 (s, 3H), 1.89 
(ddd, J = 12.2, 4.5, 2.1 Hz, 1H), 1.86 – 1.70 (m, 5H), 1.70 – 1.52 (m, 4H), 1.50 – 1.38 (m, 2H), 
1.37 – 1.28 (m, 1H), 1.28 – 1.09 (m, 7H), 1.14 (s, 3H), 1.03 (d, J = 7.3 Hz, 3H). 
 
To a solution of 4.81 (439 mg, 0.32 mmol) in DMF (6.3 mL) was added pH 7 buffer 
(0.17 mL) followed by TASF (0.87 g, 3.2 mmol). The resulting reaction solution was stirred at 
room temperature for 23 h and quenched by the addition of pH 7 buffer (7.0 mL). The product 
was extract with EtOAc (5 x 3.0 mL) and the combined organic layers were dried over MgSO4, 
filtered, and concentrated. The resulting crude product was purified by silica gel column 
chromatography eluting with 0:100 à 10:90 MeOH:CH2Cl2 to afford the desired product 4.83 as 
a beige foam (228 mg, 0.27 mmol, 86% yield). 1H NMR (500 MHz, CDCl3) δ 5.26 – 5.16 (m, 
1H), 5.06 – 4.98 (m, 2H), 4.89 (d, J = 1.7 Hz, 1H), 4.42 – 4.34 (m, 1H), 4.26 – 4.15 (m, 1H), 
4.09 – 3.98 (m, 2H), 3.76 – 3.58 (m, 3H), 3.44 (dd, J = 10.7, 6.2 Hz, 1H), 3.39 – 3.26 (m, 4H), 
3.34 (s, 3H), 2.84 – 2.75 (m, 1H), 2.45 – 2.37 (m, 2H), 2.37 – 2.27 (m, 2H), 2.26 – 2.22 (m, 2H), 
2.14 – 1.93 (m, 5H), 2.03 (s, 3H), 1.92 – 1.67 (m, 10H), 1.63 – 1.54 (m, 3H), 1.54 – 1.45 (m, 
1H), 1.42 (d, J = 14.0 Hz, 1H), 1.38 – 1.30 (m, 1H), 1.27 – 1.09 (m, 7H), 1.13 (s, 3H), 1.07 – 



















































To a solution of 4.82 (166 mg, 0.19 mmol) in CH2Cl2 (3.9 mL) was added Et3N (50 µL, 
0.36 mmol) followed by TIPSCl (45 µL, 0.21 mmol). The resulting reaction solution was stirred 
at room temperature for 45 min and quenched with the addition of saturated aqueous NaHCO3 
solution (5.0 mL). The product was extracted with CH2Cl2 (3 x 2.0 mL) and the combined 
organic layers were dried over Na2SO4, filtered, and concentrated. The crude product was 
purified by silica gel column chromatography eluting with 0:100 à 6:94 MeOH:CH2Cl2 to 
afford the desired product 4.84 as a beige foam (190 mg, 0.19 mmol, 97% yield). 1H NMR (400 
MHz, CDCl3) δ 7.96 (d, J = 8.2 Hz, 2H), 7.29 (d, J = 8.2 Hz, 2H), 5.23 (dd, J = 8.7, 3.1 Hz, 1H), 
5.06 – 4.99 (m, 1H), 4.96 (s, 1H), 4.82 (s, 1H), 4.39 – 4.27 (m, 2H), 4.09 (s, 1H), 4.07 – 3.99 (m, 
1H), 3.96 – 3.84 (m, 1H), 3.67 – 3.48 (m, 5H), 3.29 – 3.19 (m, 2H), 3.25 (s, 3H), 2.94 (t, J = 7.0 
Hz, 2H), 2.81 – 2.75 (m, 1H), 2.73 (d, J = 4.1 Hz, 1H), 2.65 (dd, J = 16.9, 7.7 Hz, 1H), 2.48 (dd, 
J = 17.0, 5.3 Hz, 1H), 2.37 (dd, J = 14.4, 8.2 Hz, 1H), 2.30 – 2.18 (m, 2H), 2.01 (ddd, J = 12.1, 
4.4, 1.7 Hz, 1H), 1.98 – 1.91 (m, 1H), 1.97 (s, 3H), 1.90 – 1.50 (m, 12H), 1.47 – 1.37 (m, 1H), 
1.33 – 1.08 (m, 15H), 1.05 (dd, J = 7.6, 1.2 Hz, 18H), 1.00 (d, J = 7.0 Hz, 3H). 13C NMR (101 
MHz, CDCl3) δ 171.07, 170.41, 165.71, 147.22, 143.49, 130.02, 129.27, 128.97, 113.90, 98.31, 
97.69, 77.36, 75.65, 73.13, 69.00, 68.24, 67.82, 66.18, 66.15, 64.79, 61.58, 60.23, 55.49, 52.08, 
46.26, 44.05, 42.52, 41.66, 41.58, 40.70, 39.31, 38.61, 37.68, 36.94, 36.60, 35.41, 34.06, 33.23, 
30.11, 28.36, 21.60, 17.95, 17.92, 13.12, 12.04, 11.71. IR (thin film, cm-1) 3529.25, 2944.72, 














































+3.8° (c 1.0, CHCl3). HRMS (ESI+) calculated for C53H85N3O14SiNa [M+Na]+ 1038.5699; 
found 1038.5691. 
 
To a solution of 4.83 (228 mg, 0.27 mmol) in CH2Cl2 (5.4 mL) was added Et3N (70 µL, 
0.50 mmol) followed by TIPSCl (64 µL, 0.30 mmol). The resulting reaction solution was stirred 
at room temperature for 45 min and quenched with the addition of saturated aqueous NaHCO3 
solution (6.0 mL). The product was extracted with CH2Cl2 (3 x 3.0 mL) and the combined 
organic layers were dried over Na2SO4, filtered, and concentrated. The crude product was 
purified by silica gel column chromatography eluting with 0:100 à 6:94 MeOH:CH2Cl2 to 
afford the desired product 4.85 as a beige foam (250 mg, 0.25 mmol, 93% yield). 1H NMR (500 
MHz, CDCl3) δ 5.08 – 5.01 (m, 3H), 4.87 (s, 1H), 4.39 – 4.26 (m, 2H), 4.12 (s, 1H), 4.02 – 3.88 
(m, 2H), 3.71 – 3.59 (m, 3H), 3.41 (s, 2H), 3.36 – 3.30 (m, 4H), 3.28 (t, J = 8.0 Hz, 2H), 3.08 – 
2.99 (m, 1H), 2.68 (q, J = 7.7 Hz, 2H), 2.48 (dd, J = 17.1, 5.5 Hz, 1H), 2.33 (dd, J = 14.4, 8.5 
Hz, 1H), 2.26 – 2.17 (m, 1H), 2.20 (s, 2H), 2.14 – 1.87 (m, 7H), 2.04 (s, 3H), 1.87 – 1.74 (m, 
2H), 1.74 – 1.48 (m, 11H), 1.42 (d, J = 14.0 Hz, 1H), 1.34 – 1.16 (m, 10H), 1.15 (s, 3H), 1.10 – 
0.99 (m, 30H), 0.92 (d, J = 7.0 Hz, 3H). 13C NMR (126 MHz, CDCl3) δ 171.18, 171.11, 170.46, 
147.57, 113.71, 98.26, 97.90, 74.92, 73.09, 69.28, 68.34, 67.83, 66.47, 66.17, 64.56, 61.55, 
60.38, 55.70, 47.70, 46.20, 45.83, 44.02, 42.47, 41.66, 41.43, 40.43, 39.66, 38.77, 38.69, 37.64, 
36.71, 33.97, 33.28, 32.22, 30.03, 28.34, 27.63, 27.51, 21.65, 17.95, 17.93, 13.21, 12.01, 11.86. 


















































1323.87, 1184.35, 1091.26,1053.16, 992.85, 884.02, 754.11, 666.71. OR [α]D22 +18.1 (c 1.0, 
CHCl3). HRMS (ESI+) calculated for C51H89N3O14SiNa [M+Na]+ 1018.6012; found 1018.6011.  
 
To a solution of 4.84 (17 mg, 0.017 mmol) in CH2Cl2 (1.1 mL) was added DMP (21 mg, 
0.05 mmol) and the resulting solution was stirred at room temperature for 1.5 h. The reaction 
solution was cooled to 0 °C and a 1:1 solution of saturated NaHCO3 to saturated Na2S2O3 (4.0 
mL) was added. Upon stirring for 0.5 h at room temperature, the product was extracted with 
CH2Cl2 (3 x 1.0 mL) and the combined organic layers were dried over MgSO4, filtered, and 
concentrated. Isolated crude 4.86 (16 mg, 0.015 mmol, 92% yield) was sufficiently pure and 
used without further purification. 1H NMR (400 MHz, CDCl3) δ 9.49 (d, J = 0.9 Hz, 1H), 7.96 – 
7.87 (m, 2H), 7.28 – 7.24 (m, 2H), 5.52 (dd, J = 9.1, 3.5 Hz, 1H), 5.03 (d, J = 4.3 Hz, 1H), 4.99 
(d, J = 1.4 Hz, 1H), 4.81 (s, 1H), 4.39 – 4.24 (m, 2H), 4.15 – 4.04 (m, 1H), 4.02 (s, 1H), 3.85 – 
3.73 (m, 1H), 3.67 – 3.57 (m, 2H), 3.54 (t, J = 7.0 Hz, 2H), 3.26 (s, 3H), 3.09 – 2.97 (m, 1H), 
2.93 (t, J = 7.1 Hz, 2H), 2.90 – 2.81 (m, 1H), 2.76 – 2.66 (m, 1H), 2.66 – 2.52 (m, 2H), 2.46 (dd, 
J = 17.0, 4.4 Hz, 1H), 2.43 – 2.33 (m, 3H), 2.29 (dd, J = 14.3, 4.2 Hz, 1H), 2.10 – 2.01 (m, 1H), 
2.00 – 1.91 (m, 1H), 1.98 (s, 3H), 1.91 – 1.83 (m, 1H), 1.83 – 1.73 (m, 3H), 1.73 – 1.64 (m, 2H), 
1.64 – 1.49 (m, 3H), 1.46 – 1.33 (m, 3H), 1.33 – 1.22 (m, 7H), 1.22 – 1.12 (m, 11H), 1.05 (dd, J 















































To a solution of 4.85 (17 mg, 0.017 mmol) in CH2Cl2 (1.1 mL) was added DMP (22 mg, 
0.05 mmol) and the resulting solution was stirred at room temperature for 1.5 h. The reaction 
solution was cooled to 0 °C and a 1:1 solution of saturated NaHCO3 to saturated Na2S2O3 (4.0 
mL) was added. Upon stirring for 0.5 h at room temperature, the product was extracted with 
CH2Cl2 (3 x 1.0 mL) and the combined organic layers were dried over Na2SO4, filtered, and 
concentrated. Isolated crude 4.87 (18 mg, 0.017 mmol, 100% yield) was sufficiently pure and 
used without further purification. 1H NMR (400 MHz, CDCl3) δ 9.59 (d, J = 0.9 Hz, 1H), 5.34 
(dd, J = 9.3, 3.1 Hz, 1H), 5.08 – 4.99 (m, 2H), 4.85 (s, 1H), 4.37 – 4.20 (m, 2H), 4.20 – 4.10 (m, 
1H), 4.00 (s, 1H), 3.89 – 3.76 (m, 1H), 3.75 – 3.63 (m, 2H), 3.36 – 3.30 (m, 1H), 3.33 (s, 3H), 
3.30 – 3.21 (m, 2H), 2.92 – 2.77 (m, 2H), 2.77 – 2.64 (m, 1H), 2.61 – 2.50 (m, 2H), 2.46 – 2.32 
(m, 3H), 2.28 – 2.21 (m, 1H), 2.16 – 2.07 (m, 1H), 2.11 (s, 2H), 2.05 (s, 3H), 2.04 – 1.90 (m, 
3H), 1.90 – 1.82 (m, 2H), 1.82 – 1.75 (m, 1H), 1.74 – 1.39 (m, 11H), 1.32 – 1.19 (m, 8H), 1.15 




















































**Note: 4.88 was prepared using and unoptimized procedure which led to lower than expected 
yield. TESOTf protection as described for 4.56 is expected to give improved results. 
To a solution of crude 4.86 (16 mg, 0.015 mmol) in CH2Cl2 (0.30 mL) was added 2,6-
lutidine (18 µL, 0.15 mmol). The resulting reaction solution was cooled to -78 °C and TESOTf 
(17 µL, 0.077 mmol) was added dropwise. Upon stirring at -78 °C for 1 h and -45 °C for 1 h, 
excess TESOTf was quenched by the addition of saturated aqueous NaHCO3 (1.0 mL). The 
reaction mixture was warmed to room temperature, and the product was extracted with CH2Cl2 
(3 x 1.0 mL), and the combined organic layers were washed with saturated CuSO4 (1.0 mL), 
dried over Na2SO4, filtered, and concentrated. The resulting residue was purified by pH 7 
buffered silica gel column chromatorgraphy eluting with 0:100 à 5:95 acetone:CH2Cl2 to afford 
the desired product 4.88 as a beige foam (10 mg, 0.009 mmol, 52% yield over 2 steps). 1H NMR 
(500 MHz, CDCl3) δ 9.48 (s, 1H), 7.91 (d, J = 7.8 Hz, 2H), 7.26 (m, 2H), 5.58 – 5.48 (m, 1H), 
5.03 (s, 1H), 4.90 (s, 1H), 4.79 (s, 1H), 4.31 – 4.14 (m, 2H), 4.14 – 4.04 (m, 1H), 3.80 (t, J = 
12.1 Hz, 1H), 3.68 – 3.56 (m, 2H), 3.53 (t, J = 7.1 Hz, 2H), 3.26 (s, 3H), 3.10 – 2.99 (m, 1H), 
2.96 – 2.89 (m, 2H), 2.89 – 2.82 (m, 1H), 2.75 – 2.66 (m, 1H), 2.65 – 2.56 (m, 2H), 2.46 – 2.28 
(m, 4H), 2.06 (dd, J = 12.6, 4.5 Hz, 1H), 2.01 – 1.92 (m, 1H), 1.95 (s, 3H) 1.90 – 1.81 (m, 2H), 
1.81 – 1.70 (m, 3H), 1.65 – 1.23 (m, 15H), 1.23 – 1.11 (m, 11H), 1.07 (dd, J = 7.8, 2.3 Hz, 18H), 






















4.86: R = H




-78 to -45 °C
 227 
δ 209.10, 202.95, 171.12, 170.70, 165.00, 146.58, 143.56, 130.07, 128.96, 128.92, 114.45, 97.06, 
74.69, 72.74, 70.54, 66.84, 64.44, 64.11, 61.36, 59.51, 55.68, 52.08, 49.06, 48.05, 47.82, 45.35, 
43.35, 42.45, 42.06, 41.25, 38.64, 38.49, 36.82, 35.44, 34.92, 34.20, 32.15, 24.88, 21.67, 17.94, 
13.18, 12.49, 12.07, 7.51, 7.07. IR (thin film, cm-1) 2947.34, 2871.24, 2098.06, 1720.30, 
1462.53, 1269.11, 1180.12, 1019.20, 753.70, 667.27. OR [α]D23 +12.2° (c 1.0, CHCl3). HRMS 
(ESI+) calculated for C59H95N3O14Si2Na [M+H]+ 1148.6250; found 1148.6245. 
 
**Note: 4.89 was prepared using and unoptimized procedure which led to lower than expected 
yield. TESOTf protection as described for 4.56 is expected to give improved results. 
To a solution of crude 4.87 (18 mg, 0.017 mmol) in CH2Cl2 (0.36 mL) was added 2,6-
lutidine (21 µL, 0.18 mmol). The resulting reaction solution was cooled to -78 °C and TESOTf 
(20 µL, 0.090 mmol) was added dropwise. Upon stirring at -78 °C for 1 h and -45 °C for 1 h, 
excess TESOTf was quenched by the addition of saturated aqueous NaHCO3 (1.0 mL). The 
reaction mixture was warmed to room temperature, and the product was extracted with CH2Cl2 
(3 x 1.0 mL), and the combined organic layers were washed with saturated CuSO4 (1.0 mL), 
dried over Na2SO4, filtered, and concentrated. The resulting residue was purified by pH 7 
buffered silica gel column chromatorgraphy eluting with 0:100 à 8:92 acetone:CH2Cl2 to afford 
the desired product 4.89 as a beige foam (14 mg, 0.013 mmol, 74% yield over 2 steps). 1H NMR 
(500 MHz, CDCl3) δ 9.56 (s, 1H), 5.42 – 5.31 (m, 1H), 5.04 (s, 1H), 4.98 (s, 1H), 4.82 (s, 1H), 
























4.87 R = H




-78 to -45 °C
 228 
Hz, 2H), 2.92 – 2.77 (m, 2H), 2.74 – 2.61 (m, 2H), 2.52 – 2.44 (m, 1H), 2.44 – 2.21 (m, 4H), 
2.16 – 2.06 (m, 3H), 2.04 – 1.95 (m, 5H), 1.90 – 1.79 (m, 3H), 1.78 – 1.70 (m, 1H), 1.65 – 1.52 
(m, 7H), 1.51 – 1.39 (m, 3H), 1.36 – 1.17 (m, 11H), 1.08 (t, J = 6.0 Hz, 25H), 0.97 (s, 6H), 0.92 
(t, J = 7.8 Hz, 9H), 0.59 – 0.49 (m, 6H). 13C NMR (126 MHz, CDCl3) δ 208.80, 203.01, 171.14, 
170.68, 170.21, 147.03, 114.08, 97.10, 97.00, 73.30, 72.78, 70.53, 66.80, 64.34, 64.15, 61.26, 
59.59, 55.79, 48.85, 48.35, 47.80, 47.73, 45.77, 45.34, 43.42, 42.38, 42.14, 41.23, 39.69, 38.63, 
37.61, 36.95, 34.95, 34.14, 32.31, 32.12, 27.50, 27.46, 24.87, 21.72, 17.94, 12.92, 12.07, 12.04, 
7.52, 7.03. IR (thin film, cm-1) 2947.44, 2871.36, 2094.74, 1724.81, 1462.93, 1370.02, 1213.98, 
1181.49, 1144.89, 1064.64, 994.08, 754.77, 667.43. OR [α]D22 +11.4° (c 0.5, CHCl3). HRMS 
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